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"A chemist walks into a pharmacy and asks the pharmacist,  
"Do you have any acetylsalicylic acid?"  
"You mean aspirin?" asked the pharmacist.  







Q: if both a bear in Yosemite and one in Alaska  
fall into the water 
which one dissolves faster? 







To my family:  
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5-HT3R   serotonin-gated mouse ion channel 5-hydroxytryptamine type-3 receptor 
8-CPT 8-cyclopentyl-1,3-dimethylxanthin 
ADA adenosine deaminase 
ATP   adenosine triphosphate 
AMPPNP adenyl-5'-yl imidodiphosphate 
CB    cytochalasin B 
CcO   cytochrome c oxidase 
CHAPS   3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
CHS   cholesteryl hemisuccinate  
cLogP  logarithm of the partition coefficient between n-octanol and water 
CMC  critical micellar concentration 
CPA N6-cyclopentyladenosine 
CTAC   etyltrimethylammonium chloride 
CTAB  etyltrimethylammonium bromide 
DDM   dodecyl-n--maltoside 
DHPC  dihexanoylphosphatidylcholine 
DMPC   dimyristylphoshatidylcholine 
DMPE  1,2-dimyristoyl-sn-glycero-phosphatidylethanolamine 
DMSO  dimethyl sulfoxide 
DPC  dodecylphosphocholine 
DPGPC    1, 2-diphytanoyl-sn-glycero-3-phosphocholine 
DPPA    dipalmitoyl L-α-phosphatidic acid 
DPPC    dipalmitoyl phosphatidylcholine 
DPPE    1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine 
DsbB  disulphide bond forming protein B 
FBDD  fragment based drug discovery 
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FID   free induction decay  
FPMSMA 4-fluorophenyl)methylsulfanylmethanimidamide 
FRAP  fluorescence after photobleaching 
GAPS  γ-aminopropylsilane  
GPCR  G-protein coupled receptor 
GR  1,2,3,9-tetrahydro-3-[(5-methyl-1H-imidazol-4-yl)methyl]-9-(3-amino-(N  
  fluoresceinthiocarbamoyl)propyl)-4H-carbazol-4-one 
HA-hH1R-HIS   heamaglutinin and 6-his tagged human histamine H1 receptor 
hA1R human adenosine A1 receptor 
HTA  -hydroxy-undecanethiol 
IMAC  immobilized metal affinity chromatography 
KcsA  K+ channel from Streptomyces lividans  
LB  langmuir–blodgett  
LPC   lysophosphatidylcholine 
N0840  N6-cyclopentyl-9-methyladenine 
NMR  nuclear magnetic resonance  
NTA  nitriolotriacetic acid 
OG   octylglucoside 
OmpA  outer membrane protein B  
PC   phosphatidylcholine  
POPC  palmitoyl-oleoyl-phosphatidylcholine 
POPG   palmitoyl-oleoyl-phosphatidylglycerol 
PBS   phosphate buffered saline 
PEEK  polyetheretherketones  
PSLB  planar supported lipid bilayers 
PWR  plasmon-waveguide resonance 
QSAR  quantitative structure activity relationship 
SAM  self-assembled monolayer 
SCA   scaffold-based classification approach 
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SDS   sodium dodecyl sulfate 
SERIAS  surface-enhanced infrared reflection absorption spectroscopy 
SPA  scintillation proximity assay  
SPFS  surface plasmon enhanced fluorescence spectroscopy  
SPR  surface plasmon resonance 
STD   saturation transfer difference 
tBLM   tethered bilayer lipid membrane 
TIFR  total internal reflection fluorescence microscopy 
TINS target immobilized NMR screening 
TMA  tetramethylammonium chloride 
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An overview of drug discovery  
 
The need to relieve pain and suffering by medication has been with us since the dawn of 
humanity.  Spiritual healing, accompanied by herbal medicines was passed on from ancestors 
who treated the symptoms of the soul.  From then, a myriad of information and technological 
advances have contributed to each step leading to modern day drug discovery (Figure 1), where 
treatments are developed to treat the body.   
 
Figure 1. Historical 




The age of botanicals2 was defined by the application of ancestral herbal medicines after trial 
and error determined which treatment was best for a particular ailment.  During those days, each 
plant was believed to be designed to heal a particular symptom.  It was not until the 19th century 
that active ingredients were isolated and characterized with the developing science of chemistry, 
such as the South American poison arrow curare by Claude Bernard3.   From then, drug discovery 
was still very random with accidental discoveries such as Penicillin by Alexander Fleming in 
19264, among many others.  Developments in the 1950s led the way to serendipity in drug 
discovery, owing its name to the random screening of a variety of known compounds on animal 
models, with successful emergence of many drugs5. With breakthroughs such as the elucidation 
of the DNA structure by Watson and Crick6, we started having a better idea of human biology. 
The low diversity of available molecules and the common usage of animal models with limited 
knowledge of drug mechanisms however, were still limiting the discovery of drugs with high 
specificity and low toxicity for the human protein targets. Finally, with emerging biotechnology 
and high throughput automated processes, the last 50 years have seen a boom in drug discovery 
strategies owing to our increasing knowledge related to handling and analysing biological 
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material.  The emergence of genetic engineering and the protein data bank7 provided us with the 
possibility of zooming into tissues, isolating and studying single protein targets to better 
understand the relationship between protein and drug structures. Combinatorial chemistry would 
enable an extremely wide variety of chemicals to be screened on a protein target rather than in an 
in vivo animal model, with potential specific changes to be made on different parts of the 
molecule to enhance qualities or decrease toxicity5. The sequencing of the human genome by the 
International Human Genome Sequencing Consortium has estimated that our genome contains 
20000 to 25000 genes8.  10 – 15 % of these have been estimated to code for drug targets9, 
exposing our bodies to modern day rational drug design.   
Naturally, increasing knowledge of animal and human biology, developing technologies, and 
market considerations have altered the way the drug discovery process occurs.  Large 
corporations of pharmaceutical companies for example are incorporating rational drug design 
strategies, in order to maximise the chances of success. The basic steps of modern rational drug 
discovery processes, which start by identifying a target and pave the way to identifying drug 
leads for clinical trials, are highlighted in Figure 2.  
 
Figure 2. Basic 
steps in modern 
drug discovery. 
 
There are increasingly perceptive methods for each of the steps involved, ranging from virtual 
to experimental ones. The central theme revolves around obtaining valuable information related 
to structure-activity relationships between the target and hit compounds in order to develop lead 
compounds which have an advanced trade off between better affinities and specificities, and 
better drug-like ADME (Absorption, Distribution, Metabolism, and Excretion) properties, as 
predicted by Lipinski’s rule of “5” 10  (Figure 3a).  
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Before sensitive molecular methods had evolved, the 
effect of a compound on a target could only be measured 
by detecting an effect on target function.  In order to 
detect such effects the compounds had to interact strongly 
with the target, often leading to the necessity of screening 
fairly large compounds in functionality based assays 
(Figure 3b).  These large compounds, however, were 
often difficult to chemically elaborate without violating 
the rule of 5 due to increased hydrophobicity upon 
chemical elaboration. This type of screening, now coined 
traditional High Throughput Screening (HTS), was 
widespread in the last decades but was not always 
successful for some targets12.  With emerging molecular 
methods such as Nuclear magnetic resonance (NMR), 
crystallography, and surface-plasmon resonance (SPR), 
fragment-based drug discovery (FBDD) was developed to 
detect hits for those targets for which HTS and other 
methods failed, and soon, the advantages of this strategy 
became more apparent.  
 
Smaller is better: Why use a fragment approach to drug discovery? 
  
As can be seen in Figure 4a with the example of a complex binding site, the increasing size of 
a molecule increases the probabilities of detecting it, but the probability of finding a unique 
match between ligand and target has an optimum at a very low complexity level. There is 
therefore a trade-off between the probability of detecting binding and the probability of finding a 
good match between ligand and target.  When screening is carried out with smaller molecules, 
there is a better chance of finding a unique binding mode, but the binding affinity is very low 
 
Figure 3. Predicting what makes a 
compound a good bioavailable drug. 
Lipinski’s rule of “5”10 defines the 
prerequisites for a good orally 
available drug (a) such as imatinib 
mesylate (Gleevec) (b), used as a drug 
to treat leukemia11. 
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compared to larger molecules.  Molecular methods are therefore required to detect the weak 
interactions between a target and a fragment. 
 
Using biophysical methods 
which detect interactions at the 
atomic level can now enable 
screening of fragments which 
were otherwise undetected by 
HTS methods.  The high 
probability of finding a good 
match between a target binding 
site and a fragment is not the only 
advantage of FBDD. By 
definition, fragments are 
molecules which are smaller, 
simpler, and more soluble than 
drug-like compounds. This brings 
the Lipinski’s rule of 5 down to a 
rule of 315 (Figure 4b) where there 
remains a larger margin to 
elaborate or link the fragment into 
a more potent drug which remains 
bioavailable. An example of a 
fragment is shown in Figure 4c. 
 
Small – With molecular 
weights ranging from 160 - 300 Da, these fragments are usually easier to synthesize than the 
larger HTS compounds. The maximum amount of fragments that can possibly be synthesized are 
estimated at 107, as opposed to 1060 larger HTS compounds16. Furthermore, as can be seen in 
 
 
Figure 4. Using fragments in drug discovery.  The success 
landscape for a binding site of high complexity, adapted with 
permission from reference 13. Copyright 2001 American 
Chemical Society (a). The rule of “3” (b) can be applied to 
predict the bioavailability of a fragment such as the one used as 
inhibitor of BclxL, a membrane protein involved in the survival 
of cancer cells14 (c). 
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Figure 5, these smaller structures are much more efficient at probing key binding areas in a target 
where larger compounds may sterically hinder access to these areas17.  Clearly, the advantage of 
using fragment libraries lies in the fact that fragments can be smaller and yet more efficient at 
probing the available structure pool! For comparison, a million compounds are often screened for 
HTS strategies, compared to 1000 fragments in FBDD18. 
 
Simple – Fragments are simple structures which tend to 
be void of reactive groups that can lead to toxicity19 or 
metabolic instability12.  Screening fragments is amenable 
to finding lead products with better starting bioavailability 
profiles20, thereby reducing the often laborious chemistry 
efforts required to remove initial unwanted functional 
groups.    
 
Soluble – As previously mentioned, previous research 
has established that elaborating compounds by modifying 
or adding chemical groups often leads to more 
hydrophobic compounds which easily violate Lipinski’s 
rule of 5.  FBDD is a good alternative approach to HTS 
because the more soluble fragments are better starting 
points for optimisation as a variety of chemical 
elaborations can be carried out with less failure in 
developing drug-like molecules with good ADME 
properties13. 
 
As explained, fragment screening relies on the detection 
of fragments which bind weakly to target proteins.  In most cases, these fragments need to be 
elaborated into larger compounds with higher affinity.  Lead optimization can be carried out in a 
variety of ways, but often depends on having a high resolution target structure available.  This 
 
Figure 5: Capacity of an HTS 
compound (top, black) or fragments 
(bottom, black) to probe the key 
binding areas of a protein binding site 
(white). Fragments are better starting 
points and can be elaborated into 
larger compounds (bottom, grey) 
with better specificity and 
bioavailability than HTS compound 
(top, grey) without easily violating 
Lipinski’s rule of 5. 
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enables one to identify which chemical groups on the fragment to modify in order to have more 
potent and specific affinities with the protein target binding site.  Computational chemistry and 
informatics therefore play a key role.  The initial idea was to link fragments together, whereby 
linking small weak fragments would lead to higher potency compounds.  Although this was 
successful in many cases20,21,22, linking chemistries are not always successful and can be replaced 
by elaboration of single or overlapping fragments by addition/removal of groups until the desired 
outcome is produced14, or by screening focused libraries around a central theme scaffold of 
previously identified hits12. 
 
Requirements for fragment-based drug discovery 
 
Interactions between proteins and fragments range from 2 M to 5000 M affinity values23, 
hence the requirement to apply molecular methods such as NMR, crystallography, or SPR to 
detect hits in fragment based screens.  These sensitive methods which generate invaluable 
information regarding target-fragment interactions at the molecular level, however, come with 
some stringent requirements when it comes to sample preparation and assay development.  
Clearly, to obtain high resolution information at the molecular level, the target protein sample 
has to be highly concentrated and purified from its environment in order to increase signal to 
noise levels.  Naturally, individual applications have their additional requirements, such as the 
need for high resolution crystals and functionally immobilized proteins in crystallography and 
SPR, respectively.  Developing individual protocols for each target protein sample preparation 
and assay development can be extremely time consuming and often cause large amounts of 
proteins to be needed in the course of action. Furthermore, large amounts of fragments are often 
also required.  
Crystallography requires 10 – 50 mg of protein, often with purity higher than 95 %, and the 
resulting crystals do not always diffract appropriately to provide high resolution structural 
information24. Screening involves either co-crystallizing targets with fragment cocktails, or 
soaking target crystals in fragment cocktails, with individual fragment concentrations ranging 
between 25 – 100 mM24. Nonetheless, there have been numerous success stories with soluble 
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protein targets at the heart of cancer, including kinases25,26 and AIDS, such as reverse HIV 
transcriptase27.   
NMR-based fragment screening is carried out in solution and involves detecting changes in 1H, 
13C, or 1H15N correlation signals of the protein target or the ligand.  Target-based screening such 
as ‘SAR (structure-activity relationships) by NMR’ developed by Abbott laboratories enabled 
identification of inhibitors for cancer target tyrosine phosphatases28 and tissue target matrix 
metalloproteases20.  It is reported that 50 – 200 mg of isotopically labelled protein, soluble within 
the range of 0.1 - 1 mM, are required for such experimentations.  These high quantities are 
necessary in order to screen one fragment at a time on individual protein samples, due to the 
inherent system which only identifies structural, albeit valuable, information regarding the 
molecular effects on the protein and not the ligand. Not surprisingly, the availability of a high 
resolution structure and assignments for the labelled protein is a prerequisite to establish the 
structural effects upon fragment binding and to identify the binding site for future chemical 
elaboration of hits into leads.   There are alternative strategies which require smaller amounts of 
unlabelled protein such as ligand-based screening methods where changes in the magnetisation 
environment of the ligand are monitored, either by magnetisation saturation transfer (STD)29 or 
by proton relaxation differences30. These systems enable higher screening throughput due to the 
smaller amounts of unlabelled protein required (down to M concentrations) and the possibility 
of identifying hits within a cocktail of fragments. The changes are often monitored by comparing 
fragment spectra in the presence and absence of the target and therefore, ligand libraries must be 
designed to allow appropriate signal deconvolution, or isolation of signals31. These NMR 
techniques can be carried out with off-the-shelf materials and rarely need as much effort in assay 
development as for crystallography and SPR techniques. 
Although SPR techniques were only used for secondary screening due to limitations in 
throughput capacities, new advances in microarray immobilization and SPR imaging techniques 
are providing platforms which can now enable SPR-based primary screening of fragment 
libraries32.  SPR measures changes in surface electromagnetic waves refraction indices upon 
adsorption of an analyte to a particular surface, such as with or without an immobilized target 
protein. Although this was limited to detect only differences caused by adsorption of large 
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biomolecules, such as target proteins or DNA, advanced techniques now enable fragment binding 
to an immobilized target.  SPR requires high efforts of assay development for each target protein, 
in order to enable monitoring and to control the stability of the surface, the levels of functional 
protein immobilized, the level of unbound protein leakage, and levels of non-specific binding of 
fragments to the surfaces33.  Nonetheless, once the appropriate assay is developed, very little 
amounts of protein are required with down-scaling of surface to several squared nanometers in 
size. Furthermore, labelled analytes or proteins are not required.   
 
Why are membrane proteins such important drug targets?  
 
60 % of today’s drugs target membrane 
proteins36. As their name indicates, these 
proteins are located within the native cell 
membrane and are therefore involved in a 
multitude of cellular processes related to 
signalling, transportation, energy production, 
metabolism, and homeostasis. Clearly, if any of 
these proteins within these complex networks 
malfunctions, onsets of a variety of symptoms 
and diseases can occur.   
Two major groups of membrane proteins are 
currently targeted due to their extremely 
important roles in maintaining healthy cellular 
processes. These are G protein-coupled 
receptors (GPCRs) and ion channels (Figure 6).  
GPCRs are proteins which span the membrane with 7 transmembrane -helices (Figure 6a) 
and are involved in translating an external stimulus (e.g., light, hormones, or neurotransmitters) 
into an internal signal in the cell. This internal signal is regulated by a signalling cascade, starting 
with the G protein to which the GPCRs are coupled to on the inside of the cell, down to complex 
Figure 6.  Structures of GPCRs and ion 
channels.  The human GPCR 2-adrenergic 
receptor (a) and the bacterial potassium channel 
KcsA which has close homology with human ion 
channels (b) have -helical transmembrane 
domains.  The structures are modified from pdb 
IDs 2rh134 and 2kb135 respectively. 
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networks of other effector proteins such as kinases, ion channels, transporters, and enzymes. As 
such, GPCRs are at the heart of almost all physiological processes and are targeted by 30 - 40 % 
of drugs on the market today37.  Faulty GPCR signalling, often due to lack of or surplus of 
neurotransmitters or hormones,  leads to many common human disorders associated with the 
central nervous system, the cardiovascular system, vision, asthma, allergies, and the immune 
system38, to name but a few. Targeting GPCRs in drug discovery is far from simple, for the 
pharmacology mechanisms are complex and diverse.  The active, inactive, or self-activating 
(constitutive activity) states of GPCRs is determined by the type of ligand and where it binds on 
the GPCR.  Agonists and antagonist ligands will therefore activate or inhibit the receptor, 
respectively.  However, research has revealed constitutive activity of some GPCRs, which 
translates to a basal activity independent of ligand binding.  Inverse agonists are therefore 
becoming interesting drugs as they block this type of signalling cascade and may at times be 
more effective than (neutral) antagonists39.  To make matters more complex, small molecules 
called allosteric modulators have been noted to modulate the way these ligands bind into stronger 
stimulation or inhibition of activity40.  
GPCRs which are targeted by drug discovery include the Class A (rhodopsin-like) receptors 
and bind a range of molecules from small molecules to large peptides41.  Some of these Class A 
receptors such as the adenosine receptors, histamine receptors, and the -adrenergic receptors are 
good candidates for small molecule drug discovery because of the small sizes of their 
endogenous ligands9, which bind to the receptors with much higher affinities than fragment 
interactions. Other classes of GPCRs targeted by drug discovery, such as the Class C GPCRs, 
have complex mechanisms such as the involvement of large N-terminal domains (Class C 
GPCRs) which act as gates to ligand binding only upon dimerization of the GPCR and its N-
terminal domain9.  Although it is beyond the scope of this introduction to discuss all the types of 
GPCR mechanisms which are targeted by drug discovery, it is clear that GPCRs are a crucial 
class of proteins to modulate in order to alleviate diseases. Unfortunately, to date, there are only 4 
GPCRs for which complete structures are available, including the crystal structures of bovine 
rhodopsin42, the 2-adrenergic receptor43 (Figure 6a), the -adrenergic receptor44, and the 
adenosine A2A receptor
45. Although the drug discovery process has enabled the successful 
General Introduction 
- 21 - 
identification of ligands with mutagenesis, computational methods, and functionality based 
assays, the structural information of the GPCRs has provided new insights on important key 
properties of each individual GPCR binding site.  Therefore, there is a need to obtain more 
structural information for other members of this class of proteins to understand where ligands 
bind, how to evolve them into more specific drugs, and how to modulate GPCR activity in the 
context of complex signalling interactions.   
The second important class of membrane proteins targeted by drugs, the ion channels, are pore-
forming proteins which are involved in the transport of sodium, potassium, calcium, and chloride 
ions through the cellular membrane in order to modulate the ionic potential between the outside 
and inside of the cell.  These ion channels can be ‘gated’ by different processes such as ligand 
binding, temperature, mechanical tension in the membrane, and voltage, all of which are often 
concerted by other proteins in the cell, such as GPCRs9.  Other molecules which can block ion 
channels include the deadly snake venom which consists of protein and peptide toxins that 
physically block the opening of the ion channels, thereby blocking all further transport of ions. 
Different venoms are being studied now in the hope to modulate this ion channel blockage in 
diseases such as multiple sclerosis46.  Needless to state therefore how complex it is to target ion 
channels without creating undesirable secondary effects. Nonetheless, current drugs on the 
market are alleviating diseases caused by mutations in these ion channels, such as high blood 
pressure and muscle dystrophy, faulty acidification levels which may lead to diarrhoea or kidney 
stones47, and naturally many diseases linked to the central nervous system such as migraines, 
seizures, and autism48.  This was just a short list of examples, which are mostly studied by 
mutagenesis and ‘macroscopic’ assays including cell-based, radioligand, or fluorescent-based 
assays instead of by molecular methods due to the limited amount of complete ion channel 
structures currently available. Some of the complete structures that exist include the crystal 
structure of the potassium channel from the gram-positive bacterium Streptomyces lividans49, as 
shown in figure 6b. 
Clearly, with GPCRs and ion channels being key proteins of important signalling cascades, 
current drugs often have high levels of secondary effects.  To make matters more complicated, 
many GPCRs and ion channels work by forming complexes of proteins by homo or hetero-
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multimerization9,50 in order to proceed with certain functions.  Research is now unveiling 
different parcels of complex networks involved in cellular processes regulated by these important 
membrane proteins, along with important interactions with other components of the cell, such as 
molecules within the native membrane itself.  The dawn of biophysical molecular methods will 
eventually lead to a better understanding of how to specifically target a membrane protein in a 
specific state and how to improve drug interactions for a particular system rather than a single 
protein target. As explained below, there are many reasons why membrane proteins are still 
difficult to study at the structural level, limiting therefore our possibilities to develop drugs which 
are more specific in the aim to limit side effects and understand new relationships between 
disease and target. 
 
Why are membrane proteins generally excluded from fragment based drug  
discovery?  
 
As previously defined, molecular approaches such as NMR, crystallography, and SPR require 
high yields of concentrated samples of protein target in order to yield high resolution data 
regarding molecular interactions. Furthermore, the sensitivity of these methods is such that 
extensive effort goes into preparing protein samples with the highest level of purity, so as to 
avoid unwanted interactions with, or signals from, other molecules. 
Applying such molecular methods to membrane proteins becomes challenging because of the 
difficulties in meeting the above requirements, as explained below. It is rarely possible to 
produce membrane proteins in sufficient quantities, and even when enough is produced, the 
proteins must be purified, concentrated, and solubilized in a hydrophobic environment which 
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Limitations in membrane protein production 
 
There is no general solution for production of membrane proteins in high quantities and the 
choice of vector sources and host cells for overexpression and production has to be defined for 
each new target.  Such decisions may be based on the source of the original gene, the protein’s 
requirements for optimal folding, and for posttranslational modifications.  Although prokaryotic 
cells are the most productive hosts for soluble proteins, they often do not possess the machinery 
required to produce membrane proteins in the correct conformation with suitable posttranslational 
modifications51.  Low success rates with prokaryotic cells are also often caused by toxicity 
induced by overexpressed levels of foreign membrane proteins52.  Although there have been 
success stories where inclusion bodies were used to produce high levels of membrane proteins in 
E.coli53 and cell-free E.coli based expression systems54, there is an extensive amount of work 
required to find the correct conditions for refolding membrane proteins into stable and functional 
conformations. 
Recombinant expression of human genes in eukaryotic mammalian cells is therefore a more 
appropriate system to use, but the yields generally obtained remain too low for studies involving 
molecular methods. GPCRs for example can be obtained in  ranges from 10 - 100 fmol/mg of 
tissue55, and the lack of purification and solubilization techniques makes it difficult to purify 
them in abundant amounts from natural sources56. Alternative eukaryotic cells which can produce 
sufficient amounts of membrane proteins for molecular methods include baculovirus infected 
insect Sf957 and yeast58 cells. The latter was quite a novelty because it proved that, against old 
beliefs, some GPCRs can be fully functional without glycosylation which is incompatible with 
crystal formation, and could be produced in high enough levels to be put through crystallization 
trials.    
There is clearly much effort toward overexpression of membrane proteins in high quantities, 
but the challenge is far from over, for mimicking the native membrane qualities in vitro is the 
most challenging of all, and has to be faced in each step of the process from membrane extraction 
to protein solubilization, and, if required by the molecular method, functional and stable 
immobilization. 
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Membrane mimics for in vitro handing of membrane proteins 
 
The native membrane which surrounds each living cell is constituted of a lipid bilayer and an 
array of proteins, either transmembrane or associated with the membrane, which function in 
concert to create, organize, and complete cellular processes.  The membrane does not only enable 
compartmentalisation of the cell’s inner processes and components, but it is actively involved in 
regulating these processes by interacting with the associated proteins59.  Although we have begun 
to understand this important role, elucidating each complex interaction between the different 
components of the membrane and individual membrane proteins is an extremely difficult task at 
hand, for the membrane is a complex system.  For example, lipid rafts are dynamic arrangements 
of lipids and cholesterol which have recently been identified as important players in the 
regulation of membrane receptor activity and localization within the membrane59. To study a 
membrane protein at the molecular level by NMR, crystallography, or SPR, clearly, its isolation 
from this intricate system is required in order to have a pure sample of the protein of interest.   
A membrane protein has a large amount of hydrophobic residues which are in contact with the 
phospholipids in the native membrane and it is estimated that the free enthalpy cost of 
solubilizing a membrane protein in water would be in the range of 150 – 200 kcal/mol60. Thus, 
when a membrane protein is removed from its native environment, the hydrophobic domains 
which were stabilized by phospholipids will be attracted to each other, causing the protein to 
collapse and precipitate. This is why it is crucial that all steps leading from initial extraction from 
the membrane to purified protein is meticulously carried out so that the target protein is 
reconstituted in a synthetic lipid environment which mimics the characteristics of the native one 
as closely as possible61.  Which strategies to use depends on the individual protein: some may 
remain stable only in the native membrane, while others may be reconstituted in the simplest 
synthetic forms.   
Approaches for solubilizing membrane proteins in vitro require the presence of amphipathic 
molecules which mimic the membrane phospholipid properties by presenting hydrophilic head 
groups to the aqueous buffer, while maintaining contacts to the proteins’ hydrophobic residues 
with the hydrophobic tail groups.  These approaches range from simple addition of high 
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concentrations of ionic or zwitterionic surfactants such as detergents or lipids in water to create 
micellar or bicellar vesicles in all handling steps61 to very complex protocols involving the fusion 
of various mixtures of detergents/lipids to form a more stable and better mimic of the membrane 
in lipid bilayers for example.  The most popular detergents include alkyl glucosides and 
maltosides, polyoxyethylenes, alkyldimethylamines, and cholate derivatives such 
dodecylphosphocholine (DPC)52 with which micelles are formed when the surfactant is in a 
higher concentration than its critical micellar concentration (CMC). Below the CMC, the 
equilibrium shifts from micellar to monomeric forms of detergent, thereby causing loss of protein 
conformation and functionality as the proteins precipitate in the absence of stabilizing micellar 
formations.  Often, detergents are used to extract membrane proteins from the native membrane, 
because they are good at dissociating lipids from proteins60.  While some proteins can continue to 
be handled in these detergents throughout the purification procedure until the final sample for 
crystallization, NMR, or immobilization for SPR, others require a more stable lipidic 
environment in bicelles (micelles formed of lipid bilayers) or bilayers. Molecular methods have 
therefore been difficult to apply to membrane proteins because the environment which keeps a 
protein stable may not be compatible with the application we one wishes to use to study the 
protein.   
Detergent micelles often lead to undesirable effects such as low stability or even denaturation, 
aggregation, and separation of subunits from multimeric formations52.  This low stability is 
clearly incompatible with NMR and crystallography as the dynamic processes lead to difficulties 
in obtaining high resolution NMR data and loss of the initial ‘true’ protein structure, and prevents 
crystals from forming.  Furthermore, detergent micelles can be too large upon solubilization of 
membrane proteins to successfully apply NMR61.  The high levels of detergents necessary to 
maintain protein conformation can lead to unwanted signals and interactions, such as non-specific 
binding to the compounds used in drug discovery during SPR or solution NMR screening 
applications.  
Although detergent micelles have been used successfully in applying NMR to the structural 
determination of the outer membrane protein A in DPC53 and the Disulphide bond forming 
protein B62, the use of more stable lipid formations such as lipid bicelles63 and lipidic cubic 
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phases64,65 are required for crystallization. Strategies are also evolving to include immobilization 
of detergent or lipid solubilized membrane proteins onto solid supports for SPR66 or solid state 
NMR67 applications.  However, although these applications have enabled structural determination 
of membrane proteins, they are limited to proteins which are obtainable in high amounts, such as 
bacterial membrane proteins, or require great efforts into finding the appropriate solubilization 
condition which is both appropriate for protein fold and functionality, but also compatible with 
the method. When drug discovery is involved however, more difficult targets such as GPCRs and 
ion channels are involved, which often call for delicate dimerizaton states or the presence of other 
players in the membrane (G proteins) for a full read out of the activity.  Furthermore, the 
synthetic membrane mimics often lead to surfaces to which fragments bind non-specifically. For 
all these reasons, to date, there have been no successful applications of fragment based drug 
discovery to membrane proteins. 
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New alternative solubilization strategies for membrane proteins in aqueous 
buffers 
 
Although there have been important 
developments contributing to more stable 
membrane proteins in vitro (better control 
of the expression systems69, mutagenesis 
of key residues for higher protein 
stability70 and better solubilization 
techniques71), these all require the presence 
of detergent. The self-assembly of 
membrane proteins in new solubilization 
alternatives such as the amphipols72 or the 
Nanodisc68 complex (Figure 7), however, 
enables handling of membrane proteins in 
aqueous buffers without needing to add 
surfactants to maintain a hydrophobically 
stable environment.  
The Nanodisc procedure consists of mixing lipids which are solubilized in mixed micelles with 
cholate, and a 23 kDa amphiphilic -helical membrane scaffold protein (MSP) to the targeted 
detergent-solubilized membrane protein to be incorporated into the complex. When these entities 
are mixed together, the lipids, detergents, and cholate form mixed micelles around the MSP and 
the target protein.  
Upon removal of detergents, by dialysis or the addition of detergent adsorbing bio-beads, the 
target membrane protein, the lipids, and the MSP hydrophobic residues self-assemble into the 
nanodisc formation. When the appropriate conditions are met, which are different for each target 
membrane protein to be incorporated, the target protein is solubilized in the center of a lipid 
bilayer which is consequently stabilized by two monomers of MSP with the hydrophobic residues 
 
Figure 7. Self-assembly of Nanodisc complexes, 
reproduced from reference 68 with permission. 
Copyright 2003 Biotechniques.  The detergent 
micelles of the target protein are replaced by a stable 
lipid bilayer surrounded by the amphiphilic MSP 
upon detergent removal.  The resulting nanodisc 
complex is fully soluble in aqueous buffers.  
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making contact with the lipids. Due to the amphiphilic nature of the nanodisc, the final complex 
can be handled in aqueous buffers without causing conformation or functional loss of the 
embedded target protein and without requiring any presence of surfactant in the buffer. This 
enables easy purification and has the potential to be applied to fragment based drug discovery 
without causing non-specific binding of ligands to the nanodisc complex. 
The nanodisc technology has been successful in embedding a variety of membrane proteins 
such as Bacteriorhodopsin73, the GPCR -adrenergic receptor74, and the metabolically important 
cytochrome P450 (CYP)75. The nanodisc system was also previously used to measure redox 
potentials on CYP3A4 in the absence and presence of substrates at the active site76. Although the 
procedure of incorporation depends on every target protein and the initial solubilization state of 
the target protein, the resulting homogenous and standard preparations, void of any surfactant and 
stable in aqueous buffers, may bridge the gaps which prevent molecular methods from being 
applied to membrane proteins. 
 
How can Target Immobilized NMR Screening address limitations posed by 
membrane proteins? 
 
Target Immobilized NMR Screening is, as its name indicates, is a FBDD method which 
screens an immobilized target for fragment binding using solution NMR.  The method involves 
immobilization of a target protein and a reference protein on an aldehyde resin with a mild 
Schiff’s base chemistry between the primary amines of the protein and the aldehyde groups 
present on the commercially available resin. A flow-injection, dual sample holder can be placed 
in the magnet to enable flow-mediated screening of fragments by automated injection of mixtures 
containing upto 8 fragments over the immobilized proteins. This method enables fragment based 
drug discovery on membrane proteins for the following reasons. 
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Immobilization allows efficient use of the target protein  
 
With the target and reference protein immobilized, a single screen of 1000 fragments can be 
carried out on one single sample of protein. Naturally, because a full screen can last 
approximately 5 days, the sample may need to be replaced if the protein shows signs of low 
stability. However, the amounts required are fairly low (50 – 100 nmoles).  This procedure is 
generally applicable to other membrane proteins because of the simple and mild Schiff’s base 
chemistry used to immobilize the protein N-terminus to the aldehyde groups on the resin23, and 
because it is compatible with the use of detergents. 
 
NMR detection of fragment signals rather than protein signals 
 
TINS focuses on the 1H 1D spectra of fragments in solution77. The difference in intensities of 
these fragments’ peaks between the presence of an immobilized target protein and the presence of 
an immobilized reference protein allows one to identify if a fragment has bound to the target. The 
fact that the method directly observes differences in fragment signals in solution means that there 
is no necessity to produce isotopically labeled proteins and there is no a priori requirement for 
the protein structures to be well resolved, as is necessary in other NMR target-based screening 
methods. Furthermore, compared to other ligand based screening methods, there is no need to 
deconvolute the signals, because mixtures are designed to be composed of ligands with a 
minimum of overlapping peaks. 
 
The reference system accounts for non specific binding of fragments to detergents 
 
When TINS is applied to soluble proteins, the level of non-specific binding to the target protein 
can be accounted for by simultaneously screening a reference protein of a relatively similar size 
which has limited small molecule binding properties.  With membrane proteins however, the 
presence of detergent leads to non-specific interactions with the fragments both in solution and 
upon contact with the immobilized, detergent solubilized protein.  It is easy to predict that the 
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amphipathic nature of the detergents can partially solubilize the fragments (which are relatively 
soluble yet also composed of hydrophobic moieties) out of solution and temporarily into 
micelles.  To minimize such interactions, the appropriate trade-off can be met, by adding 
detergent into the wash buffer but not into the independent fragment mixtures, provided the 
fragment mixture injection does not dilute the effective micelle concentration below local CMC.  
As stated, this minimizes interactions between fragments and detergents, but can not be 
eradicated due to the loss of protein functionality which would follow. Therefore, there remains a 
substantial amount of partial solubilization of fragments into the detergent micelles, with the 
effect of reducing their effective concentrations and hence, their final intensities in the NMR 
spectra. The reference membrane protein must therefore not only have minimal small molecule 
binding properties, but it must be refolded in the same detergent conditions as the target protein 
in order to obtain a reliable reference system.   In our case the outer membrane protein A (OmpA) 
(Figure 8a) which can be folded properly in a variety of detergents72,78,79, was found to have 
minimal small molecule binding. This reference system is theoretically applicable to membrane 
proteins and removes signals from fragments which are only non-specifically binding to the 
detergent micelles.  To minimize signals from detergents with a high CMC, deuterated forms can 
be used, provided they are available. 
 
Alternative immobilization and solubilization methods can be easily adapted 
 
TINS can be easily adapted to different immobilization chemistries and membrane protein 
solubilization strategies, provided the appropriate resin is used.  In our case, the sepharose 
aldehyde resin has proven to be compatible with the system by having a minimal line broadening 
effect on the fragment 1H 1D spectra. A variety of chemical linkers exist which can be used to 
tailor the immobilization chemistry based on the requirements for functional immobilization of 
the target protein, such as targeting the C-terminus when the N-terminus is involved in protein 
functionality.  Naturally, the immobilization chemistry has to be compatible with the detergents 
or alternative solubilization materials used to maintain the correct fold and functionality of the 
membrane protein. nanodiscs, as an alternative solubilization strategy to DPC micelles, have 
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potential to be immobilized to the same resin through the N-termini of the scaffold proteins.  We 
envisaged therefore that TINS would be compatible with screening membrane proteins embedded 
in nanodiscs in the absence of detergents, providing a more stable environment for the target 
protein without the disadvantages of non-specific binding interactions of fragments with 
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The aim of this thesis:  
To develop methodologies which enable the application of molecular methods for 
drug discovery on membrane proteins. 
 
With increasingly perceptive methods for solubilizing and immobilizing membrane proteins in 
functional ways, the different direct or indirect, random or oriented immobilization strategies are 
reviewed in Chapter 2. Attention is paid to a variety of applications such as chromatography, 
fluorescent and radioligand based applications, as well as molecular methods such as NMR and 
SPR. 
 
Prior to starting a TINS screen, we first wanted to test the functionality of an important class of 
membrane proteins, the GPCRs. Knowing how important the native membrane is for GPCR 
functionality, we aimed at testing functional immobilization of the human histamine H1 receptor 
and the human adenosine A1 receptor within the native membranes from stable cell lines 
overexpressing these receptors.  Radioligand binding studies of the receptors in solution were 
compared to the receptors upon immobilization within their native membrane vesicles in the 
presence of physiologically relevant G proteins, as described in Chapter 3. 
The H1 receptor mediates a variety of cellular processes which, upon faulty signalling, are at 
the heart of many diseases affecting children and adults today.  These include immunological 
responses80 such as allergies and asthma, as well as eating disorders such as anorexia81. 
Furthermore, antihistamines which are used as potent blockers of histamine induced allergic 
reactions provoke drowsiness due to the additional role of the H1 receptor in regulating sleeping 
behaviour82. The A1 receptor is just as important a pharmaceutical target as the H1 receptor, 
because of its role in the central nervous system as a regulator of adenosine and hence, the 
physiology of many tissues. The adenosine A1 receptor is ubiquitously found in the whole body 
and is at the heart of processes leading to asthma, chronic inflammatory problems, and heart 
failure83 in addition to, when located in the central nervous system, many types of 
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neurodegenerative diseases84.  It has also been reported to form dimers with itself or the 
dopamine receptor85.  Both receptors belong to the Class A of GPCRs and generally bind small 
ligand molecules, thereby making them a priori appropriate targets for fragment based drug 
discovery. Although the structures for these particular proteins do not exist, the homology with 
other known structures currently enables in silico studies of ligand binding interactions86. 
 
Currently TINS has been explored on soluble proteins. We wished however to prove the 
concept that detergent solubilized membrane proteins could practically be screened by the TINS 
methodology as well.  In Chapter 4, we carried out an initial pre-screen on a bacterial ion 
channel, the potassium ion channel KcsA, and a bacterial membrane enzyme, the Disulphide 
Bond Forming protein B (DsbB) with, as a reference, the immobilized bacterial Outer Membrane 
Protein (OmpA) also solubilized in DPC. 
The reference protein, located in the outer 
membrane of bacteria, is a -barrel 
transmembrane protein (Figure 8b), which has a 
variety of roles leading to pore formation, 
adhesion, invasion, formation of biofilms, and as 
a receptor for several types of bacteriophages87. 
However, these functions are related to the 
extracellular domain of the protein. We believed 
that the transmembrane domain, which has also 
been studied by NMR53,72 and 
crystallography88,89, however, has minimal small 
ligand binding and could act as a reliable 
reference protein to account for non-specific 
binding of fragments to the detergent micelles 
due to its similar size and appropriate fold in 
DPC micelles.   
 
Figure 8.  Structures of the target and reference 
proteins used in the TINS screen.  DsbB has -
helical transmembrane domains (a) while OmpA 
has a -barrel transmembrane domain (b).  The 
structures are modified from pdb IDs 2k7362 and 
1g9053 respectively. 
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Both target proteins for this TINS pre-screen are from bacterial origin, enabling us to obtain 
sufficient amounts for initial development of the protocol needed to adapt the TINS procedures to 
membrane proteins.  Furthermore, the crystal and NMR structures of KcsA90,91 and DsbB62,92 are 
available, enabling future studies of protein-ligand interactions on these pharmaceutically 
important proteins. DsbB is a bacterial membrane protein target (Figure 8a) which has 
pharmaceutical importance due to its role in disulfide bond formation and subsequent regulation 
of protein toxin folding leading to the virulence of Gram negative bacteria such as E.coli93 and 
Bordetella pertussis94.  KcsA is a model protein with high homology with human potassium 
channels which are important pharmaceutical targets due to their role in regulating potassium ion 
transport through the cell membrane.  As such, human potassium channels, are targeted by 
anaesthetics and drugs which partially alleviate autoimmune and neurodegenerative diseases95. 
On the other hand, ion channels are often non-specifically and unexpectedly targeted or blocked 
by drugs, causing severe secondary side effects.  An example of such a challenging  protein is the 
human ether-a-go-go related gene (hERG) potassium channel which regulates the potassium 
potential in cardiac myocytes96.  Drugs not related to the cardiovascular system have been 
removed from the market because they either blocked the hERG channel activity by non-
specifically binding to the large inner binding pocket, or by blocking its traffic to the cell surface, 
both leading to irregular (and potentially fatal) repolarization of the cardiac muscle97,98. It would 
therefore also be valuable to carry out parallel screens on liable targets such as the hERG channel 
in order to predict and avoid future drug candidates’ interactions.  
                                                                               
With the proof of principle validated on membrane proteins, we carried out a full screen on the 
pharmaceutically important DsbB with OmpA as a reference, in DPC micelles. The identification 
and validation of the hits on the membrane enzyme DsbB were possible due to an existing robust 
enzymatic assay which relies on the detection of substrate oxidation or reduction99.  A soluble 
partner protein DsbA becomes oxidized in the presence of DsbB and the synthetic DsbB cofactor 
ubiquinone (UQ1).  The enzymatic turn-over rate of DsbB can therefore be compared in the 
presence of fragment hits in order to validate their inhibitory effect on this target protein.  The 
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results of the enzymatic assays, along with confirmation of the binding modes of fragments by 
orthogonal biophysical assays (by solution NMR Heteronuclear Single Quantum Correlation) are 
described in Chapter 5. 
 
The possibility of carrying out TINS on DsbB in aqueous buffer completely void of surfactants 
was tested using the nanodisc system, whereby the membrane proteins can be solubilized in a 
lipid bilayer stabilized by a belt of two amphiphilic membrane scaffold proteins.  The results of a 
short screen on nanodisc-solubilized DsbB was tested using two references, nanodisc-solubilized 
OmpA and empty nanodiscs, containing only lipid bilayers and the amphiphilic scaffold proteins.  
The results are described in Chapter 6. 
    
Finally, a conclusion section is presented in Chapter 7, including perspectives regarding the 
future of membrane protein research when applying biomolecular methods in drug discovery. 
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Biological and pharmaceutical studies of proteins often require their immobilization on surfaces, 
and although techniques exist for soluble proteins, such applications to membrane proteins 
present challenges.  This review focuses on immobilization procedures which have been 
successful in coupling membrane proteins in a functional state. The review follows a 
technological approach. We focus on how the protein is immobilized to the surface, with 
descriptions of the various linkers used, and how specific the chemistry is.  We cover a range of 
applications including whole cell assays, radioligand binding, frontal chromatography and 
electrochemistry, as well as biophysical assays including impedance spectroscopy, plasmon-
waveguide resonance spectroscopy, nuclear magnetic resonance and surface plasmon resonance 
with special attention to which surfaces are compatible with a given technique.  Also included are 
fluorescence based assays, such as total internal reflection fluorescence and fluorescence 
microscopy.  A brief description1of the studies allowed by each immobilization strategy follows 
each section, including important results that demonstrate the feasibility. 
 
                                                          
1  This chapter has been recently submitted as a review: Virginie Früh, Ad. P. IJzerman, and Gregg 
Siegal. How to catch a membrane protein in action: A review of functional membrane protein 
immobilization strategies and their applications.  Chemical Reviews. Submitted 2009. 
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Analysis of the results from the human proteome project suggests more than 30 % of proteins 
are membrane-bound67.  Membrane proteins (MPs) are in the core group responsible for signal 
transduction, including the G-protein coupled receptors (GPCRs), which represent 30 – 40 % of 
marketable drug targets today100.  It is needless to stress, therefore, the great commercial, 
industrial, and research value of MPs.  There is growing interest in immobilizing MPs to various 
surfaces to create new biosensors or platforms enabling the study of their biological functions and 
identification of new leads for drug discovery. Soluble proteins have been readily immobilized 
through cross-linking aldehydes or thiols with protein amines or carboxyl groups for applications 
such as micro-arraying by printing101,102,103,104. Functional immobilization of MPs requires 
consideration of their physiological needs, often dictated by the quality and components of the 
natural hydrophobic environment surrounding this class of proteins.  The aim of this review is to 
focus on the immobilization chemistry applied to MPs and how these have enabled ever more 
complex assays from simple whole cell analyses to purified proteins on a chip, from the 1990s to 
2008.   
With MPs, often the challenge is not the immobilization per se, but rather the requirements of 
the analysis and the protein itself with regards to protein availability and the type of lipid 
environment needed. Earlier studies of MPs, due to the difficulty in purifying them, involved 
whole cell or membrane fragment immobilization where native biological responses could be 
followed by ‘macroscopic’ methods such as frontal chromatography (Section 1). In these studies 
immobilization was accomplished by simple techniques such as incorporation of  membrane 
fragments upon swelling of gel beads during freeze-thawing105,106 or by coating beads with 
various cell-adhesive substances107.  Although these systems allow one to study the native 
environment, the immobilization itself is random and relatively unstable. Furthermore, reliable 
signal detection is often limited by high levels of non-specific binding to the environment around 
the target MP.   
Solubilized MPs may be either used as such in detergent micelles, or reconstituted in various 
types of detergent or lipid formations108,109,110.  With recent advances in the development of 
mimics of the native membrane however, the stability and formation of various lipid assemblies 
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is becoming less problematic. However, one can not emphasize enough how challenging these 
steps are.  Removing the protein from its hydrophobic environment and reconstituting it into 
another is a difficult process that may damage the protein or result in less than optimal 
functionality68,107. Furthermore, increasing complexity arises with increasing numbers of 
transmembrane segments111. The most successful stories are currently based on the nicotinic 
acetylcholine receptor and rhodopsin, due to the availability of these MPs in large quantities and 
relatively good stabilities. Newer membrane mimics have allowed direct adsorption of 
appropriately prepared MPs to flat surfaces or chips made of glass, platinum-glass, and platinum-
silicon to create monolayers of lipids which hold the protein onto the surface (Section 2).  
Subsequent strategies have evolved to create even more stable lipid bilayers, as opposed to less 
stable monolayers, by fusing various types of solubilized MPs to lipid monolayers on surfaces.  
These methods provide more robust immobilization, applicable to more sensitive studies, 
provided fluorescently or radioactively labeled components are available to specifically monitor 
MP activity. As a result, the highly sensitive detection of such signals does not require large 
amounts of solubilized MP.  As these methods were applied to increasing numbers of MPs, it 
became clear that immobilizing membranes or mimics too close to a surface may restrict 
diffusion of solutes below the membrane, and sterically hinder extramembranous protein 
dynamics.  As a result, so-called solid-supported membranes have been developed, where the 
space below has been filled with hydrophilic polymers, combined with various linkers, to 
immobilize the MP in a manner that accommodates dynamic behavior. Solid-supported 
membranes are a better mimic of the natural environment because they create additional 
membrane fluidity and allow for mobility of large extramembranous protein domains112 (Section 
3). Many of these techniques have evolved in such a way that solubilization and purification of 
the protein may not be a prerequisite, but when this is the case, the solubilization from crude cell 
lysates or lipid reconstitution may be carried out in situ (Section 4).   
On the detection side, earlier assays primarily used biological readouts. Although these 
techniques were sufficient for high throughput or high content assays of, for example, ligand 
binding and cell signalling activation, they typically required labelling of a protein or ligand to 
produce a signal. Recently newer, so-called label-free technologies, have emerged, such as SPR 
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and NMR77, that are able to directly detect ligand binding thereby rendering use of chemically, 
biologically, or radioactively labeled protein or ligands redundant.  These technologies are 
sensitive to intermolecular interactions and capable of detecting weak binding affinities in the 
mM range (for NMR), provided the target protein is available in sufficient quantities and 
functionally solubilized. As opposed to soluble proteins, MP interactions with ligands, lipids, or 
other proteins are often specifically located on one side of the cellular membrane.  Some 
strategies have therefore been taken one step further by using high-affinity interactions for 
specifically orienting MPs in the immobilized membrane on chips (Sections 5-7). Techniques 
involving in vitro expression in the presence of the tethered lipid membrane in which the protein 
will be integrated directly upon expression113 are an elegant way to achieve oriented, 
immobilized MPs.  
As strategies to couple MPs become increasingly perceptive, a thorough summary of the 
numerous accomplishments is useful.  Here, we present such a summary in the form of text, 
tables, and a glossary (see p. 42 for table of contents), which focus on the chemistries of various 
immobilization types, with descriptions of their applications and results.  
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1.  Non-covalent interactions with the whole cell 
 
Via wheat germ lectin-agarose for whole cell immobilization –MP: Glucose transporter 
Glut1 
   
Frontal chromatography can be used to study interactions between a mobile 
phase and a stationary phase by regression analysis of the retention volumes.  
Furthermore, when whole cells are immobilized, this technique can allow the 
study of binding affinities of soluble ligands to MPs in their native 
environment.  Immobilization can be achieved by adhering whole cells to agarose gel beads via 
wheat germ lectin (WGL)107,114.   
WGL is a derivative of wheat germ agglutinin and binds to N-acetylglucosamine and to N-
acetylneuraminic acid on the extracellular face of red blood cell membranes115. The Glut1 
transporter targeted for these assays was indirectly immobilized to Sepharose 4B gel beads 
prederivatized with WGL by simply incubating cells overexpressing the receptor with gel 
beads115. The interaction of Glut1 with D-glucose and cytochalasin B (CB, a fungal alkaloid that 
inhibits glucose transport) was measured by frontal chromatography. The Kd values of Glut1 
binding of CB and D-glucose were comparable to values previously reported from studies on 
whole cells and membrane vesicles.  These immobilization methods also allowed one to compare 
the Kd of Glut1 for CB and D-glucose for different types of preparations of the reconstituted 
receptor, without any effects on the affinity.  The advantage of this technique was that cells 
remained intact, in contrast to electrostatic adsorption which causes hemolysis114.  The gel beads 
could be stored for one month, but lost 40 % of their capacity to bind cells.  It was reported that it 
was not cell integrity but rather the capacity of cells to bind to the gel (and therefore the 
remaining functionality and density of membrane glycophorins) which determined the stability of 
the column, along with physical and chemical properties of the storage environment.  Another 
advantage was that protein purification was not necessary, and manipulations involving column 
preparation and cell immobilization were simple. Nevertheless, the immobilization was sensitive 
to pressure changes, and gentle washing induced detachment of the cells, causing loss in 
WGL 
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reproducibility.  Using this immobilization strategy with other applications will depend on 
conditions for cell homeostasis and functionality, as this technique was only optimized with 
respect to haematocyte cell lines.   
 
2.  Non-covalent interactions (adsorption) with the membrane 
 
2.1 Via interactions of the native cell membrane with poly-Lysine: GPCRs and ion channels 
 
Studying whole cells by fluorescence often leads to high background signals 
from the cytoplasm. This issue, combined with limited access to the 
intracellular compartment, obscures many of the dynamic processes between 
the membrane leaflets.  To circumvent this, supported cell-membrane sheets 
allow one to observe target proteins from the intracellular side when both leaflets of a cell 
membrane are physically pulled apart116,117.  
The ligand-gated ion channel 5-HT3 receptor and the 1B-adrenergic receptor were both 
overexpressed in HEK-293 cells which were grown on poly-L-lysine (PLL) coated plastic.  
Another PLL surface was pressed down onto the cells and removed after several minutes of 
contact, ripping apart the cells and exposing the membrane’s intracellular face with endogenous 
lipids and proteins.   To visualize the target lipids and proteins, the latter were expressed as 
fusion constructs with fluorescent proteins and the former were colocalized with fluorescent lipid 
markers. The supported poly-lysine membrane sheets have also been modified to allow access to 
the extracellular side by pressing down Silicon nitride surfaces into which arrays have been cut 
out118.  
Labeling with fluoresecent probes from different sides of the membranes enabled the authors to 
study the mobility of lipids, GPCRs and G proteins within and between the leaflets117.  Following 
the dynamics of heterotrimeric G protein partitioning into lipid anchor microdomains was also 
possible along with the mobility regimes of glycosylated transmembrane proteins.  Competition 
binding studies using fluorescent ligands confirmed the functionality of the proteins studied and 
the success of the technique. 
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In comparison to whole cell analyses, the advantages of supported cell-membrane sheets are 
numerous.  The mechanical stability is excellent, minimizing unwanted movement of the 
observed membrane upon application of stimuli, which can be problematic for e.g. imaging 
applications. Although labeling is required, specific targets can be observed in their native 
surroundings even maintaining the appropriate orientation, while all the time monitoring cellular 
processes such as signaling and protein translocation.  Following populations of labeled proteins 
was therefore possible as a direct result of removing the intrinsically highly fluorescent cytosol 
during the preparation of these membrane sheets.  This strategy is generally applicable to all cell 
membranes, but is restricted to the use of labeled ligands or proteins. Adapting the 
immobilization to metallic surfaces may allow the strategy to be applied to surface plasmon 
resonance applications. 
 
2.2 Via hydrophobic interactions of attoliter size native vesicles with glass slides: Ion 
channel 5-HT3 receptor 
 
Obtaining large amounts of MPs is often limiting and therefore 
immobilizing miniaturized vesicles containing the target protein can be useful 
for studying receptor-mediated cellular responses. In this particular case, the 
authors have been able to produce vesicles straight from the native membrane 
of mammalian cells, with unprecedented attoliter volumes119. The vesicles can be immobilized in 
different manners, either through direct lipid adsorption to glass slides or via biotinylation of 
membrane components or target proteins120,121.   
Attoliter vesicles can be obtained in one step, without changes in receptor function, orientation, 
or localization in the membrane.  Vesicle formation is a simple process induced by incubating 
cells, in this case expressing the serotonin-gated mouse ion channel 5-hydroxytryptamine type-3 
receptor (5-HT3R), with CB. This causes cells to produce tubular extensions which bud off when 
agitated. Native vesicles were thus formed that could be separated from whole cells by 
centrifugation. Usefully, the vesicles could be stored at 20 °C for weeks without causing loss of 
receptor function. Co-expression of cytosolic green fluorescent protein resulted in the possibility 
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to monitor and characterize vesicle formation and the presence of cytosolic components.  Specific 
binding of fluorescently labeled ligands could be used to locate the receptor in the vesicles, and 
radioligand binding assays revealed their appropriate orientation and function.  Furthermore, 
agonist and antagonist ligands showed the same behavior with vesicles as with detergent-
solubilized receptors. Finally, Ca2+ signaling within the vesicles upon agonist activation could 
also be detected, suggesting the functionality of the complete signaling pathway.   
These micrometer-sized vesicles are novel miniaturized reaction centers where receptor-based 
assays can be carried out in physiological conditions. These experiments not only revealed the 
native function of the receptors within these vesicles, but also proved that other important players 
such as ion pumps are still present and functional.   Vesicle formation yielded native behavior 
when tested with CHO or HEK293 cells, suggesting this procedure can be generally applied to 
other cell strains. When fluorescent ligands are available, these miniaturized and stabilized 
compartments can provide the basis for high throughput assays where patterns of immobilization 
can reveal receptor function and binding affinities depending on various tailored reactive groups.  
 
2.3  Via membrane hydrophobic interactions on beads – nicotinic Acetylcholine receptor 
 
Radioligand binding assays are often used to quantify binding affinities of 
ligands to MPs because only picomolar amounts of protein are required. 
However, this requires separation of bound from unbound ligands. To 
circumvent this, the scintillation proximity assay system (SPA)122,123 was 
developed, where receptors are immobilized on solid microspheres that contain scintillation fluid. 
This homogenous assay provides specific information on radiolabelled ligand binding without the 
need for separation from unbound ligand, as scintillation is only stimulated by radioligand in 
close proximity to the microspheres124,125.   
As a first attempt to apply SPA to MPs, membranes containing acetylcholine receptor were 
isolated from the electric organ of Torpedo californica and directly added to polyvinyltoluene 
fluorophore microbeads previously suspended in Triton X- 100.  Under these conditions, the 
membrane preparations spontaneously adsorbed to the beads. These beads contained scintillation 
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fluid and upon binding of the radiolabelled ligand to the receptor, the close proximity of receptor 
led to photon emission proportional to the amounts of immobilized protein.  In addition to 
obviating the requirement for separation of unbound from bound ligand, this method has less 
non-specific binding than usually encountered in radioligand binding assays. Radioligand binding 
assays of 125I-α-bungarotoxin to the acetylcholine receptor enabled the study of various 
parameters such as dose response of acetylcholine and suberyldicholine with respect to 
radiolabeled α-bungarotoxin binding, providing apparent Ki values. The effects of different 
parameters such as concentrations of detergents and salts on the activity of the receptor were also 
studied, along with the detection of specific antigens by antibody binding.   
SPA has a number of other advantages for MPs. Due to the great sensitivity of scintillation 
counting, as little as 1 ng of receptor can be detected. Although SPA requires prior radiolabelling 
and modification of the protein or ligand, many receptor-SPA beads are available commercially. 
The method has been used in a broad range of studies, varying from identification and 
quantification of PCR products126 to high throughput screening of inhibitors of DNA binding 
proteins127,128 to studying interactions between antibodies and antigens129. Finally, due to the 
simplicity of the immobilization procedure, it should be generally applicable to all MPs. 
 
2.4 Via steric trapping of membrane vesicles – MP: Glucose transporter Glut1 
 
Quantitative affinity chromatography used to be limited to studying 
interactions between soluble substances. By immobilizing a membrane protein 
on gel beads, however, binding of soluble substances to MPs could be 
quantified by regression analysis of the retention volumes for different 
concentrations of ligands. In order to study interactions between soluble substances and the 
glucose transporter Glut1, membrane vesicles containing the latter were immobilized onto gel 
beads105,106. Membrane vesicles were obtained by stripping red blood cells of peripheral proteins 
and partially solubilizing them with octylglucoside (OG). In some cases, the vesicles were 
purified by ion-exchange chromatography for reconstitution of the Glut1 transporter into 
proteoliposomes130. It has been reported that freeze-thawing131 and freeze-drying with subsequent 
Freeze 
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rehydration132 can cause vesicles or proteoliposomes to fuse together and form larger particles. 
This approach was used to sterically trap vesicles after two cycles of freezing in ethanol/CO2 and 
thawing in the presence of gel beads105. Using the sterically trapped liposomes, specific 
interactions between Glut1 and CB, and between Glut1 and D-glucose133 were observed.  Ligand 
binding affinities and kinetics were easily studied with such a set up due to lower non-specific 
binding to the lipids in vesicles compared to whole cells. Immobilized membrane vesicles had 4 
times more transport inhibitor (CB) binding capacity than proteoliposome gel beads, showing 
that the membrane vesicles contained a high density of Glut1.  In the presence of dithioerythritol 
(DTE), the binding capacity of CB was more than 80 % stable after 20 - 40 days in all types of 
columns studied.  Furthermore, the activity could be controlled by inhibiting Glut1 with HgCl2 
and restoring Glut1 activity by adding DTE, which has an effect of partially reversing the Hg2+ 
inactivation.  
Steric trapping should enable other applications such as studies of effects of ionic strength, pH, 
temperature, and lipid composition on ligand binding characteristics. This methodology has the 
potential, as do other whole cell or membrane fragment-based applications, of enabling studies of 
interactions occurring within the native membrane because of the presence of other components 
within the membrane.   However, applications of this immobilization strategy remain limited to 
the use of gel beads for steric trapping of the swelled vesicles, where high amounts of protein per 
mg of membrane are required for sensitive read outs. Furthermore, the non-covalent 
immobilization leads to degradation during use, and, clearly, the protein to be studied needs to be 
stable to multiple freeze-thaw cycles. 
 
2.5 Via direct lipid distribution on glass cover slides -MP: fd coat protein and FXYD 
proteins. 
  
The biological role of the protein coating filamentous fd bacteriophages (fd 
coat protein), involves interacting with the host’s cellular membrane. Three-
dimensional structure determination is a powerful method to determine 
molecular mechanisms of protein function.  However, in many cases solution 
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NMR studies of an MP in detergent micelles will not provide sufficient information because the 
dynamics and orientation of the protein in detergent micelles may be very different than in a 
membrane bilayer. Therefore, the fd coat protein was immobilized onto glass slides in 
phospholipid bilayers with one simple step for structural studies using solid-state NMR67.    
For these studies 15N-labeled fd coat protein was produced in E. coli and solubilized in 
detergent micelles.  The solubilized fd coat protein was then reconstituted into phospholipid 
vesicles consisting of a mixture of POPC/POPG134.  Glass slides were covered with the vesicle 
suspension containing the reconstituted protein and the bulk water was left to evaporate. The 
slides were then stacked and bathed in saturated ammonium phosphate solution.  Finally the 
slides were placed in thin polyethylene tubing and inserted into a rotor for NMR studies which 
allowed complete resolution of the amine resonances in a 3D magic angle spinning (MAS) NMR 
correlation spectrum. The choice of lipids determines the level of bilayer orientation on the slides 
and allows control over the horizontal and vertical spacing between phospholipids109. The 
presence of unsaturated chains leads to more fluid bilayers, and larger vertical spaces between 
bilayers can be obtained by incorporating negatively charged lipids109. The non-covalent, 
hydrophobic interactions with the glass were strong enough to hold the vesicles immobile on the 
substrate for the duration of an NMR experiment, despite the considerable shear forces generated 
by spinning the sample. No details were given on the protein stability or functionality, but it was 
fully incorporated into phospholipid bilayers onto the glass support.  This immobilization 
strategy allows a wider range of MPs to be studied by solid-state NMR, and may be used in other 
applications compatible with glass surfaces. The extensive vesicle preparation was a complicated 
process however, and may not be generally applicable to other MPs. Although fd coat protein 
could be obtained in relatively large quantities, this is rarely the case with other MPs. Further, it 
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2.6   Via liposome fusion into lipid bilayers on platinum/glass or silicon slides  – 
Bacteriorhodopsin 
  
In order for an immobilized MP to remain functional, the fluid lipid or 
detergent environment must not become too rigid upon immobilization or it 
would impede the MPs dynamic behavior. Lipid rigidification can be 
minimized when proteoliposomes are immobilized by fusion with monolayers 
on glass surfaces to form bilayers without any chemical cross-linking. To demonstrate the 
approach, bacteriorhodopsin from purple membranes of Halobacterium halobium was added to a 
lipid, cholesterol, and octylglucoside mixture, and upon removal of octylglucoside during gel 
filtration, proteoliposomes were formed by the so-called detergent depletion technique135. LB 
lipid monolayers136 were used to treat platinum/glass surfaces, and subsequently converted into 
bilayers when fused with the bacteriorhodopsin proteoliposomes137. Bacteriorhodopsin 
photoactivity in the reconstituted bilayers, monitored by electrochemistry, was comparable to 
natural membrane fragments containing bacteriorhodpsin on platinum surfaces. Three other MPs 
were also studied, including acetylcholinesterase from bovine brain, cytochrome oxidase from 
bovine heart and the nicotinic acetylcholine receptor from the electric organ of Torpedo.  The 
purification and incorporation into proteoliposomes of the three MPs varied depending on 
suitable detergents, but they were all incorporated into stable lipid bilayers following the same 
protocol. Acetylcholinesterase enzymatic activity was easily studied by fluorescence 
measurements despite low immobilization yields, but only semi-quantitative data was available 
for Cytochrome C oxidase, while studies of the nicotinic acetylcholine receptor with its ligand 
125I--bungarotoxin, were hindered by issues of non-specific binding. 
Although this technique provided a surface with a fluid membrane environment, meeting 
criteria for efficient molecular assays and potentially providing access to printing arrays, the 
usual challenge of obtaining functional protein in proteoliposomes remains.  The bilayers did 
remain immobilized to the supports for prolonged periods of time after storage, but no 
information was provided on the stability of the immobilized MPs.  
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2.7 Via microarrayed γ-aminopropylsilane (GAPS)-derivatized surfaces –GPCR: adrenergic 
receptor, neurotensin receptor and dopamine receptor 
 
Reducing the demand for protein and reagents has been one of the strategies 
used to address the limitations faced when MP purification and solubilization 
result in low yields.  This limitation is even more critical when MP 
immobilization is at the heart of high throughput screening for drug discovery.  
An innovative way of addressing both limitations has been to immobilize GPCRs through 
microarray printing assays138,139. A nice example of this technique has been developed at 
Corning. Membranes in vesicular solutions of DPPC and DMPC or egg-yolk PC were printed via 
a robotic-pin printer on γ-aminopropylsilane (GAPS)-derivatized gold surfaces140. The details of 
the methods used with GAPS are proprietary to Corning. GAPS-coated slides exhibited high 
mechanical stability during printing, with no dependence on lipid phases, thereby overcoming the 
desorption encountered when withdrawing the slides through air141.   
While covalently attaching membranes has been noted to impede lateral fluidity of membrane 
lipids, and consequently protein function, non-covalent printing techniques have proved to 
preserve GPCR and G protein functionality.  Thus binding constants of known ligands were 
readily obtained, as well as compound selectivity between and within GPCR families. However, 
the assay in this format could not be used to differentiate between agonists and antagonists. 
Arrays of the 1-adrenergic receptor, the neurotensin receptor (NTR1) and the dopamine (D1) 
receptor have been created. As an example, upon incubation with fluorescently labelled 
neurotensin, fluorescence was restricted to areas in which NTR1 had been immobilized, as 
expected. Binding constants consistent with literature were also determined for known small 
molecule ligands using the printed array112,140. A recent exciting advance in printing is the 
adaptation to porous substrates onto which the membranes are transferred, allowing access to 
both sides of the membrane142.   
Array printing is expensive due to the costs involved in acquiring such printers and also in time 
spent to optimise procedures which involve correct buffer compatibility, ligand specificities, 
affinities, and association and dissociation rates. However, although at present microarrays have 
GAPS 
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been analysed with fluorescent or radiolabeled138 ligands, they can in principle be adapted for 
other applications such as SPR and electrochemistry, providing the surfaces are compatible. 
Information on cell-surface interactions and ligands for orphan receptors might also be derived 
from these microarrays, potentially enabling lead finding and validation, high throughput 
screening, and bioassays for compound screening. 
 
3. Covalent interactions with linker/spacer to membrane 
 
3.1 Via thiopeptide tethered membrane bilayers –MP: Cytochrome C oxidase 
 
SPR applications require flat, metallic surfaces upon which proteins must be 
immobilized at very high densities and ideally, as close to the surface as 
possible. However, studies of immobilized MPs have revealed the need to 
create space between the protein and the surface to reduce steric hindrance of 
MP dynamics.  Therefore molecules such as thiolipids143 and thiopeptides have been developed 
as linkers, also called tethers, because they couple the membrane in close proximity to the surface 
but allow the membrane to remain fluid.  Thiopeptides have been used previously144,145 as a more 
hydrophilic alternative to thiolipids, for example, to immobilize cytochrome C oxidase 
(CcO)146,147.  In this particular case, a thiopeptide-lipid monolayer was covalently linked to gold 
surfaces with subsequent incorporation of the MP within the lipid bilayer.   
An oriented peptide monolayer was created by covalently binding an N-terminally thiolated, 
oligo-serine peptide to a gold surface148.  To complete the tethered membrane mimic, vesicles 
obtained by dialyzing Lipoid Egg PC149 were incubated with the monolayer surfaces to form the 
thiopeptide-lipid bilayer by adsorption.  CcO, previously solubilized with Triton146,150, was added 
to the cell containing the thiopeptide-lipid bilayer surface and spontaneously became 
incorporated into the bilayer with the micellar dilution technique.  All steps of the process could 
be monitored by SPR, and final thicknesses of bilayers measured.  Active proton transport driven 
by CcO had been established before, but it was measured here for the first time using impedance 
spectroscopy. This immobilization strategy proved to be compatible with the sensitive 
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measurements of proton transport through the lipid bilayer.  Furthermore, kinetics and binding 
interactions of cyanide with CcO could be studied. 
Due to the reported difficulty in preparing thiopeptide or thiolipid compounds in the bulk 
phase, this strategy allowed the simplified formation of a robust tethered bilayer in steps.  
Furthermore, the tethered bilayer allowed surface analytical techniques involving electric currents 
due to the metal surface used as a support, suggesting the technique may be adaptable to other 
applications with such requirements. Again, the challenge is to find the appropriate solubilization 
condition for the protein, but the space conferred between the surface and the bilayer 
environment of the protein by the tethered membrane bilayer can minimize steric hindrance of 
large, dynamic MPs and allow small molecule transport and diffusion.  
 
3.2 Via polymer cushion- supported lipid bilayers –GPCR:  Rhodopsin 
 
As discussed, previous studies revealed how immobilizing lipid bilayers 
containing MPs too close to the surface may hinder protein dynamics and 
membrane stability. An alternate solution to tethered membrane bilayers has 
been the introduction of a hydrophilic polymer cushion interspaced with 
hydrophobic anchors below the lipid bilayer The cushion, formed by a hydrophilic polymer 
interspaced with long alkyl chains, provides a lubricating surface which allows the lipid bilayer 
to remain mobile and provides a better mimic of the native environment151,152. 
 The gold L1 SPR chip used for such polymer-supported lipid layers consisted of a 
covalently linked, carboxymethyl-modified, dextran polymer hydrogel where a large part of the 
sugar moieties were grafted with lipophilic alkyl side chains to which liposomes adhere151,153.  
Whereas the preparation of small unilamellar vesicles (SUVs) containing rhodopsin used to be 
necessary153, here, fusion of crude rhodopsin-enriched membranes directly onto Biacore L1 chips 
was used instead of purification151,153. SPR, atomic force microscopy (AFM) and electrochemical 
impedance spectroscopy (EIS) were used to follow receptor immobilization.  The receptors 
remained mobile in the plane of the lipid, suggesting that this strategy has the potential to be used 
to study receptor dimerization or interaction with other proteins153. Furthermore, the chips could 
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be used directly, without prior treatment, and repeatedly with different receptors after washes 
with detergents to remove earlier immobilized proteins.  This may be generally applicable to 
other systems as the strategy allows on-surface enrichment for low yields of MPs. 
  
3.3 In vitro synthesis in presence of a tethered lipid membrane – GPCR: Odorant receptor 
OR5 
 
Biophysical analysis requires pure protein preparations functionally 
immobilized to a surface, and obtaining such conditions for GPCRs remains 
challenging due to loss of functionality and refolding problems typically 
encountered with GPCR solubilization and purification. To address this 
limitation, a new strategy that uses in vitro GPCR synthesis in the presence of a previously 
established144,145, solid-supported, peptide tethered lipid membrane (tBLM) has been 
developed113.  
 Using an approach similar to that described in Section 3.1, a hydrophilic peptide spacer was 
covalently attached to gold slides through amino-terminal thiol groups. The carboxyl group of the 
peptide was subsequently activated and amino-coupled to dimyristoyl-l-α-
phosphatidylethanolamine (DMPE), forming a lipid monolayer. The monolayer was subsequently 
fused with lipid vesicles to create the final bilayer.  The odorant receptor, OR5 from Rattus 
norvegicus, was expressed in vitro directly on the sensor surface113. This caused spontaneous 
integration of the GPCR into the tBLM upon biosynthesis. The procedure was monitored by 
surface plasmon enhanced fluorescence spectroscopy (SPFS) where fluorescent antibody binding 
to the GPCR created signals when the fluorophore was close to the surface.  The OR5 receptor 
was successfully oriented on the surface in such a way that it mimics the orientation in the native 
endoplasmic reticulum, with the N-terminus facing the extracellular side. Ligand binding was 
monitored by surface-enhanced infrared reflection absorption spectroscopy (SERIAS) where 
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Details were not provided concerning the stability of such slides, and although this application 
requires fluorescently labeled ligands, the success with GPCRs, which tend to be the most 
challenging MPs due to conformational heterogeneity, instability and low expression yields, 
suggests that the procedure has potential to be generally applied to other MPs and to analytical 
methods which do not necessitate labeling, such as SPR. 
 
3.4 Via polymerized lipid monomers -GPCRs: Rhodopsin 
 
Rhodopsin has been used extensively to study efficient immobilization into 
lipid environments, but these lipids have shown to be unstable when used for 
immobilizing MPs on chips. This is because the hydrophobic interactions 
which keep the lipids adsorbed to the glass are not strong enough to resist 
eventual desorption after extensive washing.  To address this issue, cross-linked synthetic lipids 
were developed to provide a more stable environment154.  A planar supported lipid bilayer 
(PSLB) composed of 1,2-bis[10-2’,4’-hexadienoyloxy)decanoyl]-sn-glycero-3-phosphocholine 
(bis-SorbPC)155 was used for these studies. The bis-SorbPC can be covalently cross-linked by 
exposure to UV light providing the necessary resistance to washing.  Rhodopsin was solubilized 
in buffer containing OG for these experiments156,157.  Reconstitution of rhodopsin into the PSLBs 
was carried out in a plasmon-waveguide resonance (PWR) cell.  The PWR cell was set up in such 
a way that UV light could be directed to it from a Mercury lamp, with a band-pass filter to 
remove all visible light which would irreversibly photoactivate rhodopsin.  More than 95 % of 
the bis-SorbPC was polymerised, as monitored by UV absorbance. PWR spectroscopy was used 
to characterise rhodopsin immobilized in the cross linked PSLBs. Within the PSLBs, the opsin 
isomerization and G protein activation could be monitored and rates were found to be similar to 
those obtained in a fluid dioleoylphosphatidylcholine (DOPC) bilayer.   
 MP immobilization via this procedure has the advantage of being completed in a few 
hours resulting in a system with intact and functional immobilized protein. Although no details 
were given on the reversibility of this polymerisation, it rendered the lipids resistant to Triton X-
100 treatment.  Although this method has high potential for on-surface purification and 
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immobilization of other GPCRs, preserving their functionality in such a cross-linked environment 
may not be as easy to achieve.  
 
4.  Covalent interactions with protein followed by lipid reconstitution 
 
Via carbodiimide coupling of carboxymethyl-modified dextran with lipid reconstitution –
GPCR: Rhodopsin 
 
GPCR biosensor studies require high densities of pure and functional 
immobilized protein and this is the limiting factor with regards to most 
GPCRs. To address this limitation, a technique was developed in a flow cell to 
allow stepwise addition and removal of mixed detergent and lipid micelles and 
protein to create an on-surface lipid bilayer reconstituted around a solubilized GPCR108. In 
principle, large quantities of unfolded GPCR could be used as input for this approach. 
The gold L1 sensor chip was treated to create covalently linked carboxymethyl-modified 
dextran polymer with random glucose moieties substituted by alkyl groups153.  The alkyl groups 
hydrophobically bound to mixed micelles of OG detergent and POPC lipid as they were injected 
over the surface to create the initial lipid layer. OG-solubilized rhodopsin143 was injected and 
immobilized on the surface by both the amide chemistry and the strong hydrophobic interaction 
between the surface lipid layer and the OG micelles.  The immobilized rhodopsin was 
immediately reconstituted in a POPC bilayer by injection of mixed OG and POPC micelles over 
the surface. The technique makes use of the high CMC of OG (25 mM). As buffer is injected 
over the flow cell, OG monomers detach much quicker than POPC and as they detach and wash 
away, the remaining POPC micelles spontaneously fuse into a continuous lipid bilayer over the 
sensor surface and the immobilized rhodopsin. The functionality of rhodopsin after 
immobilization was tested by surface plasmon resonance with light activation and measurement 
of transducin dissociation from the membrane as it consumed GTP143.  Signalling was only 
detected in the sample flow cell containing rhodopsin-POPC. There was no signal in absence of 
lipids, which proved that their presence158 and correct reconstitution159 was necessary for 
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rhodopsin’s functionality108,160.  The ligand binding capacity of the receptor was therefore 
preserved through this immobilization procedure and could be repeatedly measured. 
This technique resulted in reasonably high densities of up to 4 ng/mm2 of immobilized protein 
while the use of a polymer hydrogel layer improved the stability of the immobilized bilayer.  
Although protein solubilization and lipid reconstitution were fast and straightforward via the 
commercially available Biacore systems, defining the correct lipid and detergent stoichiometries 
for new target proteins will require significant optimization161.  The technique however can be 
adapted to different immobilization chemistries, including high-affinity interactions with 
antibodies to capture the protein in a defined orientation162.   
 
5.0 Specific immobilization of protein in native membrane via linkers  
 
Via biotinylated protein bound to streptavidin or avidin – GPCR: Neurokinin-1 receptor 
 
Many MPs have specific roles in binding extracellular ligands. Therefore, 
when immobilizing such proteins to study their biological activity, it is 
desirable to orient them in a controlled manner so as to maximise the 
accessibility of the ligand to its binding site. Specific interactions between the 
protein or membrane and the surface have been used in place of random ones for a better control 
of the protein’s orientation. The most common strategies involve the biotin interaction with 
streptavidin or avidin110,163,164,165. In one case, a biotinylated Neurokinin-1 receptor was 
overexpressed in CHO cell lines and immobilized through a streptavidin linker to a biotin 
covered slide165. The procedure was very simple, consisting primarily of treating the quartz slides 
with biotinylated BSA, which results in a surface resistant to salt and detergent washes. The 
multivalent streptavidin was then used to bridge the biotinylated GPCR to the biotinylated BSA 
for immobilization. The cell lysates containing overexpressed C-terminally biotinylated 
Neurokinin-1 receptor were then injected into the chamber directly to yield a specifically oriented 
immobilization of the receptor. Total internal reflection fluorescence (TIRF) was used to detect 
binding of streptavidin to the BSA-biotin surface and to detect binding of the fluorescently 
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labelled substance P (SP), a Neurokinin-1 receptor agonist, to the oriented receptor. Binding 
studies revealed functionality of the receptor in accordance with previous studies166 but used as 
little as 1 attomol of receptor due to the controlled orientation and high sensitivity of TIRF.  
This simple immobilization was the first example of biotinylated MP on quartz surfaces 
directly from crude cell lysates without purification, thus allowing one to study e.g. mechanisms 
involved in GPCR and G protein interactions in the native system. This technique has the 
potential to be applied to a wide array of applications and if higher densities of proteins are 
needed for read-outs, on-surface purification and enrichment is possible due to the high affinity 
of the immobilization reagents. It was also suggested that artificial integration of biotinylated 
lipids into the plasma membrane of cells prior to homogenization could be an alternative and in 
some cases, chemically oxidized silicon surfaces may be used to avoid interactions with the 
lipids164.   
 
6.0  Specific immobilization of detergent-reconstituted protein via linkers  
 
6.1 Via N-terminus of protein on sepharose resin –Potassium ion channel KcsA and 
membrane enzyme: DsbB (See Chapters 4 – 6). 
 
Fragment based drug discovery, an approach that consists of screening small 
molecules (< 300 Da) with weak interactions to a pharmaceutical target but with 
promising bioavailability properties13, has gained considerable attention in the 
pharma industry. Sensitive techniques, such as crystallography and NMR, are 
required to detect the weak binding of fragments to the target. However, many biophysical 
techniques require large quantities of stable protein in a pure form, and that is generally not 
possible with many MPs.  Although 60 % of all drugs target MPs36, it has not proven possible to 
apply fragment methods to them. Target Immobilized NMR screening (TINS) has addressed 
some of these limitations23 (Chapter 4)  and shows promise as a fragment screening method on 
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of immobilized reference and target MPs in order to detect specific binders above the non-
specific level of fragments interacting with detergents. 
All proteins in this case were solubilized in dodecyl-phosphocholine (DPC) during the 
purification procedure, which involved simple metal affinity chromatography followed by gel 
filtration in the presence of the detergent.  The immobilization procedure used Schiff’s base 
chemistry between primary amines of the protein and aldehyde groups on the commercially 
available sepharose resin. The immobilization efficiencies were reported similar to previous 
studies on soluble proteins, with a final concentration equivalent of 100 M of both the reference 
and target proteins on the resin. The functionality of immobilized DsbB was confirmed by an 
enzymatic assay which indicated that immobilized DsbB retained 90 % of its functionality. The 
functional immobilization of both KcsA and DsbB was further demonstrated by detecting binding 
of known ligands using TINS23 (Chapters 4 & 5). 
TINS addresses the protein demand by reusing a single sample of the target to screen the entire 
library, thereby requiring only 50 nmol of protein. Immobilization can be achieved via the N-
terminus or a variety of other chemical strategies making it potentially broadly applicable to 
MPs.    OmpA has been noted to retain conformation in a variety of surfactants53,72,78,88,89 making 
it a useful reference. Although this was the first example of fragment based drug discovery 
applied to MPs, there remain several limitations. A full screen of 1000 fragments required a week 
to complete, and most MPs may not be stable in such conditions, although, in some cases, 
immobilization has proven to improve MP stability. Furthermore, the solubilization processes 
must still be tailored to each protein. However, alternative solubilization media such as 
Amphipols167 and Nanodiscs68,168, which appear to be compatible with TINS, offer the possibility 
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6.2 Via FLAG tag and biotinylated antibody linked to streptavidin or avidin on BSA-biotin 
surfaces -GPCR: β2 Adrenergic receptor 
 
High-affinity interactions have been used successfully to immobilize GPCRs 
in their native membrane. However, many applications require pure protein in 
order to provide results with high signal to noise ratios.  Here, the high affinity 
streptavidin-biotin interaction has been used to capture detergent solubilized 
GPCRs in a controlled and oriented manner and monitor activity by fluorescence microscopy110.   
To detect ligand binding, the detergent solubilized 2 adrenergic receptor (2AR) was 
specifically labelled with fluorescein at Cys265, a conformationally sensitive site. The specific 
labelling of only Cys265 by the sulfhydryl-reactive fluorescent probe fluorescein maleimide was 
possible because the other cysteines of the protein were either inaccessibly located in the 
transmembrane domains, or non-reactive because of the presence of disulfide bonds169. For 
exploitation of the biotin-avidin interaction, two strategies were used in conjunction with an 
avidin or streptavidin linker.  In the first, the protein was modified with an N-terminal FLAG 
epitope and indirectly linked to the avidin surface through a biotinylated anti-FLAG antibody.  In 
the second strategy, a second cysteine residue was biotinylated and linked to the surface through 
avidin or streptavidin as in Section 5. Ligand-dependent activation of the 2AR was detected with 
fluorescence microscopy by monitoring changes in fluorescence intensity upon ligand binding 
and receptor translocation. The 2AR immobilized via the antibody displayed nearly identical 
responses to an agonist as the receptor in solution.  The 2AR directly immobilized by the biotin 
tag yielded less consistent responses that were significantly smaller than for the receptor coupled 
via the antibody.  Whether this was an artefact of the immobilization itself or due biotinylation of 
the GPCR was not clear.   
This method did not require protein reconstitution into a lipid bilayer and could immobilize 
protein with minimal loss due to the high affinity coupling.  Although this detection method 
required the GPCR to be labelled with a fluorophore at a sensitive site, the immobilization 
strategy allowed the authors to study conformational changes of the protein and is compatible 
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with array technologies involving high throughput screening of MPs on chips for example, 
provided solubilization conditions have been found for a particular MP.  
 
6.3 Via HIS tag on quartz surface – Serotonin-gated ion channel 5-HT3R 
 
Many applications require pure protein immobilized at very high density. 
Immobilized metal affinity chromatography (IMAC) has been used to 
successfully immobilize the detergent solubilized serotonin-gated ion channel 
5-HT3R to quartz slides without the need for further lipid reconstitution
111. 
This approach may be generally applicable to all MPs that can be solubilized and functionally 
expressed with a HIS tag. Prior to immobilization, the glass slides were first modified to contain 
thiol groups by gas-phase silanization. The thiol groups were then covalently linked to a lysine 
derivative of nitriloacetic acid (NTA) using a bifunctional maleimide-succinimide cross-linker.  
The newly created surface was fused to a Teflon spacer to create a flow-through cell and was 
subsequently charged with Ni2+.  The 5-HT3R ion channel containing a HIS tag, was solubilized 
in nonaethyleneglycol monododecyl and immobilized via chelation to the Ni2+-NTA.   
The metal affinity based immobilization procedure was reversible, allowing quantification of 
immobilized receptors by elution with imidazole. Total internal reflection fluorescence 
spectroscopy was used to carry out competition binding experiments using the non-labelled 
competitor quipazine against GR-fluorescein ([1,2,3,9-tetrahydro-3-[(5-methyl-1H-imidazol-4-
yl)methyl]-9-(3-amino-(N-fluoresceinthiocarbamoyl)propyl)-4H-carbazol-4-one]). The affinity of 
GR-fluorescein for the receptor in solution was identical to the surface-bound protein, 
demonstrating the feasibility of the process for identifying potential new drugs and quantifying 
their affinities with dose-response curves. This procedure was extremely simple and could 
potentially be applied to a variety of analytical techniques, given the usual constraints that the 
MP can be functionally solubilized and expressed with a HIS tag. The current application is 
limited to fluorescent ligands, but the sensitivity of the methods results in signal detection with as 
little as 1.6 attomol of immobilized MP, corresponding to the yield of a single mammalian cell! 
The detection is real-time, mass-independent and can be combined with micro-fluidic 
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applications to further explore high throughput analysis for drug discovery. Further, given the 
nature of the immobilization surface it seems likely that this procedure could be readily adapted 
to SPR applications. 
   
6.4 Via biotinylated ligand – GPCR: Neurotensin receptor-1 
 
SPR analysis of GPCRs is often limited by the fact that low molecular 
weight ligands do not generate large signals.   However, by immobilizing the 
ligand instead, the method allows one to study GPCR binding to biotinylated 
ligands immobilized to streptavidin-covered Biacore chips170, without the need 
for lipid reconstitution.  
For these studies the Neurotensin receptor-1 was expressed in E. coli as an N-terminal fusion 
product with the maltose binding protein, and a C-terminal His tag for stability and purification 
purposes.  Receptor purification by IMAC and neurotensin affinity chromatography preceded 
solubilization in detergent micelles containing (3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulfonate), DDM, and cholesteryl hemisuccinate (CHS).  The peptide ligand Neurotensin 
(NT) was N-terminally biotinylated and immobilized onto the streptavidin-coated Biacore chips 
as the positive control.  A ligand containing a scrambled version of the primary structure was also 
synthesized and immobilized on a second streptavidin-coated chip as a negative control.  Binding 
was monitored by SPR by flushing the flow cells with the detergent-solubilized receptor, and 
highly specific interactions could be observed and confirmed. The chips could be regenerated by 
uncoupling bound receptors with high salt washes.  The authors reported lower amplitude 
response than expected at higher levels of immobilized ligand, which they explained by potential 
ligand occlusion that could be prevented by the use of a longer linker between the surface and the 
ligand.  Although no quantification of the binding affinities was provided, the technique has 
potential in array technology provided small molecular weight ligands are available and 
biotinylation does not affect their binding affinities to the target protein studied.  Further, the 
technique could also be adapted to imaging mode SPR110. Although this technique was possible 
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with detergent-solubilized protein, the limitation of finding appropriate detergents for protein 
solubility remains a protein-specific issue. 
 
7.0 Specific immobilization of lipid-reconstituted protein via linkers 
 
7.1 Via biotinylated proteins in a mixed self-assembled monolayer -GPCR: Rhodopsin 
 
In order to study MPs which specifically bind ligands from the extracellular 
side of the membrane, methods have tended towards developing controlled, 
oriented immobilization in order to expose the appropriate side of the protein 
to the ligands. For such a controlled immobilization, a specific chemistry 
reacting to the appropriate terminus of the protein is necessary.  Here, 
carbohydrate-specific chemistry171,172 for N-terminal biotinylation of glycosylated proteins was 
combined with thiolipids to anchor rhodopsin to gold surfaces66.   
Gold sensor chip surfaces were covered with a homogeneous self assembled monolayer 
(SAMs) of -hydroxy-undecanethiol (HTA), interspaced with biotin attached to the surface 
through thiol groups, by micropatterned printing.  The HTA layer was created to avoid protein 
immobilization in these areas.  Subsequent addition of BSA blocked all non-specific binding sites 
and addition of streptavidin provided appropriate high affinity binding sites for the biotinylated 
receptor.  The glycosylated receptor was specifically biotinylated on the carbohydrate chains near 
the N-terminus by oxidising the carbohydrate moieties with NaIO4 prior to adding biotin-
hydrazide171. Since only the extracellular facing portions of the receptor are glycosylated, 
rhodopsin was immobilized with the intracellular side facing away from the surface, allowing for 
maximal interaction with G proteins.  
Surface plasmon resonance in the presence of GTP demonstrated the possibility of studying the 
receptor’s constitutive activity.  Interaction with the G protein was directly observed after a flash 
of light and the initial slope of the desorption signal was a good approximation of receptor 
density/unit area of surface.  Relaxation of the activated G protein was also measured and binding 
of agonists such as 11-cis- or 9-cis-retinal was used to show that the immobilized rhodopsin was 
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functional.  This immobilization strategy stabilized the GPCR for several hours and multiple 
cycles of ligand addition and removal, for which activation could easily be monitored.  
Furthermore, due to micropatterns with and without the receptor, non-specific binding was 
calculated as a localised reference, adding robustness to the data not otherwise available in SPR 
analyses.  Although this particular biotinylation method may be limited to MPs with glycosylated 
regions near the targeted terminus, it is an attractive method for studying G protein mechanisms. 
However, when applying MPs in native environments, SPR often proves less sensitive than when 
used with the well behaved and highly overexpressed proteins such as rhodopsin. 
  
7.2 Via lipid bilayer tethered through HIS-tagged protein -MP: Cytochrome c oxidase 
 
Studying MPs by electrochemistry is often limited by the insulating 
properties of the lipids or detergents if they are applied directly onto the 
metallic surface.  For detection of electron transfer, the protein therefore needs 
to be immobilized away from the surface. Here, a combination of lipid 
reconstitution and tethering the target protein through a HIS tag was used to immobilize 
Cytochrome c oxidase (CcO) to a silver surface173,174.  The surfaces were roughened by 
electrochemical processes and functionalized with N-hydroxy succinimide ester (NHS) groups by 
addition of dithiobis-(N-succinimidyl propionate). An ion chelating layer of nitrilotriacetic acid 
groups (NTA) was finally created by binding the terminal amino groups of N-(5-amino-1-
carboxypentyl) iminodiacetic acid to the existing NHS layer.  Complexation of this new NTA 
monolayer layer with Cu2+ ions made it possible to reversibly immobilize HIS-tagged proteins.  
Immobilization was simply accomplished by flow-mediated addition of C-terminally HIS-tagged 
CcO in DDM.  Finally, the lipid bilayer was established around the receptor by incubation with a 
buffer solution of DPGPC with subsequent removal of DDM. The heme groups of CcO remained 
intact and functional upon immobilization, as the ferric and ferrous states of hemes a and a3 could 
be monitored repeatedly after electrode potential changes.  The electron transfer rates of the 
protein were found to remain unchanged after immobilization, demonstrating an efficient electron 
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An additional benefit of the IMAC methodology is that it can be used to purify and enrich the 
protein in situ173. This chemistry has been exploited by tagging C-termini of GPCRs175,176,177,178 
and is being used to produce high throughput screening platforms with flow cytometry179.  
Details were not supplied regarding stability of the surfaces or of the immobilized target.  
Although protein solubilization remains a challenge, a particularly exciting possibility is the 
potential to use crude cell lysates with this approach173. 
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Table 1. Summary of direct (D) or indirect (I) immobilization methods with random (R) or oriented (O) 
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Table 2:  Summary of protein immobilization solubilization requirements, shelf life, type of analytical 
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Biophysical assays of protein function and/or ligand binding are playing an ever increasing 
role in both academic and industrial life science research. Applications in academic labs include 
determining and understanding protein interaction networks that lead to regulation of cell 
behavior (e.g. proteomics) while the primary use in industry has been for the discovery of ligands 
that modulate protein behavior. In order to scale these assays down and/or make efficient use of 
limited resources, the proteins are often immobilized on flat metallic or glass surfaces with little 
or no biocompatible characteristics. While the array of biophysical techniques that have been 
successfully applied to soluble proteins is impressive, until recently similar applications to 
membrane bound proteins were sparse. Here we have highlighted many of the success stories 
culled from the literature of the last few years. One common denominator of these success stories 
is the innovation and effort required to overcome the bio-incompatibility of the surfaces. A 
second recurring theme is that each solution must be tailored to the individual protein being 
studied. Together these two remaining issues represent a bottleneck to widespread, high 
throughput biophysical assays that could take advantage of, for example, printing techniques. 
We see two developments that, when combined with methodologies that have been described, 
offer exciting opportunities for more generic application of biophysical techniques. Interestingly, 
these developments come from both sides of the problem, that is the protein itself and the media 
used to solubilize the protein, and therefore are potentially complementary. Approaching the 
problem from the protein point of view, the group of Christopher Tate at Cambridge University 
(UK) has developed a technique for selecting mutants that provide enhanced thermal and 
conformational stability while retaining desired ligand binding properties70. Importantly, these 
stabilized proteins are compatible with a much wider range of detergents than the wild type 
protein and thus should be more amenable to large scale immobilization studies. From the media 
point of view important advances have been made in developing alternatives to detergents for 
functional solubilization of MPs. Nanodiscs68,73,74, bilayer lipid assemblies surrounded by a 
stabilizing protein, and amphipols72,180,181, synthetic amphipathic polymers, have successfully 
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replaced detergents to solubilize a variety of MPs including GPCRs. Lipidic sponge phases 
represent an even more recent addition to this list, which, so far, shows promise for 
crystallization of MPs182. The crucial advantage of these new media is that they represent a more 
or less “one size fits all” solution that holds the promise of eliminating, or at least greatly 
minimizing, the requirement to precisely tailor each solution to the MP.  
Ultimately applications which combine the high sensitivity of biophysical methods with the 
possibility of studying an MP in its native environment without the need for purification and 
reconstitution represent the Holy Grail for many research goals. While at present still out of 
reach, the growing body of information on production and immobilization strategies and the ever 
increasing sophistication of biophysical methods will undoubtedly conspire to enable this in situ 
approach. The combination of such biophysical studies with increasing success in the 
crystallization and NMR analysis of MPs should prove a powerful approach to both reveal 
molecular mechanisms of membrane protein function and enable rational elaboration of small 
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Glossary 
 
Adsorption: The process of accumulating a substance onto a surface through hydrophobic 
interactions.  
Bicelle: A micelle containing a bilayer of amphipathic molecules as opposed to just one layer. 
Black membranes: An artificial planar membrane that forms over a hole in the partition between 
two aqueous compartments and is optically black when viewed in incident light; used to study the 
permeability of bilayer membranes and the mobility of bilayer components. 
Critical Micellar Concentration (CMC): The concentration of amphiphilic molecules at which 
a micelle is formed.  
Detergent Depletion Technique: Also called the micellar dilution technique.  In a mixed 
detergent-lipid system, dilution with detergent and lipid free buffer will cause the detergents, 
which have a lower critical micellar concentration than lipids, to detach from the system and 
cause the remaining lipids to fuse together. 
LB monolayers: A Langmuir–Blodgett monolayer: contains one layer of organic material, 
deposited from the surface of a liquid onto a solid by immersing (or emersing) the solid substrate 
into (or from) the liquid.  
Liposomes: An artificial vesicle consisting of an aqueous core enclosed in one or more 
phospholipid layers. 
Membrane vesicles: Closed, unilamellar shells formed when membranes are mechanically 
disrupted because the free ends of a lipid bilayer are highly unstable. 
Micellar dilution technique: See Detergent Depletion Technique. 
Micelle: A colloidal aggregate of a unique number (50→100) of amphipathic molecules. In polar 
media such as water, the hydrophobic “tails” of the amphiphilic molecules tend to locate away 
from the water while the hydrophobic “heads” are located towards the water. 
Planar supported lipid bilayer (PSLB): Lipids arranged in micropatterns with high stability on 
a flat surface.  
Proteoliposomes: A liposome with embedded membrane proteins. 
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Self assembled monolayers (SAMs) are surfaces consisting of a single layer of molecules 
covalently linked to a surface through functional groups. 
Small unilamellar vesicles (SUVs): Small vesicles consisting of one layer of lipid molecules. 
Solid supported membranes: Membranes immobilized to a surface through a linker.  A 
hydrophilic polymer, often grafted with hydrophobic chains, is placed in between the membrane 
and the surface in order to provide a lubricating supportive, layer for the membrane. 
Tethered bilayer lipid membrane (tBLM): A lipid membrane anchored to a surface through a 
long linker which does not impede membrane mobility
 







Functional immobilization of histamine 
H1 and adenosine A1 receptors on 
sepharose beads:  
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G protein-coupled receptors (GPCRs) are responsible for signal transduction across cell 
membranes and are involved in many pathologies. Emerging new biophysical techniques can 
potentially provide more detailed information on protein-ligand interactions at the atomic scale. 
However, many of these technologies require protein immobilization, which remains a challenge 
when applied to GPCRs due to the absence of a generally applicable procedure. Here we address 
this issue by developing a simple and widely applicable immobilization protocol and applying it 
to crude membrane preparations containing either the human histamine H1 receptor (hH1R) or the 
human adenosine A1 receptor (hA1R). Native G proteins involved in the signalling cascade are 
retained during this process due to immobilization of crude, non-solubilized membrane fractions. 
The immobilization is based on Schiff’s base formation between aldehyde groups on the resin 
and primary amines present in membrane-spanning proteins. Radioligand binding assays and dot 
blots show that this methodology succeeds in consistently yielding between 1 to 2 pmol of 
functional receptor per ml of resin. Pharmacological characterisation indicates that both 
antagonists and inverse agonists have similar affinity for immobilized and non-immobilized 
receptors suggesting the approach should be sufficiently reliable to carry out analytical assays for 
ligand discovery and characterisation.  Furthermore, receptor immobilization results in significant 
stabilization and therefore the ability to store them.  Thus, the method is promising as a means to 
immobilize a wide range of membrane proteins, including GPCRs without prior modification, 
solubilization, or lipid reconstitution. 
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G protein-coupled receptors (GPCRs) are responsible for transducing sensory and chemical 
signals across the cell membrane, and as such, their involvement in a wide range of pathologies 
makes them important drug targets and study foci. It is reported that approximately 30 - 40 % of 
marketable drugs target this class of proteins100. The two model receptors used in the scope of 
this study are prime drug targets since the histamine H1 receptor mediates a variety of allergic 
reactions183 and the adenosine A1 receptor is involved in neurotransmission and thus a variety of 
neurodegenerative diseases84. Most GPCRs are ligand activated, yet a substantial number remain 
“orphaned”, where the native activating ligand is not known. Discovery of non-native, small 
molecule modulators of GPCR function is also an area of highly active research for which gaps 
remain in current technologies. These issues underline the need to improve our understanding of 
this group of proteins by developing tools that provide new information in an efficient and 
detailed manner.  
High throughput ligand screening assays of GPCRs typically use membrane-based assays 
involving microprinting66,112,139 or rely on cell-based assays184,185,186, where as many as 150,000 
compounds can be screened in 8 hours. These assays are good at finding “drug-like” (300-500 
Da) modulators of GPCR function, along with "macroscopic" parameters such as IC50 values, as 
well as some biological functionality characterizing the ligand-GPCR interaction. For an 
alternative and more "microscopic" approach, however, new biophysical methods are being 
developed in which the atomic or molecular interactions between a ligand and a protein are 
emphasized. Biophysical methods present many advantages such as the ability to directly detect 
physical interactions and differentiate between reversible and non-reversible processes. 
Furthermore, known functionality of the target protein is not required. Due to their intrinsic 
sensitivity to weak intermolecular interactions, many biophysical methods can be used to screen 
small molecule libraries of so-called drug fragments (150 - 300 Da)22  (that obey Lipinski’s 
rules)10. As a result, subsequent stages of the drug discovery process should yield compounds that 
are more orally bioavailable and less toxic.  
Although biophysical techniques for high throughput screening have been successfully applied 
to soluble proteins that have been immobilized via a multitude of chemical linkers101,102,103, 
applications to immobilized GPCRs still pose a challenge. GPCR conformation, stability, and 
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functionality are all dictated by experimental conditions ranging from cell culture and storage to 
the composition of the necessary presence of the lipid membrane148.  In addition to this 
sensitivity, it is difficult to immobilize GPCRs with sufficient density to allow reliable signal 
detection. Many immobilization strategies employ protein modification by biotinylation66 or the 
adjunction of antibodies162 to a surface in order to have a well defined target orientation. 
Functional GPCR immobilization is commonly achieved by adsorption137,187 or anchorage146 of 
lipids on flat glass or gold surfaces, and are typically applied to purified, solubilized preparations 
which undergo subsequent lipid reconstitution108,162,173 (Chapter 2). Schiff’s base chemistry has 
been used in liquid chromatography as an immobilization strategy, but it has been reported to 
result in high non-specific binding188. Solubilization and lipid reconstitution of GPCRs require 
specific protocols for each protein, and finding the correct mixture of detergents can be extremely 
time consuming189 or even futile. Furthermore, solubilization and purification results in the 
removal of the native membrane and associated proteins, such as the appropriate G proteins, 
which are important players in the signalling cascades85,190. A generally applicable method to 
immobilize GPCRs within their native membrane would clearly be welcome.  
The aim of this study, therefore, is to determine whether GPCRs, as exemplified by the hH1R 
and the hA1R receptors, remain functional when they are immobilized in their native membranes 
on sepharose beads without modification, purification, or lipid reconstitution (Figure 1). This 
would provide a ready alternative to gold or glass chip surfaces used in current research and 
would allow GPCRs to be studied by a variety of biophysical methods such as SPR170 and Target 
Immobilized NMR23,77. 
Figure 1. Immobilization of GPCRs on 
sepharose resin via native membrane 
vesicles. The immobilization is carried 
out via primary amines of the GPCRs 
(B) or of other integral or membrane 
associated proteins (A). The ligand 
binding properties (C) of such a system 
are essentially unchanged with respect to 
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The construction of the Chinese Hamster Ovary (CHO) stable cell line overexpressing the 
human H1 receptor doubly tagged with heamaglutinin and 6-His (HA-hH1R-HIS) will be reported 
elsewhere. The CHO stable cell line overexpressing the human A1 receptor (hA1R) was provided 
by Prof. Steve Hill at the University of Nottingham. HA-hH1R-HIS and hA1R had a maximum 
amount of binding sites (Bmax) of 6.2 pmol/mg of total protein and 8.5 pmol/mg of total protein, 
respectively. All cell culture products such as Dulbecco's modified Eagle Medium, Penicillin, 
Streptomycin, Newborn bovine serum, G418, and Trypsin were purchased from standard 
suppliers. ALD Actigel coupling resin and coupling reagent NaCNBH3 (sodium 
cyanoborohydride) were purchased from Sterogene (CA, USA). CH Sepharose 4B and NHS 
activated Sepharose 4 FF were purchased from GE Healthcare. [3H]mepyramine (specific activity 
32 Ci/mmol) was purchased from Amersham Biosciences (Roosendaal, NL) and [3H]DPCPX 
(specific activity 127 Ci/mmol) was purchased from NEN (Du Pont Nemours, 's-Hertogenbosch, 
NL). Histamine and mianserin, as well as all chemicals used for buffer preparations, were 
obtained from Sigma-Aldrich (Zwijndrecht, NL). CPA, 8-CPT, and N0840 were purchased from 
RBI (Natick, MA, U.S.A) and ADA (adenosine deaminase) was acquired from Roche 
Biochemicals (Mannheim, Germany). The antibody recognising Gαq/11 proteins (sc-392) was 




Cells were cultured weekly in 30 Petri dishes (15 cm) with 20 ml modified Eagle’s medium 
containing 50 IU/ml penicillin, 50 g/ml streptomycin, 10 % (v/v) newborn bovine serum, and 
400 g/ml G418, at 37°C in humidified 5 % CO2. 
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Membrane isolation and preparation 
 
Weekly, cells were harvested and prepared according to the method described previously191, 
with minor modifications to create a finer suspension. Cells were rinsed with PBS, detached by 
scraping, and washed by centrifugation at 2700 rpm for 5 min, with resuspension in 30 ml cold 
membrane buffer (15 mM Tris, 1 mM EGTA, 0.3 mM EDTA, 2 mM MgCl2, pH 7.4 at 4°C). 
Cells were then homogenized in a tight-fitting 30 ml Potter-Elvehjem tube with 10 slow up and 
down strokes at 700 rpm (pottering), and immediately centrifuged at 1000 rpm for 10 minutes to 
remove unwanted pelleted cell debris. The supernatant was collected, pottered, and precipitated 
via ultracentrifugation at 31000 rpm for 20 minutes. The pellet was resuspended in 20 ml cold 
membrane buffer, and the pottering and ultracentrifugation steps were repeated. The resulting 
pellet was resuspended in 4 ml cold phosphate buffer (50 mM Na2HPO4, 50 mM KH2HPO4; pH 
7.4 at 4 °C). For hA1R containing membranes, an additional 0.8 IU/ml ADA was added to the 
final preparation. Total protein concentration was determined using the bicinchoninic acid (BCA) 




The ALD Actigel resin was used as a 50 % slurry. When possible, all procedures were carried 
out at 4 °C. The resin was first washed with filtered water prior to being washed 3 x with cold 
phosphate buffer (50 mM Na2HPO4, 50 mM KH2HPO4; pH 7.6 at 4 °C) by centrifugation at 3000 
rpm and resuspended in an equal volume of the same buffer. Membranes were thawed and 
pottered with 5 strokes before being added to the Actigel resin at a ratio of 1 mg total protein to 1 
ml of resin. Coupling reagent (1 M NaCNBH3) was added to a final concentration of 0.1 M. The 
tubes were placed at 4 °C and gently rotated for 18 h so as to avoid pellet formation. After 
immobilization, the supernatant was collected for quantification after a 5 minute centrifugation at 
3000 rpm.  The pelleted resin was resuspended with 1 ml Tris buffer (100 mM Tris; pH 7.6 at 
4ºC) and 0.1 M coupling reagent for 2h at room temperature to block the remainder of the free 
aldehyde sites on the resin. Reducing agent was always removed prior to continuing with 
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experiments by washing the resin four times with Tris buffer (50 mM Tris; pH 7.4 at 4 °C). To 
determine the effect of linker length on GPCR immobilization, a similar procedure was followed 
using either activated CH Sepharose 4B which has an 8 atom linker or NHS activated Sepharose 
4 FF which has a 14 atom linker. Membrane vesicle preparations were thawed and immobilized 
according to the manufacturer’s suggestions for each of the three resins using 1 mg total protein 
per 1 ml of resin. Immediately before radioligand binding assays, the resin was washed 4 times 
with cold Tris buffer. The amount of functional receptors immobilized was quantitated by 
radioligand binding studies as described below. 
 
Quantitation of total receptor immobilization efficiency 
 
To obtain an approximate quantification of the total amount of HA-hH1R-HIS or hA1R 
immobilized, dot blots were used with anti-HIS tag or anti-A1R antibodies. 10 l of fresh 
membrane preparations overexpressing the receptors were used as reference, while equivalent 
preparations from the non-recombinant, parental cell line membrane preparations not 
overexpressing receptors (CHOK1 for hH1R and CHOkool for hA1R) were blotted as negative 
controls. Corresponding volumes of supernatants before and after the immobilization procedure 
were also blotted. The pelleted resin containing immobilized receptors were also sampled for 
blotting, after a 1:1 dilution in denaturing buffer used in SDS-PAGE analyses, but lacking 
bromophenol blue (50 mM Tris/HCl pH 6.8, 1 % SDS, 15 % glycerol, 1 % -mercaptoethanol at 
room temperature) and a 15 minute incubation at 95 °C for removal of protein from the resin. 
After a 3 minute centrifugation at 2500 rpm, the supernatant containing the membrane vesicles 
stripped off the resin, along with denatured receptors, was blotted. All samples went through the 
denaturing step in order to compare results, and each lane consists of a serial dilution by a factor 
of 0.5.  The bands were quantified by volume density analysis.  The background level from the 
negative control was subtracted from the final values which were extrapolated by comparing the 
standard curve obtained with the known Bmax and density analysis from the positive control. 
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Detection of Gαq/11 proteins present with immobilized receptors on resin 
 
Western Blot analysis of whole cell lysates, isolated membranes, and immobilized receptors 
was carried out to identify the presence of native Gαq/11 proteins in the immobilized receptor’s 
environment. Whole cell lysates and isolated membranes were used as positive controls and 
prepared in equivalent volumes for direct comparison with immobilized receptors. To prepare 
whole cell lysates, densely cultured cells overexpressing the HA-hH1R-HIS were washed 3 times 
with PBS and scraped into tubes on ice before being centrifuged at 4000 rpm for 5 min at 4 °C. 
Cells were then resuspended in RIPA buffer (150 mM NaCl, 1 % NP-40, 0.1 % SDS, 2 μg/ml 
aprotinin, 5 μM leupeptin, 50 mM Tris; pH 8.0) and incubated for an hour at 4 °C before being 
pottered. Membranes were isolated and immobilized as described previously, but with the 
presence of 2 μg/ml aprotinin and 5 μM leupeptin. The pelleted resin containing immobilized 
receptors was washed 3 x to remove non-immobilized material and incubated for 15 minutes at 
95 °C to melt the agarose resin, leading to collection of protein which was bound to the resin in 
the supernatant. Samples were centrifuged at 3000 rpm for 3 minutes and the supernatant was 
diluted 1:1 in loading buffer. Whole cell lysates and isolated membranes were diluted 1:1 and 1:2 
in loading buffer. All samples were loaded at 10 l, separated by 12 % SDS-PAGE and blotted 
onto a polvinylidene difluoride membrane before being detected by an enhanced 
chemiluminescence assay, with the Gαq/11 protein antibody as a primary antibody. The bands 
were quantified by volume density analysis with subtraction of the background levels from the 
negative control, extrapolated values from the standard curve obtained with the known Bmax and 
density analysis from the positive control containing 1:1 cell lysates. 
 
Pharmacological characterisation of non-immobilized and immobilized HA-hH1R-HIS 
receptors and hA1R receptors 
 
Displacement studies were carried out by incubating HA-hH1R-HIS membrane aliquots of 5 g 
total protein for 30 min at 30 °C in 400 l Tris buffer (50 mM Tris; pH 7.4 at 4 °C) containing 
final concentrations of 1 nM [3H]mepyramine and increasing concentrations of displacer, either 
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mianserin (antagonist) or histamine (agonist). Saturation studies were carried out by incubating 
HA-hH1R-HIS membrane aliquots of 5 g total protein with increasing concentrations of 
[3H]mepyramine ranging from 0.1 nM to 8 nM with non-specific binding determined by the 
presence of 1 M mianserin. The incubations were stopped by rapid dilution with ice-cold Tris 
buffer. The bound radioactivity was separated by filtration through Whatman GF/C filters 
(Whatman, Belgium) that had been treated with 0.3 % polyethylenimine as described 
previously193. Filters were washed four times with binding buffer, and radioactivity retained on 
the filters was measured by liquid scintillation counting. Binding studies for hA1R were similar, 
however a 60 min incubation time at 25 °C was required with final concentrations of 1 nM 
[3H]DPCPX with increasing concentrations of CPA (agonist), N0840 (antagonist), and 8-CPT 
(inverse agonist). Saturation curves were determined with increasing concentrations of 
[3H]DPCPX ranging from 0.1 to 4 nM, using 10M CPA to determine non-specific binding. 
Filtration was done over Whatman GF/B filters without prior polyethylenimine treatment. 
Immobilized receptors were characterised in an identical manner to the respective non-
immobilized receptors, by using an amount of resin which corresponded to 5 g of total 
immobilized protein.  All radioligand binding studies of membranes immobilized on resin 
required special attention because resin covered the filter surface and could easily be dispersed. 
Furthermore, the incubation steps were carried out without shaking to prevent loss of resin due to 
adherence on the edges of the tube. 
 In order to quantify the amount of functional receptor immobilization, samples were incubated 
with and without a displacer to determine saturation curves in the presence of the corresponding 
radioligand (1 nM). Appropriate controls were chosen to determine fmol of functional receptor 
present in the various steps. To determine the effect of the reducing agent on ligand binding, 
membranes were incubated with 0.1 M NaCNBH3, which was subsequently removed by pelleting 
the membrane preparations and resuspending in Tris buffer. For stability studies, samples were 
kept for one week at 4 ºC and subjected to quantification as described above. 
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Data analysis 
 
Receptor binding data were analysed using the non-linear regression curve fitting program 
Graph Pad Prism v. 4.01 (Graph Pad, San Diego, CA, U.S.A.). Statistical significance was 
evaluated with the student's T-test. Saturation experimental data (Kd and Bmax values) were 
obtained by computer analysis of saturation curves. Inhibitory binding constants (Ki values) were 
derived from the IC50 values according to the Cheng & Prusoff equation Ki=IC50/(1+[C]/Kd), 
where [C] is the concentration of radioligand used in competition binding, and Kd its dissociation 
constant194. All values obtained are means of at least three independent experiments performed in 
duplicate. Values of functional receptor were derived by the following equation, assuming that 
each mole of radioligand binds to one mole of receptor: R= [[C]/(Kd + [C])] x [S/(2220 x SP)] 
where R is the amount of functional receptors (moles) per 50 l resin, [C] is the radioligand 
concentration, S is the radioligand specific binding (dpm), and SP is the radioligand specific 
activity (Ci/mmol). In all assays, care was taken to assure total binding never surpassed 10 % of 
total radioligand added. In order to determine how much total protein was immobilized, the 
amount of protein added to resin and the amount present in supernatants after immobilization 
were subject to BCA protein assays, after a wash with buffer and an ultracentrifugation step to 
remove NaCNBH3 due to its negative effect on the assays. The volume density analysis of dot 
blots and western blots were carried out using Quantity One imaging software (BioRad, USA). 
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RESULTS 
 
We sought an immobilization procedure that would both maintain the native environment and 
be widely applicable to an array of potential membrane protein targets, yet compatible with 
various biophysical assays. We therefore began by attempting to immobilize membrane 
preparations of cells stably expressing human GPCRs. We chose sepharose based resins that are 
well characterized for bio-compatibility, have low non-specific binding and are highly porous 
endowing large specific binding capacity. The Schiff’s base chemistry used to immobilize 
proteins on commercially available sepharose resins is very mild, yet stable. Various membrane 
preparation methods were tried, but ultimately, that which resulted in a fine suspension by 
repeated pottering and centrifugation was used (see Methods). Using this method, a 
Heamaglutinin and 6-His tagged human H1 receptor (HA-hH1R-HIS) and untagged human A1 
receptor (hA1R)
 were consistently immobilized on the Actigel ALD resin (Figure 2, panels a and 
















Figure 2. Immobilization efficiency of HA-hH1R-HIS 
membranes (a) and hA1R membranes (b) as measured by 
radioligand binding. The height of each bar represents the 
fmol of radioligand bound per 100 l of starting material. 
Black bars represent controls of membrane preparations 
with the first being the starting material stored at -20 °C (1) 
and the second representing preparations that were 
maintained at 4 °C for the same duration as samples that 
were immobilized (2), the same as 2 but in the presence of 
reducing agent (3) and after removal of the reducing agent 
(4). Non-specific ligand binding to untreated resin was 
measured (5), along with the washing efficiency (6). The 
amount of functional, immobilized GPCR was determined 
(7) as well as that which remained in the supernatant after 
immobilization (8). The average of 3 experiments 
performed in duplicate is shown 
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The starting material consisted of membrane preparations that had been stored at -20 °C. We 
first titrated the amount of membrane preparation used for immobilization and observed a distinct 
optimum achieved when adding receptors at 1 mg total protein/ml concentration, at a maximum 
of 1 mg total protein per ml (settled bed volume) of resin (data not shown). Assuming 1:1 ligand 
binding stoicheometry, this amount corresponds to 620 fmol of active HA-hH1R-HIS and 850 
fmol of active hA1R per 100 l of starting material (Figure 2a and Figure 2b, column 1). Both 
receptors show consistency in the proportion of active receptors remaining at each step of this 
experiment. Simple storage of the membrane preparations at 4 oC for 18 h resulted in a 10 % loss 
of ligand binding capacity for both receptors (Figure 2a and Figure 2b, column 2). While the 
presence of the reducing agent sodium cyanoborohydride (NaCNBH3, for reducing the Schiff’s 
base to a primary amine) had a slightly negative impact on the radioligand binding assays, this 
was completely reversible (Figure 2a and Figure 2b, columns 3 & 4). There was little non-
specific binding of the radioligand to the resin in the absence of receptor and the washing step 
was efficient in removing all receptors that were not irreversibly immobilized by NaCNBH3 
(Figure 2a and Figure 2b, columns 5 & 6). The mild procedure results in consistent functional 
immobilization of 20 - 25 % of both the hH1R and hA1R receptors. Essentially no detectable 
functional receptors remained in the supernatant fraction after immobilization for 18 h (Figure 2a 
and Figure 2b, columns 7 & 8). This equates to 1.3 pmol of functional HA-hH1R-HIS and 2.1 
pmol of functional hA1R per ml of resin. 
Since the radioligand binding assay could only detect functional receptors, we wished to know 
whether or not the coupling procedure was selecting for functional receptors leading to the 
apparent 20 - 25 % yield. Using a total protein quantification method, we found approximately 1 
% of the input protein remaining in the supernatant after an 18 h immobilization (not shown). 
This data corresponds well to the amount of receptors in the supernatant after immobilization 
when determined by radioligand binding studies. We used a dot blot assay in order to specifically 
follow the fate of the HA-hH1R-HIS during immobilization (Figure 3a).  
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Figure 3. Immobilization 
efficiency of HA-hH1R-HIS-
containing vesicles. A dot blot 
assay was used to quantitate the 
amount of HA-hH1R-HIS 
present in various fractions of 
the immobilization procedure 
using anti-HIS tag antibodies 
(a). A control vesicle 
preparation with approximately 
6 fmol/l of HA-hH1R-HIS 
(lane 1) is compared to the supernatant of an immobilization reaction before (lane 2) and after immobilization (lane 
3), from which it can be seen that the majority of receptor is removed from solution. Analysis of the supernatant 
after stripping the receptors off the beads (lane 4) indicates that the majority of receptors were tightly bound to the 
resin (lane 4). Vesicle preparations from the parental CHOK1 cell line that does not express the receptor indicate the 
level of non-specific staining (lane 5). The dot volume densities were quantified by QuantityOne (BioRad) and the 
amount of HA-hH1R-HIS in the first row of each lane is represented in (b) after subtraction of non-specific signal in 
lane 5. 
 
The blots were quantified and the amount of receptor in the first row of each lane is 
represented in Figure 3b after subtraction of background signal from the negative control in lane 
5. Fresh membranes stored at -20 ºC were blotted in (lane 1) and represent the positive control.  
Membrane suspensions before (lane 2) and after immobilization (lane 3) show that a significant 
fraction of the receptor has been removed from solution (compare lanes 2 and 3) and as expected, 
was bound to the resin (lane 4). The apparent increase in signal was due to concentration of the 
receptor sample upon immobilization which was difficult to precisely correct for due to the 
unknown efficiency with which the covalently bound protein could be removed from the resin by 
heating. The signal remaining in the post-immobilization supernatant was consistent with the 
amount observed with radioligand studies of the supernatant after immobilization, and is within 
the same level, within error, of the negative control membranes that do not express His-tagged 
receptors (lane 5). This data suggests that nearly all of the GPCRs have been successfully 
immobilized on the resin and that therefore, only 20 - 25 % of this population remained 
a                                     b 
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a                                           b 
functional as suggested by the data in Figure 1.  Similar experiments were attempted for the 
hA1R but dot blots were inconclusive as the anti-hA1R antibodies apparently did not recognize 
denatured receptors.  
The aim of immobilizing GPCRs via their native membrane was to keep as much of the native 
environment present as possible, specifically including all proteins necessary for signal 
transduction. Thus we sought to determine whether the appropriate G proteins for hH1R, Gαq/11, 
were co-immobilized on the sepharose beads. Western Blot analysis (Figure 4a and Figure 4b)  
 
show that the amount of Gαq/11 proteins immobilized equates to 45 % of the amount present in 
HA-hH1R-HIS whole cell lysates and isolated membranes. It was not our goal to quantify the 
exact amount of Gαq/11 proteins which were co-immobilized, because the level of uncoupling 
from the resin achieved with our method is not fully quantifyable.  Therefore, although it is 
 
Figure 4. Detection of 
Gαq/11 proteins (42 kDa) 
present on the resin with 
immobilized HA-hH1R-
HIS by Western Blot 
analysis. Gαq/11 anti-
bodies were used to 
detect Gαq/11 proteins (a) 
and the corresponding 
quantities of Gαq/11 are 
represented as percen-
tages of lane 1 (b). Lanes 
1 to 4 correspond to positive controls, where lanes 1 and 3 are lysates of whole CHO cells overexpressing the 
receptor, with no dilution and a dilution of ½ respectively, and lane 2 and 4 are the corresponding isolated 
membranes, with the same pattern of dilutions. Lane 5 corresponds to the supernatant containing membrane vesicles 
which have been denatured off the resin after immobilization, with no dilution. Lane 6 contains the standard 
proteins used as a ladder for the MW weights, and consists of a negative control due to the absence of Gαq/11 
proteins.  The quantification reveals that 45 % of the proteins applied to the resin (lane 2) were collected from the 
resin after denaturation (lane 5). 
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difficult to say whether there were more Gαq/11 proteins immobilized but only 45 % were 
effectively stripped off the resin, this data suggests that the physiologically relevant Gαq/11 
proteins were co-immobilized on the resin and therefore enabled agonist binding pharmacology 
on the immobilized HA-hH1R-HIS receptors. 
We wanted to determine any possible influence of linker length on functional immobilization 
of receptors. The sepharose ALD has a relatively short 5 atom linker so we tested resins with 
hydrophilic linkers of 8 and 14 atoms for functional immobilization of hA1R and HA-hH1R-HIS 
receptors (Figure 5).  
 
 
Figure 5. Determination of linker 
length on efficiency of functional 
immobilization of hA1R and HA-hH1R-
HIS. The total amount of functional 
receptor bound was determined by 
saturation binding experiments. The 
average of 3 experiments performed in 
duplicate is shown. 
 
 
Both resins resulted in a near doubling of the amount of functionally immobilized receptors. 
Since the immobilization chemistry of all three resins is very similar, it seems likely that there is 
a threshold of linker length required for maximal functionality. This data is consistent with the 
idea that the receptor is sterically hindered by shorter linkers189. 
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To characterize the pharmacology of immobilized receptors, both saturation and competition 
binding studies were performed on non-immobilized and receptors immobilized on the ALD 
resin with a 5 atom linker. Values 
obtained from saturation studies 
(Figure 6) showed similar 
equilibrium dissociation constants 
(Kd) of [
3H]mepyramine for the 
non-immobilized and immobilized 
HA-hH1R-HIS.  
As can be seen in Figure 2a, the 
immobilized receptor has a lower 
Bmax (1.3 pmol/mg vs. 6.2 pmol/mg 
for non-immobilized, Table 1) 
while displaying a level of non-
specific binding consistent to the 
levels found when the receptor was not coupled to the resin. Displacement studies were used to 
determine the binding constant of the agonist histamine and the antagonist mianserin on both 
non-immobilized and immobilized HA-hH1R-HIS. In the case of histamine, both non-
immobilized and immobilized receptor data were best fit by a 2-site model (Figure 7a, T-test; p < 
0.01 and Figure 7b, T-test; p < 0.01, Table 1). 
 Figure 7. Displacement of specific 
[3H]mepyramine binding to non-
immobilized (a) and immobilized 
(b) HAhH1R-HIS receptors by the 
agonist histamine. Both curves are 
best fit by a two-site model. The 
average of 3 experiments performed 
in duplicate is shown. 
 
Figure 6. Saturation binding of [3H]mepyramine to non-
immobilized (a) and immobilized HA-hH1R-HIS (b). The 
amount of [3H]mepyramine bound is indicated for the various 
fractions of total (▲), non-specific (▼),and specific binding (●). 
The average of 3 experiments performed in duplicate is shown. 
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The affinity of the immobilized HA-hH1R-HIS receptor for histamine was similar to the non 
immobilized receptor.  Although there may be a slightly larger fraction of high affinity receptors 
in the immobilized sample (Table 1), it is not possible to distinguish a difference due to 
experimental uncertainty. hA1R immobilized on the 5 atom linker ALD resin displayed the same 
pattern of ligand interaction as the HA-hH1R-HIS receptor.  
 
Table 1. Affinity and binding capacity 
estimates obtained from saturation 
binding curves (A) and competition 
binding curves (B) of non-immobilized 
(N) and immobilized (I) HA-hH1R-HIS. 
Dissociation constants (Kd) and 
maximum amount of binding sites (Bmax) 
were obtained from saturation curves, 
with 1 M mianserin to determine non-
specific binding.  Competition binding 
constants of the agonist histamine and the 
antagonist mianserin provided low 
affinity constants (KL), high affinity 
constants (KH), and percentages of high 
affinity receptor populations (RH) from 2-











 Kd  1.1 ± 0.1 nM 
6.2 ± 0.3 
pmol/mg total 
protein 
 I   Kd  0.7 ± 0.7 nM 
1.3 ± 0.0 
pmol/mg total 
protein 
B N Histamine KL  20 ± 2 M  
 N  KH  0.4 ± 0.4 M  
 N  RH  55 ± 10 %  
 I  KL  38 ± 6 M  
 I  KH  1 ± 2 M  
 I  
2-site 
RH  78 ± 24 %  
 N Mianserin Ki   0.3 ± 0.0 nM  
 I  
1-site 
Ki   0.6 ± 0.1 nM  
Figure 8. Saturation binding of 
[3H]DPCPX to non-immobilized (a) and 
immobilized hA1R (b) receptors. The 
amount of [3H]DPCPX bound is 
indicated for the total  (▲), non-specific 
(▼), and specific binding (●).  The 
average of 3 experiments performed in 
duplicate is shown. 
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The saturation curve again indicated that approximately 25 % of the input receptor (relating to 
maximum functionality at 4 °C after 18 h incubation) had been functionally immobilized (Figure 
8) and that non-specific binding, determined in the presence of 10 M N6-cyclopentyladenosine 
(CPA), was consistent with than for the non-immobilized preparation. 
The equilibrium dissociation constant (Kd) of [
3H]8-cyclopentyl-1,3-dipropylxanthine 
([3H]DPCPX) for non-immobilized receptors was marginally larger than for immobilized ones,  
but still within experimental error (Table 2). 
Table 2. Values obtained from 
saturation binding curves (A) and 
competition binding curves (B) of 
non-immobilized (N) and immo-
bilized (I) hA1R. Dissociation 
constants (Kd) and maximum 
amount of binding sites (Bmax) 
were obtained from saturation 
curves, with 10 M CPA to 
determine non-specific binding.  
Competition binding constants of 
the agonist CPA, the inverse agonist 
8-CPT, and the antagonist N0840 
provided low affinity constants (KL), 
high affinity constants (KH), and 
percentages of high affinity receptor 
populations (RH) from 2-site binding 
curves and affinity constants (Ki) from 1-site binding curves.  
 
Agonist binding of CPA to non-immobilized and immobilized receptors was modelled on the 
basis of two different binding populations (Figure 9a, T-test, p < 0.01, Figure 9b, T-test, p <0.01, 
Table 2).  As for the HA-hH1R-HIS receptor, the affinities of CPA for the receptors, whether 
immobilized or in solution, were very similar.  In the case of the hA1R receptor however, the 
 
 




A N [3H]DPCPX  Kd  1.7 ± 0.7 nM 
8.5 ± 0.8 
pmol/mg 
total protein 
 I   Kd  2.1 ± 0.4 nM 
2.1 ± 0.2 
pmol/mg 
total protein 
B N CPA KL  250 ± 50 nM  
 N  KH  3 ± 0 nM  
 N  RH  55 ± 10 %  
 I  KL  202 ± 100 nM  





RH  41 ± 7 %  
 N 8-CPT 1-site  Ki   28 ± 1 nM  
 I   Ki   39 ± 16 nM  
 N N0840 Ki   440 ± 80 nM  
 I  
1-site 
Ki   540 ± 70 nM  
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fraction of high affinity receptors is slightly less in the immobilized state than non-immobilized 
state and the difference is greater than the experimental error. The inverse agonist 8-cyclopentyl-
1,3-dimethylxanthine (8-CPT) binds the immobilized receptor with slightly reduced affinity 
although again, within experimental error, while the antagonist N6-cyclopentyl-9-methyladenine 






lization due to 
decreased entropy 
of the unfolded state 
(from steric 
hindrance of the 
support). However, 
in the case of 
integral membrane proteins whose entropy in the unfolded state may be constrained by the 
membrane, it is not clear whether immobilization would have any effect. We investigated the 
effect of immobilization on GPCR stability by storing immobilized and non-immobilized 
preparation at 4 oC. After one week at 4 °C, both hA1R and HA-hH1R-HIS receptors maintained 
significantly higher activity when they were immobilized compared to when they were kept in 






Figure 9. Displacement of specific [3H]DPCPX bin-ding to non-immobilized 
(a) and immobilized (b) hA1R receptors by the agonist CPA. Both curves are 
best fit by a two-site model. The average of 3 experiments performed in 
Figure 10.  Stability of HA-hH1R-HIS (a) 
and hA1R (b) membranes as measured by 
radioligand binding and normalized to 
percentage on day 0. Membrane preparations, 
both immobilized and non-immobilized, 
were stored at 4 oC. Black bars represent 
immobilized membranes. White bars 
represent membrane preparations in solution. 
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DISCUSSION 
 
Our results show that it is possible to immobilize functional GPCRs within their native 
membranes on sepharose beads without receptor solubilization, purification or lipid 
reconstitution. The method resulted in the co-immobilization of other membrane proteins, both 
integral and membrane associated with similar efficiency. Furthermore, receptors immobilized in 
this manner remained stable for up to a week at 4 ºC at least. The methodology applied was 
simple, repeatable, and consistently yielded up to 1 - 2 pmol of functional receptor per ml of resin 
with two different receptors. While we only used GPCRs in our work, it is reasonable to expect 
that a similar approach should also work for other integral and membrane associated proteins 
such as ion channels, chemokine receptors or cytochrome P450s. 
A significant shortcoming of methods that rely on purification and solubilization is that 
upstream or downstream components of the signalling cascade may be lost upon immobilization. 
In the case of GPCRs, full functionality clearly requires the presence of other players within the 
cell membrane195,196. For example, Gαq/11 proteins have been reported to increase constitutive 
activity of the histamine H1 receptor
197 and have a role in dimerization198. Data in Figure 4 
clearly indicate that Gαq/11 proteins, which have been estimated to have a molecular weight of 42 
kDa199, were present in both non-immobilized and immobilized vesicles containing HA-hH1R-
HIS. We can not be certain about the proportion of immobilized Gαq/11 proteins which were 
effectively stripped off the resin, because we may only be collecting proteins which were 
immobilized via other proteins in the membrane, and not those which were directly covalently 
linked to the resin.  However, while not a complete inventory of all of the proteins required for 
GCPR signalling, the presence of the membrane associated Gαq/11 proteins is strongly suggestive 
that other such proteins are likely co-immobilized as well. The presence of other members of the 
signalling cascade may play a role in maintaining a similar pharmacology for immobilized and 
non-immobilized receptors (see below) and likely contributes to the enhanced stability of 
receptors in immobilized vesicle preparations. 
The efficiency of immobilization is an important aspect. We readily determined conditions 
under which the actual cross-linking process is quite efficient. Under these conditions the density 
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of receptor on the beads is then a simple function of the expression level. However, achieving a 
high level of functionality of the immobilized receptors required investigation of a number of 
parameters. Increasing the linker to 8 atoms from 5 yielded a near doubling of the amount of 
functional receptor immobilized. The reason for the sensitivity to linker length is not clear at this 
point, however, it is known that GPCRs require a fluid membrane environment112 and space 
between the surface and the membrane for extracellular domain movement143 for full 
functionality. It therefore seems possible that a short spacer leads to vesicle restriction and alters 
dynamics and mechanical properties.  
When all of the optimisation steps were combined, it proved possible to functionally 
immobilize these two GPCRs with an efficiency of approximately 25 % in comparison to 
similarly treated but non-immobilized vesicle preparations. The yield of functional immobilized 
GPCRs was very similar to what we have observed for model bacterial membrane proteins that 
have been purified and solubilized in micelles (Chapters 4 - 6). The current yield of 25 % is 
likely not an upper limit as can be seen from improved functionality upon increasing linker 
lengths, and further investigation into various matrices and linking chemistries should prove 
useful for further improvement of the efficiency. Furthermore, although we use a pH that favours 
the reaction at the N-terminus, the current chemistry may still be affecting some lysines which 
may be important for activity, such as Lys5.39 in the hH1 receptor ligand binding site, established 
from mutagenesis studies200,201. The N-terminus itself may also be too close to the binding site 
and steric hindrance may be limiting the activity of the immobilized GPCRs. However, the major 
limiting factor at this point appears to be the density at which the receptors were expressed. This 
issue could best be addressed by investigating other systems geared towards higher level 
expression. We have focussed on stably transfected mammalian cell culture as a source of 
material to develop the immobilization protocol. Clearly, one could produce similar vesicles from 
insect cells expressing the protein of interest at 10 - 100 fold higher levels. We are also 
investigating the possibility of on-bead enrichment strategies to improve the density of 
immobilized receptors to a level which would be sufficient for screening GPCRs with TINS. 
Immobilization of vesicle bound receptors had had only limited impact on their pharmacology. 
The immobilized HA-hH1R-HIS and hA1R populations bound antagonists and inverse agonists, 
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with affinity similar to non-immobilized receptors. Interestingly, the proportions of high and low 
affinity agonist populations typical of non-immobilized receptors191 seemed to change slightly 
upon immobilization of the hA1R while that of the HA-hH1R-HIS is indistinguishable within the 
limits of experimental error. At present the basis for this difference is not known but may be 
related to the co-immobilization of the appropriate G proteins.  
Screening of collections of compounds for target binding is often the first step in new drug 
discovery projects. Presently cell-based assays are the primary method of carrying out such 
programs for membrane bound targets. A generally applicable procedure for functional 
immobilization of membrane proteins could potentially be applied in any of the current bead 
based assays, for example our own NMR-based method77 (Chapters 4 - 6) or Scintillation 
Proximity Assays. Use of an appropriate reference such as a parental cell line would enable these 
methods to be applied to membrane proteins. In some cases a secondary immobilization of the 
sepharose bead itself may also be necessary.  Additional biophysical techniques to detect or 
characterise ligands for which the present immobilization method could be useful include frontal 
affinity chromatography-mass spectroscopy202 and affinity capillary electrophoresis203. In 
addition to ligand screening, functional immobilization could be a powerful tool for 
deorphanization studies. The method has the potential of being generally applicable to all GPCRs 
without being G protein or secondary messenger system specific. Although challenging subjects 
for biophysical applications due to their fragile and exigent nature, GPCRs have, on the contrary, 
proven to be easy targets for this simple immobilization methodology. This fact is accentuated by 
the absence of a requirement for tags, biotinylation, or the use of antibodies as tools for 
immobilization. Furthermore, the increased stability of the receptors upon immobilization will 
allow longer high throughput screening experiments to be carried out.  Our immobilization 
strategy therefore should enable the study of a broader range of membrane proteins, including 
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Target-immobilized NMR Screening: 
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Due to their involvement in a large number of pathologies and ease of access, membrane proteins 
are at the forefront of pharmacological interest. A number of high throughput screening 
technologies, including membrane and cell-based assays, have been used to develop lead 
compounds. Emerging biophysical techniques such as nuclear magnetic resonance (NMR) can 
potentially be used to find novel ligands, however to date they have only been applied to soluble 
proteins. We seek to apply our newly developed ligand screening technology, Target 
Immobilized NMR Screening (TINS), to membrane proteins. In TINS the target to be screened is 
immobilized on a porous support and flow-injection NMR spectroscopy is used to detect binders 
in mixes of compounds. Immobilization potentially allows TINS to be applied to membrane 
proteins. Here we address this issue by developing a simple and widely applicable 
immobilization protocol and applying it to model bacterial membrane proteins.  Since TINS is a 
comparative method, we have developed a reference system to control for non-specific binding of 
hydrophobic compounds to lipids or detergents used to solubilize the membrane proteins. This 
control protein is of the same size as our target and refolded in the same lipid micelles. The proof 
of principle was tested with a limited screen small fragment (150 - 300 Da) library on a bacterial 
ion channel solubilized in dodecylphosphocholine micelles and a larger screen of approximately 
1000 fragments was carried out on a membrane enzyme the Disulphide Bond Forming protein B.  
For both screens, 7 % of the fragments showed substantial changes in the NMR spectrum that 
were specific to the target and were considered binders. No loss of target binding capacity was 
detected after 1 month of storage of the samples. With the proof of principle validated, TINS is 
now ready to be applied to pharmaceutically2 important, membrane bound drug targets.  
 
                                                          
2 This chapter is a modified version of the published book chapter: Früh, V.; Heetebrij, R.; Siegal, G. 
Target Immobilized NMR Screening: Validation and Extension to Membrane Proteins. In Fragment-
Based Drug Discovery: A Practical Approach; John Wiley & Sons: Chichester, 2008; Ch. 6. 
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Fragment based drug discovery (FBDD) methods have been widely embraced in the last few 
years. Nearly all of the major pharmaceutical firms have developed fragment screening and 
evolution programs and a number of biotech firms have sprung up that make exclusive use of the 
approach to develop small molecule therapeutics. Amongst the variety of fragment screening and 
evolution methods that have been implemented, there are two common themes. First, the 
collection of compounds to be screened consist of small (typically less than 300 Da), highly 
soluble molecules. As such, they typically interact with the target weakly, with binding constants 
in the range of 2 to 5,000 M.  Second, the low affinity hits discovered by screening such a 
collection must be developed into high affinity, high specificity ligands. This process is much 
more successful when 3D structures of target-compound complexes are available21.  
The promise of FBDD, that is compounds that through obeying Lipinski’s rules10 are more 
likely to make orally bioavailable, safe drugs, is starting to be put to the test as compounds begin 
to move into clinical trials. The number of such compounds is rising rapidly due to the successes 
of Plexxikon, Astex, Sunesis, SGX Pharma, and a host of other biotech companies that place 
FBDD at the core of their activities. However, a third common theme that applies to all FBDD to 
date is that is has been strictly applied to soluble targets. On the other hand, the attractiveness of 
membrane proteins as pharmaceutical targets has been well documented204 with approximately 
60% of all current targets being membrane proteins. Thus it would be a significant advantage to 
be able to apply FBDD to the class of targets that includes integral and membrane associated 
proteins. 
We have developed a technology called Target Immobilized NMR Screening (TINS)77,205 that 
in principle can be applied to screening of membrane proteins. In TINS, the target to be screened 
is immobilized on a commercially available chromatography resin in a simple and efficient 
process. The immobilized target, along with a second, reference sample, is placed in a flow-
injection, dual cell sample holder in the magnet and the compounds to be screened are injected in 
mixes of about 5 compounds each205. Spatially selective spectroscopy206 is then used to 
independently acquire a 1D 1H spectrum of the compounds in the presence of the target or the 
reference. Comparison of the two spectra directly yields the identity of any compound that binds 
the target due to the simple reduction in peak amplitude of all resonances from the ligand. This 
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configuration yields a number of advantages for ligand screening. The combination of effective 
T2 relaxation and chemical exchange endows the method with great sensitivity with specific 
binding as weak as 5 - 10 mM (Kd) being readily detected. On the other hand, the presence of a 
reference sample in routine use cancels the weak, non-specific interactions typically observed 
between many of the compounds to be screened and the target. Thus the presence of artefacts in 
TINS screens is greatly reduced as is the false positive rate. The sensitivity can also be used to 
reduce the concentration of immobilized target to as low as 5 M solution equivalent, which 
combined with the fact that the entire compound collection is routinely screened with a single 
sample, means the screening can be carried out with as little as 5 nmols of the target. 
TINS has been applied to a variety of soluble proteins and in this chapter we will present some 
of these results. In principle, immobilization should allow an extension of the range of targets to 
which TINS can be applied to include insoluble membrane proteins. This idea is not new and 
others have attempted to apply biophysical methods for detecting ligand binding to immobilized 
membrane proteins151. In particular, surface plasmon resonance (SPR) has been used for this 
application. Membrane proteins represent difficult targets for in vitro ligand screening studies 
however since they are insoluble, often require the presence of specific lipids for proper function, 
are highly challenging to purify, and rarely amenable to high resolution structural analysis. 
Furthermore, a general limitation that has always been encountered is the difficulty of 
functionally immobilizing membrane proteins in a form appropriate for the assay. SPR for 
instance requires a flat surface with an underlying metal layer (to provide the material with 
dielectric constant opposite that of water). While a few cases of successful immobilization of 
membrane proteins have been reported under these conditions, a widely applicable method is still 
lacking. Here we will report on our initial efforts in two areas, the ultimate goal of which is to 
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We will focus on the principles and benefits of the TINS fragment library designed and tested 
as collaborative effort between ZoBio (www.zobio.com) and Pyxis Discovery (www.pyxis-
discovery.com) of Delft, the Netherlands207. 
It is now a well accepted principle that the “rule of 3”15 forms an approximate limit guiding the 
chemical nature of compounds that should be considered as a fragment for inclusion in a 
collection for ligand screening. At the other end of the spectrum, recent work from the 
Shoichet208 lab suggests that including very simple fragments of less than approximately 150 Da 
could cause difficulties downstream during the lead evolution process. Clearly a number of in 
silico filters must also be employed to remove undesirable compounds such as known 
toxicophores or reactive groups. In our efforts we also placed great emphasis on water solubility 
of the compounds. In one of the first publications concerning fragment library design, only about 
50 % of the selected fragments possessed sufficient solubility (1 mM) to be screened18. In more 
recent publications, better results for the water solubility of fragment libraries have been 
reported31,209. The prediction of water solubility however remains a challenge because one has to 
take into consideration both the crystal and solution state of the compound. Moreover, in our own 
analysis, we have not been able to find a simple correlation between the number of H-bond 
donors/acceptors and water solubility. Since computational methods for better prediction of water 
solubility are still under development, one must experimentally determine the solubility of a 
given fragment. However, by applying cut-off values based on experience, for properties that can 
be better predicted, such as cLogP and the number of hydrogen bond  donors and acceptors, 
which have a profound influence on water solubility, the fraction of water soluble fragments can 
be increased considerably. In our own efforts, about 90 % of compounds that were selected were 
soluble as singletons at 500 M in phosphate buffered saline and 5 % DMSO. Evotec has 
recently mentioned an in-house QSAR model to predict solubility which is claimed to be useful, 
but no data is presently available210. While originally our emphasis on water solubility stemmed 
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from practical aspects of making mixes of compounds at 500 M each in aqueous buffer, this 
effort has been well served when screening membrane proteins since we feel that it is one of the 
important reasons that we have so far experienced a very low false positive rate.  
Our library, which is intended to serve as a source of chemical diversity, is composed of 
compounds selected from four themes: (1) diversity using the scaffold-based classification 
approach (SCA)61, (2) amino acid derivatives, (3) scaffolds found in natural products, and (4) 
shape diversity. All compounds were selected from a carefully prepared database representing 
70,000 compounds that would make desirable starting points for drug discovery, including “rule 
of 3” compliance, and were commercially available from reliable suppliers. One of our explicit 
intentions in forming the library upon these design principles is to evaluate the performance of 
the various classes of compounds against different targets, both soluble and membrane bound. 
While it remains too early to make sensible conclusions from the roughly 10 targets that have 
been screened to date, in many cases there are up to two fold differences in hit rates between the 
different themes for a given target. 
 
Immobilization and reference protein 
 
 The strength of TINS lies in the fact that it is a referential system. That is the signal acquired 
in the presence of the target protein is compared to the signal acquired in the presence of a 
reference sample consisting of a known protein immobilized at approximately the same density 
as the target. The requirement for a reference protein comes from the fact that TINS is highly 
sensitive to even very weak interactions between the compounds and the immobilized target. 
Therefore the choice of reference protein is important. Ideally one would like to have a reference 
protein which is convenient to produce in large quantities, can be readily immobilized, has the 
roughly “typical” amounts of exposed surface charge and hydrophobicity and has essentially no 
small molecule binding capacity.  The PH domain of the cellular kinase AKT is a nearly ideal 
candidate which we use for screening of all soluble targets. Hajduk and colleagues showed that 
this protein was essentially refractory to small molecule binding using their well-known SAR by 
NMR assay211.  
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While we initially had concerns that this small protein would be unrepresentative of larger, 
potentially multi-domain targets, or that proper cancellation of non-specific binding would 
require accurate matching of total surface area, this turns out not to be the case as shown in 
Figures 1 and 2.  
Immobilization is a constant source of questions with regards to TINS screening. In principle, 
one is free to choose any immobilization approach which is compatible with a) the biochemical 
function of the protein and b) the constraints of NMR. Specifically the major concern related to 
NMR is susceptibility mismatch between the solid support and the surrounding aqueous 
environment. The group of Meyer had originally demonstrated ligand binding to targets 
immobilized on glass beads212. However, the susceptibility mismatch was so severe in this case 
that magic angle spinning NMR was necessary to average out the inhomogeneity. Clearly this  
Figure 1. Cancellation of non-specific binding by the reference sample in TINS screening. The left hand 
panel shows difference 1H NMR spectra of a mixture of non-binding compounds acquired in the presence of 
sepharose resin to which 6 mg/ml of an SH2 domain (111 amino acid residues) had been immobilized or just 
the resin itself. The indicated additive was included  with each of the compound mixtures. The right hand 
panel shows the same difference spectra however the second spectra was acquired in the presence of a resin 
to which 6 mg/ml of FKBP had been immobilized. The improvement in cancellation when an immobilized 
protein is used as a reference is clear. 
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Figure 2. In this example taken from a screen of a soluble target, both the target and the reference protein 
(the PH domain of the kinase AKT) were immobilized on Actigel ALD (Sterogene, USA) at a solution 
equivalent of 100 M. A mix consisting of three different compounds (upper three 1D 1H NMR spectra are 
of each compound in the mix separately) was applied simultaneously to the sample of immobilized target 
and reference protein in the dual cell sample holder.  Spatially selective Hadamard spectroscopy was used to 
simultaneously acquire separate spectra of the compound mix in the presence of the immobilized target and 
reference. These spectra are overlaid at the bottom of the figure. The similarity of the two spectra indicates 
that none of the compounds specifically bind the target. The weak interactions with any immobilized protein 
that are observed for most compounds in the library are approximately the same for both the reference and 
target.  
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arrangement would not be compatible with flow-
injection NMR and so we sought a solid support 
which would not bind the compounds, would 
provide high capacity to immobilize proteins, and 
would minimize susceptibility differences. 
Sepharose based affinity resins turn out to be very 
useful in that they are very good matches for this 
list of requirements. In contrast to glass beads, 
sepharose beads can be more readily described as a 
three dimensional, bio-compatible mesh which is 
highly hydrated, yet sufficiently rigid to maintain 
good flow characteristics even after 300 
applications of compound mixes. The 
susceptibility mismatch is minimal such that under 
our current screening setup, using the dual-cell 
sample holder made from KelF, we routinely 
obtain a linewidth of about 12 Hz. However, the 
nature of the immobilization chemistry of the 
sepharose bead also appears to play a role in the 
linewidth observed for the compounds, as can be 
seen in Figure 3. 
A wide range of immobilization chemistries are 
commercially available in conjunction with 
sepharose beads. We have investigated a limited 
subset of these possibilities which include: direct, 
non-oriented immobilization via Schiff’s base 
chemistry, oriented non-covalent immobilization 
via immobilized metal affinity chromatography 
Figure 3. Effect of immobilization chemistry 
on the linewidth of compounds in solution. 
1D 1H spectra of the aromatic protons of 
phosphotyrosine (pY) are shown with the 
fitted linewidth. From top to bottom, pY in 
solution, in the presence of Actigel ALD, 
streptavidin-sepharose, Zn-IDAA sepharose, 
Zn-NTA sepharose, Zn-NTA silica and 
controlled pore glass beads (for comparison).  
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resins and oriented non-covalent immobilization via biotin-streptavidin binding. At present we 
favour direct, covalent attachment of proteins via primary amines since it is highly efficient 
(typically better than 85 % yield), minimizes leaching, and provides the best NMR results (Figure 
3).  
At the pH we typically carryout immobilization (pH 7.4), this reaction is rather specific for the 
amino terminus. In principle one could imagine that immobilization might interfere with the 
functionality of certain proteins, such as kinases that contain a lysine at an active site. Thus far 
we have not encountered this issue, but it is always possible to block access to this lysine by 
immobilizing in the presence of high levels of an ATP mimic such as AMPPNP. Kinases have 
been successfully immobilized for Biacore studies using related chemistry213. We have 
investigated the use of IMAC resins to immobilize proteins via a 6 his tag. While this method is 
convenient, it is not possible to use Ni2+ as the ion for chelating the tagged protein due to the 
potent paramagnetic relaxation. It is possible to immobilize his tagged protein using Zn2+ instead 
and leaching does not pose a problem. However, despite the fact that a sepharose resin is used in 
conjunction with a diamagnetic ion, there appears to be additional linebroadening effects (Figure 
3). These may result from non-specific interactions with available NTA sites on the resin which 
turn out to be difficult to block. We have also used streptavidin sepharose to immobilize 
biotinylated ribonucleotides for ligand binding studies. This system is convenient and yields high 
quality NMR spectra (not shown). By blocking unoccupied binding sites with free biotin (and 
naturally using streptavidin sepharose as the reference sample) one should be able to limit small 
molecule binding to sites that are not on the target, however we have not carried out a full screen 
on such a system so it not possible to make a definitive statement at this time.  Other affinity tags 
can also form the basis of successful, NMR compatible immobilization as well. For example, 
Haselhorst and colleagues have recently reported the use of Strep-tactin sepharose, a variant of 
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Ligand Screening 
 
We decided to carry out our ligand screening studies using mixes of compounds at a very early 
stage in the process of developing TINS. This decision was made on the basis of throughput and 
robustness. Since our mixes consist of on average 5 compounds, obviously throughput is 
increased by a factor of 5 with respect to screening singletons. Also, since it is expected that only 
1 (and occasionally 2) compounds per mix bind to the target, most peaks in the reference and 
target spectra should be of the same amplitude. If this is not the case it may be a sign that there is 
a problem with the screening sample. The use of mixes requires a strategy to design them 
properly. Given the constraint of increased linewidth generated by the heterogenous TINS 
system, the primary factor governing the selection of compounds for a mix is the number of well 
resolved peaks for each. We have therefore recorded a reference 1D 1H spectrum of every 
compound in the ZoBio/Pyxis fragment collection at 500 M in phosphate buffered saline (PBS) 
in the presence of a fixed amount of TSP. The reference spectra serve the dual role of quality 
control as well. The reference spectra are automatically peak picked and the peak positions stored 
in our database.  We have developed an in-house algorithm to randomly select compounds from 
the collection and rapidly test them for TINS compatibility, that is at least 3 well resolved peaks 
for each compound (when available). This allows us to directly read out the ligand from the mix 
without further deconvolution (see below). The algorithm also places explicit limits on the 
number of aromatic compounds per mix and avoids mixing compounds with pKa extrema.  Once 
designed, the mixes are then made at 500 M for each compound in PBS. The mixes are stored at 
room temperature and subsequently visually inspected for signs of precipitation. About 1/3 of 
mixes are rejected at this point. Mixes that do not precipitate are subjected to 1H NMR analysis 
where we expect to see that the NMR spectrum of the mix is a simple sum of the NMR spectra of 
the individual compounds using TSP as a reference. Changes to the NMR spectrum of the mix, 
which we rarely observe, are indicative of possible aggregation behaviour of the compounds. 
In order to carry out a ligand screen, the resin bearing the target and reference proteins, which 
have been immobilized at a solution equivalent of about 100 M,  must be packed into the dual-
cell sample holder. A homemade packing reservoir has been built to fit on top of the dual-cell 
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sample holder and double the volume of each cell. The resin (as a 50 % slurry) is pipetted in to 
each cell one at a time, allowed to settle by gravity and packed at a pressure of 0.5 bar. Once 
packed the cell can be connected to the sample delivery system via PEEK capillary tubes and 
inserted into the magnet using an aluminium arm. By attaching the cell to the aluminium arm we 
can readily orient it such that the plane that bisects each of the two cylindrical cells is parallel to 
one of the transverse gradients in our triple-gradient, flow injection probe205. In this way 
optimization of the NMR experiment for each screen is minimized. All that is necessary is to 
perform routine tuning and matching and shim, which we do using the FID of water. When 
known ligands are available, initial tests are performed to insure the integrity of the immobilized 
sample. This same experiment is repeated 4 - 5 times throughout and after the screen to detect 
possible target degradation (Figure 4). Once prepared, the mixes are placed in the Gilson 
autosampler in 96 positioned, deep-well plates and the Bruker HyStar software is programmed 
for each. We also use standard ICON NMR in Topspin to acquire the TINS data. A complete 
screen of about 1,500 unique compounds (including some replicates for quality assurance) 
requires about 7 days and runs without human intervention. Having evaluated a variety of 
different spatially selective NMR experiments, we have settled on the Hadamard sampling 
approach. The quality of the data using this experiment with carefully designed mixes is rather 
high, as can be seen in Figure 5.   
Figure 4. Determination of target 
integrity during a TINS ligand 
screen. A known ligand was applied 
to both the target and reference cells 
and the reduction in peak amplitude 
was measured (‘TINS effect’). This 
experiment was carried out serially 
after the indicated number of mixes 
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We have now screened a number of different targets, both soluble and membrane bound, using 
TINS. The hit rate for targets has varied from a low of 3 % to a high of about 10 %, where we 
define a hit as having at least a 30 % difference in amplitude between the reference and target 
spectra for all well resolved peaks. This cut-off was chosen for practical reasons based on the fact 
that the difference was sufficiently large to overcome artefacts related to spectral noise, minor 
lineshape differences between the two samples and spectral crowding and therefore enabled 
Figure 5. Direct determination of ligand identity using TINS. A mix of 5 compounds was applied to the 
dual sample holder containing immobilized target and the PH domain of AKT, both at 100 M solution 
equivalent. The individual spectra of each cell, acquired with 30’ of measuring time, are overlaid at the 
bottom of the figure. The 1H spectra of four of the five compounds are shown above for reference. The 
identity of the ligand (fourth spectrum identifier 1059) is readily obtained by simple inspection. 
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reliable detection of a hit. This latter fact is particularly important since we wish to automate the 
data analysis process. Since screening on these targets has only been carried out using TINS, it is 
not possible to directly compare the observed hit rates with other methods including High 
Concentration Screening (i.e. screens based on inhibiting and enzymatic activity). Where Hajduk 
and colleagues reported essentially a 0 % hit rate for the PH domain of AKT211, we in fact do 
detect some compounds binding, but our “hit rate” is about 0.2 %, some 10 fold lower than the 
lowest rate obtained for a target that is expected to be “drugable”. In their work Hajduk and 
colleagues reported hit rates of up to 1 % for SAR by NMR. Interestingly, the 3 % hit rate for 
TINS was found when screening a soluble “NTPase” in the NDP bound form. The hit rate for the 
apo protein was about 9 %. The low hit rate found when the nucleotide binding pocket is 
occupied is expected and suggests that the high hit rates that we observe are not due to artefacts, 
but rather to reliable sensitivity to binding events. This idea is further supported by follow-up 
biochemical studies that we have now performed for two targets with enzymatic activity. 
Considering a soluble enzymatic target for which we found a hit rate of 9.5 %, approximately 50 
% of the TINS hits showed significant inhibitory activity at 500 M, while we would expect this 
number to go up even further if tested at the 1 - 2 mM typically used in high concentration 
screening. A similar pattern has been observed for membrane proteins (see below).  
 




Although TINS removes limitations such as size and solubility of the target protein to be 
applied, there still remain quantity limitations with regards to membrane proteins.  At present the 
practical lower limit for screening is roughly 25 M solution equivalent (e.g. nmol/ml settled bed 
volume). Since we typically prepare 500 l of immobilized resin to fill one cell of the sample 
holder, we require about 15 nmol of target. For a 50 kDa protein this works out to slightly under 
1 mg and therefore it is safe to use 1 mg as a lower limit. For soluble proteins in which structure 
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guided hit optimization is the primary means for evolving fragments, this limit does not generally 
present a problem. However, for many membrane proteins formidable efforts are required to 
produce even this quantity. Accordingly, efforts are underway in our laboratory to enhance the 
sensitivity of TINS towards an eventual goal of being able to screen recombinantly expressed 
proteins in their native membrane environment, that is, without purification. Below we present 
data demonstrating the feasibility of immobilizing such native membrane fragments. Since this 
approach is beyond the present sensitivity limits of our TINS ligand screening station however, 
current efforts utilize highly expressed, purified, and functionally solubilized membrane proteins. 
Given the current requirement for about 1 mg of functional protein to carry out ligand 
screening, it is clear that an appropriate system must be available to produce large quantities. Due 
to the interest in pharmacology and structure of membrane proteins, tremendous efforts have 
been made in recent years in developing new means to express, purify and solubilize them. It is 
not our intention to catalogue these approaches here, merely to mention some which show 
promise with respect to producing sufficient quantities for ligand screening and subsequent 
structural studies. Conceptually the simplest method for membrane protein production is via cell-
free expression. Recently 6 different GPCRs have been produced in mg quantities using an E. 
coli based expression system that included Brij78 as a solubilizing detergent215. Studies were 
performed to show that at least one of the in vitro expressed GPCRs was functional. Interestingly, 
all appeared to be dimeric. Bacterial expression of membrane proteins typically results in the 
protein being unfolded and located in inclusion bodies. While purification of proteins from 
inclusion bodies is easy, the requirement for refolding can represent a considerable hurdle. 
Nonetheless, companies such as M-fold have successfully produced isotope labelled GPCR using 
this approach and showed that the protein was amenable to NMR studies216.  
Beyond bacterial expression systems, a number of eukaryotic expression systems have also 
been developed.  One simple method of producing functional membrane proteins is to generate 
recombinant transient or stable cell lines based on CHO or HeLa cells. Such cell lines have the 
benefit of providing appropriate posttranslational modifications such as glycosylation which are 
not available in prokaryotic expression systems217.  Often these modifications are required for 
protein function as shown for rhodopsin where folding is inefficient when the glycosylation site 
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at its N-terminus is suppressed218. Unfortunately the yield of proteins from stable cell lines is 
more often than not insufficient for ligand screening studies. Transient expression of membrane 
proteins can increase the yield by as much as a factor of ten but results in other inconveniences 
such as repeatability issues.  Alternatives that have seen increasing success include recombinant 
expression in insect SF9 cells219, use of Semliki Forest virus infected cells220, and expression in 
the yeast Pichia pastoris58. All of these systems are capable of yielding sufficient quantities of 
folded, functional membrane proteins for ligand screening and structural studies. Unfortunately 
none is perfectly general and the rate limiting step remains finding the best system for a particular 
target of interest.   
 
The membrane environment 
 
Membranes are structured as stable phospholipids bilayers which delimit the boundaries of the 
organelle or the cell.  The membrane provides an environment where chemical signals can be 
emitted and detected, where energy can be converted into inter- and intra-cellular functions, and 
through which materials can be transported.  For all these activities, there are complex networks 
of interactions between the membrane-associated proteins, such as receptors, ion channels, and 
enzymes, and the ligands which stimulate or inactivate them.  The membrane itself plays more 
than a passive role in these processes. Current understanding suggests that interaction between 
the membrane and embedded proteins is at least required for and may regulate protein function. 
Therefore the ultimate goal of research in our group is to be able to perform NMR based ligand 
screening studies on membrane proteins in their native environment. However, in light of the 
discussion in the preceding section it is clear that this is not yet possible and therefore membrane 
proteins must be recombinantly expressed and purified. Given the intimate interaction between 
protein and membrane, functional solubilization represents a major hurdle.  
In order to retain functionality of a membrane protein, it is imperative to refold it or 
reconstitute it into a synthetic lipid environment which mimics the properties of its natural 
membrane as closely as possible61.  Integral membrane proteins must be solubilized before being 
purified, and this often calls for addition of detergents after the initial centrifugation steps.  For 
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example, the potassium channel KcsA was extracted from the cell membrane by addition of DPC 
prior to purification using IMAC and gel filtration chromatography221.  Transmembrane proteins 
have large hydrophobic domains which can cause aggregation during purification.  This can be 
avoided by using high concentrations of urea to prevent random folding before reconstitution in 
lipids222.  These solubilization and purification steps are important because lipid reconstitution 
success depends on the state of the protein at this point. Organic solvents are the simplest 
approach to mimicking a membranous environment, but have only been possible to use with 
proteins with stable native folds such as ATP synthase223 or colicin E1 immunity proteins224.  The 
simplest true mimic of a membrane occurs when ionic or non ionic surfactants in organic 
solvents or water create micellar vesicles61.  Micelles, which are 10 - 100 kDa in size when there 
is low ionic concentration, are very convenient since they are readily formed and can be used to 
solubilize membrane proteins in a monomeric form amenable to high resolution structural 
studies. To date all TINS screening of has been applied to micelle solubilized membrane proteins. 
However, due to, at least in part the monolayer and the extreme curvature of micelles, they are 
only rarely compatible with native functioning of membrane proteins. Surfactants used for such 
preparations include, but are certainly not limited to, sodium dodecyl sulfate (SDS), 
cetyltrimethylammonium chloride and bromide (CTAC and CTAB), lysophosphatidylcholine 
(LPC), Triton X-100, and dodecylphosphocholine (DPC)61.  For NMR studies, deuterated 
surfactants are at least convenient and many times may be required. At present only DPC and 
SDS are commercially available in this form, although the latter tends to denature some 
proteins225.  Micelles are formed when the surfactant is in a higher concentration than its critical 
micellar concentration (CMC), which can vary from 0.01 mM for non-ionic ones to 10 nM for 
short chain ionic ones, such as SDS61. The equilibrium shifts from micellar to monomeric forms 
of the surfactant when diluted with buffers that do not contain the detergent and therefore buffers 
must always contain a concentration of surfactant above the CMC to prevent micelle disruption 
and loss of protein conformation. In our hands, there is rapid exchange of surfactant molecules 
from the micellar to the monodispersed form resulting in rapid breakdown of micelle bound 
proteins when the surfactant is not included (see below). Bicelles are micelles which are 
composed of phospholipids rather than detergents and are slightly more complex than micelles.  
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Usually bicelles are composed of long chain phospholipids such as dimiristoyl-
phosphatidylcholine (DMPC) forming bilayers and one shorter chain phospholipid such as 
dihexanoylphosphatidylcholine (DHPC) which lines the hydrophobic edges of the bilayer226.  
Bicelles, being mostly planar, represent a better membrane mimic than micelles and should be 
more compatible with protein function. The utility of bicelles for functionally solubilizing 
membrane proteins has recently been demonstrated by their use in crystallization of the GPCR, 
2-adrenergic receptor43. However, we have not yet tested bicelles for compatibility with TINS.  
In addition, there are more complex stable bilayer or multilayer vesicles of synthetic 
phospholipids which can be used to immobilize and orient membrane proteins  on glass slides in 
solid-state NMR227, but there usefulness for membrane protein immobilization on supports that 




The TINS methodology, by definition, requires immobilized protein to allow flow-through 
screening of ligands.  Clearly, the choice of the surface upon which the protein will be 
immobilized and the choice of the immobilization chemistry have to be made within the 
limitations of the TINS equipment. The general requirements for immobilization compatible with 
high resolution NMR have been discussed so we focus on issues specifically related to membrane 
proteins here. We have taken a pragmatic approach when attempting to apply the TINS 
methodology to membrane proteins by beginning with what has worked for soluble proteins. To 
date we have immobilized three purified, micelle solubilized membrane proteins KcsA, OmpA 
and DsbB, all of which are from bacterial sources. All three membrane proteins were solubilized 
in dodecylphosphocholine micelles (DPC). In all three cases we have simply utilized the same 
immobilization scheme that has been successfully applied to soluble proteins i.e. Schiff’s base 
chemistry to primary amines. We have found that the yield of immobilized micelle solubilized 
protein is nearly identical to that of soluble proteins. Further, immobilization has not had any 
detectable effect on the functionality of the immobilized, micelle solubilized proteins. This has 
been checked in two ways. For KcsA a panel of known ligands was available and we simply 
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assayed for binding using TINS. Since DsbB has an enzymatic activity, we adapted a 
spectrophotometric assay1 for use with beads containing immobilized protein. 
Enzyme inhibition studies were carried out by adding a reduced partner enzyme, and 
ubiquinone, whose reduction can be monitored by measuring the absorption decrease at 275nm 
over time. In order to reduce non-specific interactions to the resin and thus to compare enzymatic 
activity of the target prior to and post immobilization, there was an equivalent presence of resin 
in both cases. Results showed an efficient enzymatic activity post immobilization.  Considering 
the imprecision in determining the amount of immobilized enzyme, the rate of the reaction of 
immobilized enzyme (3 M Ubiquinone-5/M DsbB s-1) was close to that of the enzyme in 
presence of, but not immobilized to, the resin (4 M Ubiquinone-5/M DsbB s-1) (Figure 6). 
Naturally more complex strategies can be envisioned and may prove necessary for membrane 
proteins that are less robust than those used so far.  One interesting strategy immobilizes protein 
first, followed by subsequent reconstitution into a 
synthetic lipid environment108. As with soluble 
proteins, active site blockers may be necessary in 
cases where illicit immobilization of lysine side 
chains in close proximity to the binding site may 
occur and thereby inhibit protein function. Various 
native or synthetic lipid assemblies have been 
extended to encompass the use of high affinity 
immobilization reagents such as biotin and 
streptavidin66,163,165,228, antibodies229,230,231, or 
nickel affinity173,174 in order to immobilize the 
protein in more oriented manners. Thus as with 
soluble proteins, these approaches should also be compatible with TINS.   
As a first step along the road to enabling TINS ligand screening for a truly broad range of 
membrane targets, we have begun to immobilize GPCRs in native membrane fragments (Chapter 
3). In this experiment the idea was to use standard, stable animal cell expression systems such as 
CHO or HeLa cells as a source of material. In this way, all membrane proteins that can be 
 
Figure 6.  The target immobilized to the resin 
shows significantly similar enzymatic activity 
to the target in the presence of, but not 
immobilized to, the resin. 
No DsbB
   
  Solution 
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recombinantly expressed in these simple systems could potentially be used in fragment screening 
campaigns. Thus far we have succeeded in immobilizing membrane fragments produced by 
pottering (gentle disruption of animal cells) of post centrifugation membrane preparations. We 
have applied the procedure to both histamine receptors and adenosine receptors and in both cases, 
the pharmacology of immobilized receptors was similar to non-immobilized receptors. The 
efficiency of immobilization is quite reasonable with approximately 35 % of total receptors 
functionally immobilized and in comparison to non-immobilized ones; the immobilized receptors 
appear significantly more stable. At present the density of receptors is insufficient to perform 




We have developed a diversity library for use in TINS and it is our intention to screen it 
against all targets. The design requirement for high solubility (to maximize oral bioavailability) 
pays dividends when used in membrane protein ligand screening since partitioning to the lipid 
phase is minimized. Nonetheless, as with soluble proteins, it remains important to use an 
appropriate reference system to cancel out non-specific binding events. We have used the E. coli 
protein OmpA as a successful reference protein in one partial screen of about 200 compounds and 
one complete screen of about 1,300 compounds. Its advantages include easy expression and 
purification, solubility in DPC and low small molecule binding. One potential way to avoid the 
use of a reference protein would be to screen using a known, competitive ligand. We are 
presently adapting the hardware of the TINS ligand screening station to enable competition 
ligand screening studies. In this arrangement the target is immobilized in both cells of the sample 
holder and the same mix applied to both cells while the competitor is added to only one of the 
cells. Competition ligand screening will eliminate the need for a separate reference protein but 
has the drawback that one can only find ligands to known binding pockets.  When it becomes 
possible to screen proteins in native membrane vesicles, then a preparation of membrane vesicles 
of parental cell lines not expressing the target should serve as an ideal reference.   
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In order to further improve the robustness of TINS we include a reference compound in all 
mixtures that can be used to scale the two spectra post acquisition. With membrane proteins, even 
more than with soluble proteins, it is important to ascertain whether the reference compound 
interacts with the target or the surfactant used to solubilize it. The ideal reference compound has 
only one peak outside of the 
spectral range of all compounds and 
naturally, does not interact with the 
reference, target or surfactant. TSP 
fulfils most of these requirements 
but does bind to some targets. 
Alternatives we have used include 
glycine and tetramethylammonium 
chloride (TMA).  A crude scaling 
factor for the two cells can be 
experimentally determined by 
integrating the water signal from 
each cell using a standard 1D 
imaging experiment with a single 
scan. Binding of potential reference 
compounds can readily be 
established by simply conducting 
TINS experiments on all, applying 
the scaling factor and analyzing the 
spectra for equal peak intensity in 
both cells. So far we have not 
encountered a case where more than 
one of the three potential reference compounds bound to the target. 
As previously noted, individual detergent molecules rapidly exchange between the micellar 
and monomeric forms. Thus, washing of immobilized micelles in buffer without detergent leads 


















Figure 7. Requirement for the presence of detergent while 
screening micelle solubilized membrane proteins. In this 
series of experiments both the target (KcsA) and the 
reference (OmpA) were immobilized at a solution equivalent 
of 150 M. The histogram represents the fractional 
difference in peak amplitude of a known ligand of KcsA in 
the presence of KcsA and OmpA. The bar labelled control 
represents the first application of the ligand. Subsequently 3 
injections of the ligand were performed using buffers that 
contained no detergent. A further 3 injections were 
performed where the buffer used to wash the immobilized 
samples contained deuterated DPC. 
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to rapid loss of protein functionality, as shown in Figure 7. At least for the case of KcsA, which 
consists of a single polypeptide, the loss of functionality (as measured by binding of a known 
ligand) appears to be perfectly reversible. Nonetheless, it is clear that DPC must be applied 
throughout the screening procedure. Since DPC is available in deuterated form its presence does 
not interfere with the acquisition of the NMR spectra of the compounds. For convenience we 
chose to include DPC only in the buffer used to wash the compounds out of the cells of the 
sample holder and not in the mixes themselves. Since this approach has lead to two successful 
screens of membrane proteins we are optimistic it will be general. In this way it may prove 
possible to acquire NMR spectra even in the presence of non-deuterated detergents since the 
concentration of the monomer is reduced by application of the compound mix in the absence of 
detergent. However, we have yet to test this hypothesis. Once the immobilized protein 
functionality has been verified, it is also important to create checkpoints at different time points 
of the screen with mixes containing a known binder as a positive control to check that protein 
functionality and thus conformation is maintained through the screen.   
One final issue deserves special attention when considering carrying out ligand screening 
studies on a membrane protein, the kinetics of ligand binding. While low affinity ligands for 
soluble proteins nearly always exhibit rapid exchange kinetics on the NMR time-scale, this may 
not be the case for membrane proteins. For example, histamine binds the human H1 receptor with 
a Kd of 20 M232. Such a small molecule (histamine fits well within the definition of a 
“fragment”) binding with moderate affinity would normally imply a fast on rate. However, in this 
solid state NMR study, the on rate was found to be in the order of minutes! Likely mechanisms 
for such slow binding include access to the active site of the protein via the membrane or slow 
conformational exchange of the protein due to interaction with membrane (or membrane 
mimetic). Since the dynamic behaviour of detergents and phospholipids are strongly temperature 
dependent, it may be necessary to carryout screening at near physiological temperature where the 
long term stability of the target may be less than optimal. In such situations it may be necessary 
to prepare multiple samples in order to successfully carryout a screen of a complete fragment 
library.    
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Application of TINS to Ligand Discovery 
  
                          
Soluble Targets 
 
To date TINS has been applied to five different soluble targets. We have immobilized the 
target at a range of concentrations for the various screens, from as high as 500 M to as low as 
100 M solution equivalent. We now typically screen at 100 - 150 M which represents an 
optimal balance between sensitivity, artefact suppression and protein consumption. In all cases 
we have used the PH domain of AKT as the reference. Typically we immobilize the target and 
reference on the activated sepharose, Actigel ALD (Sterogene, USA). The efficiency of 
immobilization is monitored by UV absorption of the supernatant and visual inspection to insure 
that no precipitation has occurred. If an enzymatic assay of the target is available, we use it at this 
stage to confirm that the immobilized protein remains functional. The derivatized supports are 
subsequently packed into the dual-cell sample holder under pressure (0.5 Bar/cell), connected to 
the solvent delivery lines from the sample handling system, and then placed into the magnet. In 
most cases a small number of known weak ligands (up to 6) are available to test whether the 
target has been functionally immobilized and to demonstrate that we can indeed detect ligand 
binding. One of the known ligands is then selected for use in monitoring the condition of the 
target during screening. We routinely monitor the condition of the immobilized target through 
repeated injection of the known ligand throughout the screen.  
 Once the immobilized target has been deemed functional we carry out the actual screen. The 
mixes are delivered in 1 ml volumes in deep 96 well plates to the Gilson autosampler. Sample 
handling is controlled by Bruker HyStar software which communicates with Bruker TopSpin to 
acquire the NMR data. Using the Hadamard sampling experiment described earlier we currently 
acquire data for 30 minutes with an additional 5 minutes for sample handling resulting in a cycle 
time of about 35 minutes. In a recent screen 324 experiments were run in total to assess binding 
of 1,393 compounds from our fragment collection. This number includes repeated assaying of the 
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positive control to assess target condition and some overlap of compounds (e.g. compounds 
appear in two different mixtures). This design allows us to assess the repeatability of the 
screening data. Such a screen was carried out without human intervention in under eight days. 
Finally, since the target and reference are immobilized, it is possible to change buffer conditions 
to closely match crystallography conditions without regard to protein stability. We routinely 
screen under solution conditions in which the reference protein would precipitate if not 
immobilized. Nonetheless it ligand binding characteristics vary only very moderately from one 
set of solution conditions to the next. 
 
TINS proof of principle application to a bacterial membrane protein 
 
TINS is a comparative method, where detection of ligand binding to the immobilized target is 
quantitated by comparison to an immobilized reference. With membrane proteins, partitioning of 
ligands can occur on the native or synthetic lipids surrounding the target present on the resin. An 
appropriate reference system had to be developed to control for non-specific binding of 
hydrophobic compounds to lipids or detergents used to solubilize the membrane proteins. An 
appropriate choice for such a reference protein would be one with few known binders, in order to 
minimize the chances of non-specific binding. The E. coli Outer membrane protein A (OmpA) 
was chosen for such qualities.  This reference protein was of similar size as our intended target 
and also refolded in DPC micelles. To get an initial feel for whether we could detect specific 
binding to a membrane protein using TINS, we conducted a proof of principle study with a 
screen of a small subset (about 100 compounds) of our compound library using KcsA from 
Streptomyces as the target and OmpA as the reference. 
Prior to screening it was necessary to establish an appropriate 1) level of DPC to include in the 
wash buffer to maintain the integrity of the immobilized, micelle solubilized target and 2) internal 
reference compound.  If the DPC concentration in the environment of the target decreased to 
below its CMC, the micelles formed by DPC would start to slowly dissociate into monomers and 
be flushed away. Simple calculation suggested that it was necessary to use DPC at 5 mM in the 
wash buffer to in order to maintain the concentration above the CMC (1 mM) upon dilution with 
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the compound mix absent DPC. We tested both TSP and TMA as possible internal standard by 
including both in a mixture with (4-fluorophenyl)methylsulfanylmethanimidamide (FPMSMA, 
Figure 8a), a known ligand for KcsA. These tests indicated that both TSP and the known ligand 
FPMSMA specifically bind KcsA and we therefore chose to use TMA as an internal standard. 
Repeated application of TMA and FPMSMA, followed by washing with buffer plus 5 mM 
DPC demonstrated stability of the immobilized KcsA and so these conditions were used for the 
limited library screen. During the screen the immobilized target showed insignificant loss of 
binding capacity for the control compound and only 12 % loss after 3 months of storage.  Out of 
a b 
Figure 8. Proof of principle ligand screen against a bacterial membrane protein. a. Structure of the known 
ligand (4-fluorophenyl)methylsulfanylmethanimidamide used determine the integrity of the immobilized 
KcsA. b. Detection of ligand binding in one mix during the screen. A mix containing 5 different 
compounds  was applied simultaneously to the cell containing immobilized KcsA and to the cell containing 
OmpA. The individual 1H NMR spectra of each cell are overlaid (labeled TINS). The 1H NMR spectrum of 
each individual compound, which has been intentionally linebroadened to approximately match the 
linewidth of the TINS spectra, is shown above (numbered). All peaks from compounds 1 & 5 were reduced 
in amplitude in the presence of the immobilized KcsA with respect to OmpA, indicating that these 
compounds bind to KcsA. The structures of compounds 1 & 5 are shown. 
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the 95 fragments that were screened, 7 % showed substantial changes in the NMR spectrum that 
were specific to the target and were considered binders after analysis of spectra intensities 
(Figure 8b). This is in line with target hit rates obtained for soluble proteins applied to TINS. Of 
the potential new hits, 2 structures had a similar scaffold to the known binder.  The other hits had 
a variety of scaffolds with a variety of shapes and numbers of rings.  
 
Development of a high affinity inhibitor of bacterial membrane protein DsbB using TINS  
 
Very recently we have undertaken a program to develop high affinity inhibitors to the bacterial 
inner membrane protein DsbB in collaboration with Prof. John Bushweller’s group at the 
University of Virginia (USA). DsbB is a redox enzyme involved in the production of toxin in 
gram negative bacteria94 and as such is a potentially medically interesting target. The crystal 
structure of DsbB bound to its redox partner, DsbA has been solved92 and the Bushweller group 
has solved the solution structure of a disulfide mutant of DPC solubilized DsbB62. For ligand 
screening we immobilized both the functional wild type DsbB (see above) and OmpA (as a 
reference) at a solution equivalent of 100 M. We used the compound Ubiquinone-5 (Figure 9) 
which binds competitively with the native DsbB ligand. Similarly to KcsA, deuterated DPC was 
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Using this arrangement 1,270 
fragments were screened in mixtures that 
averaged a little over five compounds 
each. Figure 9 demonstrates that the 
immobilized DsbB remains intact 
throughout the screen. In the screen we 
found 93 compounds that specifically 
bind DsbB for a hit rate of 7.3 %. The 
hits have been investigated for enzyme 
inhibition at 250 M and the best 9 of 
these compounds had IC50s of 150 M 
or better where a representative curve is 
shown in Figure 3. We have carried out 
both competition binding and competition 
enzyme inhibition analyses on a limited 
subset of the hits. Most of the hits are 
competitive with ubiquinone binding and 
this seems to represent the major small 
molecule binding pocket. However, one 
of the subsets of hits is not competitive 
with ubiquinone. Follow up biochemical 
and biophysical analyses are presented in 








































Figure 9. Ligand screening of a bacterial membrane 
protein. a. The structure of Ubiquinone-5 used to asses 
the integrity of immobilized DsbB during the screen. b. 
Ubiquinon-5 binding to immobilized DsbB during the 
screen. Binding is defined as in Figure 2.  c. Enzyme 
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Outlook 
 
In the past decade an impressive repertoire of methods has been developed to enable drug 
development against soluble targets at the molecular level. In addition to fragment screening 
methods, structural biology has played a key role in this process. Although at present no drugs 
are marketed that are the exclusive result of the fragment approach the principles can clearly be 
seen in the remarkable specificity and potency of recently marketed kinase inhibitors such as 
Imatinib and Gefitinib and indeed, many fragment based drugs are in the late stages of clinical 
trials21. Membrane proteins represent a similar pharmacological challenge in that one would like 
to be able to specifically address individual targets from amongst large numbers of closely related 
members of a protein family. However, it is presently not possible to use the molecular methods 
developed for soluble proteins for drug discovery efforts on membrane proteins.  
A major goal of the research in our laboratory is to adapt methods developed for soluble targets 
to membrane proteins or to develop alternative ones. While we are clearly only at the beginning 
stages of this process we have nonetheless made a promising start. We have been able to 
immobilize a variety of membrane proteins in functional form and have carried out ligand 
screening on two. Our current efforts are geared toward finding new ways to solubilize and 
immobilize membrane proteins that can be more widely applied. We are also looking towards a 
variety of methods to improve the sensitivity of TINS including experiments that are better 
optimized for the diffusion limited nature of the heterogeneous system we employ and possible 
implementation of a TINS cryoprobe.  
Once one finds and validates hits, it is of course necessary to evolve these towards high 
affinity, high specificity ligands. The hit evolution process is greatly aided by the availability of 
three dimensional structural information of target-ligand complexes for soluble targets. Since 
crystallography of membrane proteins is not yet widely applicable it will be imperative to 
develop alternate approaches. We envision a number of such approaches that utilize the power of 
liquid or solid state NMR. In recent years both solid state NMR233 and solution state NMR234 
have made significant progress in elucidating 3D structures of either the membrane protein itself 
or ligands bound to membrane proteins. While it is vital that these efforts continue, it is also 
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logical that NMR should be employed to take advantage of its unique ability to rapidly generate 
local, low-resolution structural information. For this we foresee new applications in chemical 
shift perturbation based modelling of protein-ligand complexes235, sparse NOE based 
methods236,237 and paramagnetic NMR238. With the foreseeable advancements in ligand screening 
and structural analysis, the era of molecular drug discovery on membrane protein targets should 
soon be upon us. 
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Membrane proteins are an interesting class due to the variety of cellular functions and their 
importance as pharmaceutical targets, but they pose significant challenges for fragment based 
drug discovery approaches. Here we present the first successful use of biophysical methods to 
screen for fragment ligands to an integral membrane protein. Using the recently developed Target 
Immobilized NMR Screening approach, we screened 1,200 fragments for binding to the enzyme 
Disulphide bond forming protein B. Biochemical and biophysical validation of the 8 most potent 
hits revealed an IC50 range of 7 to 200 M, which could be categorized as cofactor binding 
inhibitors or mixed model inhibitors of both cofactor and substrate protein interaction. Our results 
clearly establish the utility of fragment based methods in the development of inhibitors of 
membrane proteins, making a wide variety3of important membrane bound pharmaceutical targets 
amenable to such an approach. 
 
 
                                                          
3  This chapter has been recently submitted as a manuscript: Virginie Früh, Yunpeng Zhou, Caroline 
Loch, Eiso AB, Herman Verheij, John H. Bushweller and Gregg Siegal. Application of Fragment Based 
Drug Discovery to Identify Inhibitors of the Integral Membrane Enzyme DsbB.    
Nature Chemical Biology.  Accepted for review 2009. 
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With 60 % of currently marketed drugs targeting membrane proteins36, it is clear that finding 
small molecules to modulate the function of such proteins is essential.  High throughput 
screening (HTS) methods have been successful in identifying such compounds, but because the 
methods of detection rely on functional assays, they are generally only sensitive to 
submicromolar interactions. Such relatively tight interactions are generally only observed for 
larger compounds (300 - 500 Da). However, it has proved challenging to simultaneously 
optimize potency and absorption, distribution, metabolism, and excretion (ADME) properties of 
these “lead-like” or “drug-like” compounds. Furthermore, such large compounds inefficiently 
explore the binding sites of proteins17. Fragment-based drug discovery (FBDD) has become a 
powerful complementary approach to HTS for generating novel chemical modulators of 
pharmaceutical targets. FBDD screens small libraries (1,000 - 20,000 compounds) of so-called 
drug “fragments” that are typically described by a “rule of threes”15 (Ro3, Mr < 300 Da, cLogP < 
3, H-bond donors < 3, H-bond acceptors < 3, number of rotatable bonds < 3 and TPSA (total 
polar surface area) < 60 Å2) for binding to the target. Ro3 compliant compounds typically bind 
the target with Kd greater than 10 M. In order to detect such weak binding, sensitive biophysical 
techniques are required. Commonly used techniques for detecting fragment binding include 
NMR, X-ray crystallography and surface plasmon resonance (SPR)207. Although these methods 
have been successfully applied to an array of soluble protein targets239, they have failed in one 
way or another when applied to membrane proteins. There are two primary reasons for this 
failure: insufficient quantity of the target and non-specific binding of compounds to the 
solubilization media. Since many biophysical methods require tens or even hundreds of mg of 
protein and most membrane proteins are difficult to produce in even single mg quantities, many 
potential applications of FBDD to membrane proteins have been impractical. For those 
membrane proteins that can be produced in sufficient quantity, non-specific partitioning of 
fragments into the detergent micelle or lipid bilayer used to solubilize the protein has been a 
severe and limiting problem.  
We have developed an NMR-based fragment screening approach which has proven, in 
principle, capable of overcoming the challenges posed by membrane proteins23 (Chapter 4). The 
approach, called Target Immobilized NMR Screening (TINS)77, involves immobilizing a target 
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and a reference protein in two compartments of a dual-cell sample holder205 and simultaneously 
injecting mixtures of fragments in an automated process.  For each mixture a 1D, spatially 
selective 1H NMR spectrum, which only contains contributions from the fragments in solution, is 
recorded. Fragment binding to the target protein is readily detected by the decrease in peak 
amplitude resulting from the greatly enhanced transverse relaxation experienced in the bound 
state. The reference protein, which is selected for minimal specific small molecule binding, 
serves to cancel out non-specific binding of fragments to protein surfaces.  Hits can therefore be 
easily detected by comparing spectra recorded in the presence of the target to those recorded in 
the presence of the reference.  By repeatedly using the same sample to screen the entire fragment 
collection (~1,500 compounds) typically only ~25 - 50 nmol of protein is required. Furthermore, 
the reference system is expected to account for non-specific binding of fragments to the detergent 
micelles in which the membrane proteins are solubilized. We therefore sought to apply TINS to a 
bona fide, integral membrane pharmaceutical target. 
The inner membrane protein of E. coli Disulphide bond forming protein B (DsbB), and its 
homologs in other gram-negative bacteria, is an oxidoreductase that is essential for protein 
disulfide bond formation in the periplasm. Periplasmic DsbA functions as the catalyst for protein 
disulfide bond formation and is reoxidized by DsbB with concomitant reduction of bound 
ubiquinone or menaquinone. Since many bacterial virulence factors are secreted proteins that 
require disulfide bonds for proper folding and function, the DsbA/DsbB system is a potential 
antimicrobial drug target94,240,241.  DsbB is an ideal candidate to test the TINS methodology since 
it can be readily produced and solubilized in detergent micelles where it retains a robust 
enzymatic activity which is easily assayed. In addition, a wealth of biochemical data is available 
that describes the enzymatic activity of the wildtype as well as numerous relevant 
mutants242,243,244,245. Finally, the 3D structures of the wildtype DsbB bound to its redox partner 
DsbA92 and of a mutant representing an enzymatic intermediate are available62. Selection of an 
appropriate reference protein is critical to insure the robust performance of TINS. Our previous 
experience using the E. coli Outer membrane protein A (OmpA) transmembrane domain, which 
has native structure under the same detergent micelle conditions as DsbB, in a limited screen of 
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about 200 compounds, suggested that it had minimal small molecule binding23 (Chapter 4). Thus 
we have utilized OmpA as a reference protein. 
Here we report the first complete screen of a fragment library against an integral membrane 
protein. Hits from the screen have been validated and characterized with respect to mode of 
action using an enzyme inhibition assay. Finally, the binding mode of two classes of inhibitors 
has been investigated by analysis of chemical shift perturbations induced upon fragment binding 






DsbA, DsbB, and OmpA were expressed and purified as previously reported1,79,99. The Actigel 
ALD resin (Sterogene, Carlsbad, CA, USA), available commercially, was used as a 50 % slurry 
and all experiments were carried out at 4 ºC when possible. The resin was washed with cold 
phosphate buffer (50 mM Na2HPO4, 50 mM KH2HPO4, 100 mM NaCl) at pH 7.5.  200 nmol of 
DPC solubilized DsbB was added to 1 ml bed volume of resin. The reductant sodium 
cyanoborohydride (NaCNBH3) was added to a final concentration of 0.1 M.  After an overnight 
incubation at 4 °C, residual unreacted aldehydes were blocked by addition of 50 mM Tris buffer 
and NaCNBH3 for another 2 hours. The same procedure was repeated for DPC solubilized 
OmpA. Quantification of immobilized protein was monitored by absorption of the supernatant at 
280 nm before and after immobilization, and by SDS-page gel with a known standard curve and 
volume analysis. This data indicated that a final concentration of 100 M of both immobilized 
DsbB and OmpA was achieved, equating to a 50 % yield. 
 
DsbB activity assays 
 
DsbB activity was quantified by measuring the capacity of the enzyme to reoxidize the protein 
DsbA or reduce its cofactor Ubiquinone-5, also called Coenzyme Q1 (UQ1) at pH 6.2.  DsbA 
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was reduced with 10 mM DTT for 10 minutes on ice.  DTT was subsequently removed by gel 
filtration on a PD-10 column pre-equilibrated with degassed distilled water containing 0.1 mM 
EDTA.  EDTA was used to chelate metal ions which would otherwise give rise to spurious 
reoxidation of DsbA244.  DsbA fluorescence (excitation at 295 nm and emission at 330 nm) was 
measured in the presence of DsbB and UQ1 in 50 mM sodium phosphate, 100 mM NaCl, 0.1 % 
detergent (DPC or DDM depending on which was used to solubilize DsbB) and 0.1mM EDTA) 
at 30 ºC. The activity of DsbB in terms of moles ubiquinone reduced/moles DsbB min-1 could be 
calculated by using the initial slope of fluorescence decrease upon DsbA oxidation, or by using 
the slope of absorption decrease at 275 nm upon reduction of UQ199. 
To measure activity of immobilized DPC solubilized DsbB, resin was aliquoted and diluted 
with degassed activity assay buffer to a final protein concentration of approximately 20 nM.  For 
an appropriate baseline, an equivalent amount of resin without protein (blank resin) was prepared 
in the same manner. Quinone reduction was monitored in both samples after addition of 20 M 
coenzyme Q1 and 20 M DsbA. 
 
Target Immobilized NMR Screening 
 
Immobilized, DPC solubilized DsbB and OmpA were each packed into a separate cell of a 
dual-cell sample holder205.  The cell was attached to a Gilson 210 autosampler via capillary 
tubing and inserted into an 8 mm, 1H selective, flow-injection probe in a 500 MHz magnet. 
Mixes of the 1,270 fragments were made by 200 fold dilution of a 100 mM stock of each 
compound in d6-DMSO such that the final DMSO concentration was never greater than 5 %. 
Upon injection of each mix into the dual-cell sample holder, flow was stopped and spatially 
selective Hadamard spectroscopy206 was used to acquire a 1D 1H spectrum of each sample 
separately.  A CPMG T2 filter of 80 ms was used to remove residual broad resonances from the 
sepharose resin. The cycle time was about 35 minutes, with 30 minutes required for the NMR 
experiment and 5 for sample handling, resulting in a total time of about 5 days to complete the 
screen. To maintain proper fold of each protein, 5 mM deuterated DPC was included in the buffer 
(20 mM phosphate buffer in D2O, 100 mM NaCl, pH 7.6)  used to wash the fragment mixes from 
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the sample holder. Scaling of peak intensities and positions between the two cells during data 
analysis was facilitated by adding glycine and TSP in all fragment mixes. 
 
Biochemical hit validation 
 
All fragments from the screen that were designated as positive for binding were assayed for 
DsbB inhibition at 250 M.  The amount of DMSO in all biochemical assay controls was 
adjusted to match the amount present when fragments were tested. Those compounds that 
showed more than 70 % inhibition at 250 M were further characterized by titration from 0.0001 
mM to 10 mM to generate IC50 curves. The mode of action for the 8 most potent fragments was 
determined from competition enzyme assays.  For this analysis either DsbA or UQ1 was titrated 
in from 0.2 to 40 M, while the other was kept constant at 40 M. For each titration point, slopes 
were measured in the presence of 5, 10, and 75 M of the fragment. DsbB activity data was 
analyzed using the non-linear regression curve fitting routines in Graph Pad Prism v. 5.01 (Graph 
Pad, San Diego, CA, U.S.A.). Statistical significance was evaluated with the student's T-test. 
Depending on the light absorbing properties of the fragments, they were used in either the 
fluorescence or UV-absorbance assay. Compounds which were not compatible with the assays 
due to high intrinsic fluorescence, high UV absorbance or irregular baselines were not included in 
the analysis.  
 
Biophysical hit validation 
 
Due to the poor quality of the NMR spectra of the wild-type DsbB, it was necessary to use a 
mutant that represents an intermediate in the disulfide oxidation pathway62.  Accordingly, 
validated hits from the screen were titrated at 1, 5, and 10 mM into 15N-labelled DsbB[CSSC] 
mutant (C44S, C104S). [15N,1H] HSQC experiments were acquired at 40 ºC in a Bruker DRX 
600 MHz spectrometer equipped with a cryoprobe. A reference titration of DMSO and a non-
binding fragment from the screen were used to subtract chemical shift perturbations not related to 
fragment binding.  
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RESULTS 
 
Structure of a micelle solubilized DsbB disulfide intermediate 
 
We have previously reported the solution structure of a mutated form of DsbB in which cysteines 
44 and 104 have been mutated to serine, resulting in a stable disulfide bridge between Cys41 and 
Cys130 in DPC micelles (referred to as DsbB[CSSC], Figure 1)62.  
Figure 1. Solution NMR structure of DsbB[CSSC] (PDB 
2K74), viewed approximately parallel to the membrane plane. 
The upper surface faces the periplasm while the lower surface 
faces the cytoplasm. DsbB has four transmembrane helices 
(TM 1 - 4) and an N-terminal cytoplasmic amphipathic helix 
(H1). The functionally important second periplasmic loop is 
divided into two parts (PL2 and PL2') by a short horizontal 
helix (H2). The four essential Cys residues (yellow) are 
located at the N-terminus of TM2 and in PL2 and PL2'. The 
binding site for the ubiquinone cofactor (black and red) lies on 
the periplasmic side of DsbB and is formed by TM1, TM2 and 
TM4. Two regions in PL2 and PL2' that form the DsbA 
binding site are colored red. 
 
This form of the protein, with a disulfide bridge between 
periplasmic loops 1 and 2, is an intermediate in the redox reaction that results in transfer of 
electrons from DsbA to a ubiquinone buried in DsbB246.  The N-terminus of micelle solubilized 
DsbB[CSSC] forms an amphipathic helix that runs parallel to the cytoplasmic side of the inner 
membrane. The ubiquinone binding site is near the periplasmic side of the inner membrane with 
the isoprenoid tail extending down the groove between TM1 and TM4. The interloop disulfide 
between Cys41 and Cys130 is approximately 7.5 Å from the benzoquinone ring. 
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 DsbB functional immobilization and 
enzymatic activity 
 
Wildtype DsbB (containing endogenous 
quinone), solubilized in DPC micelles, was 
immobilized on a Sepharose resin containing a 6 
atom hydrophilic linker terminating in an 
aldehyde via a Schiff’s base intermediate. At the 
pH selected (7.4), this reaction is relatively 
specific for the free N-terminus. A final 
concentration of approximately 100 M DsbB 
(nmol protein per ml settled bed volume) was 
readily achieved. The functionality of the 
immobilized enzyme was compared to non-
immobilized, micelle solubilized enzyme.  
Figure 2 shows that immobilized wildtype DsbB 
retained 90 % activity in comparison to the non-
immobilized protein and that the Kcat of both 
forms of the protein was close to values 
previously reported1.   
DsbB[CSSC] was assayed for enzymatic 
activity in both immobilized and non-
immobilized forms and, as expected, had no activity (Figure 2)1,62,245.  The ready immobilization 
with retention of enzymatic activity suggests that the N-terminus of DsbB is accessible in the 
micelle solubilized protein. Given the success of the immobilization strategy with DsbB, we used 
the same approach with OmpA which had also been solubilized in DPC micelles. We observed a 
similar yield of OmpA immobilization. Since OmpA has no enzymatic activity, we had to assume 
that its structure was not grossly perturbed by the immobilization process.  Independent 
Figure 2: Enzymatic activity of wildtype DsbB 
(wt) and DsbB[CSSC] in solution and 
immobilized. Both forms of DsbB were assayed at 
5 nM. The graph shows the reduction of UQ1 
observed by a decrease in absorption at 275 nm 
(a). The calculated Kcat values for each form of 
DsbB are compared with literature values *1(b).
* 
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experiments showed that immobilized samples of DsbB were stable for at least one month after 
storage at 4 ºC (data not shown). 
 
Target immobilized NMR Screening (TINS)  
 
In order to screen our fragment collection, DsbB and OmpA were immobilized at a solution 
equivalent of 100 M and separately packed into cells of the dual-cell sample holder205.   
Preliminary studies clearly demonstrated that repeated cycles of compound application and 
washing in the absence of added detergent resulted in rapid degradation of DsbB activity, as 
would be expected of a membrane protein23 (Chapter 4). Therefore deuterated DPC was included 
at a minimum concentration of 5 mM (5 x critical micellar concentration) in the buffer used to 
wash the compounds from the sample holder. To monitor the integrity of the DsbB sample during 
the screen, the binding of synthetic UQ1 was observed. The TINS effect, defined as the average 
ratio of the amplitude of peaks in the presence of DsbB to that in the presence of OmpA, 
remained constant for UQ1 throughout the screen23. This fact suggests that either the bound 
quinone was not cumulatively displaced or leached from the DsbB or that the injected UQ1 was 
sufficient to replace any lost quinone. A total of 1200 fragments, in 182 mixtures containing 3 - 9 
fragments at 500 M each, were assayed for binding to DsbB. A spatially selective Hadamard 
NMR experiment206 was used to simultaneously acquire a 1D 1H spectrum of compounds in the 
presence of DsbB or OmpA. The data resulting from the screen could be analysed directly 
without deconvolution because fragments could be directly identified by comparing peaks from 
TINS spectra with the fragment’s individual reference spectra (Figure 3).  The ready 
identification of binders enabled a totally automated analysis of the complete screening data,  
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from Fourier transform and phasing to comparison of peak amplitudes and binder identification. 
The analysis was performed using in house written routines implemented in TopSpin, the 
spectrometer control and data analysis software. The screen resulted in 93 hits for DsbB, defined 
as fragments which had a TINS effect less than 0.3, as shown by an example of a mix containing 
a hit in Figure 3. This particular cut-off was chosen by virtue of a step-like relationship between 
the observed TINS effect and the number of “hits” whereby even slightly raising the cut-off gave 
a large increase (more than two fold) in the number of compounds that were selected as hits (not 
shown). The resulting hit rate for DsbB was 8.7 % which is well within the range we typically 
Figure 3. Detection of ligand binding to immobilized DsbB using TINS. The 1D 1H NMR spectrum of 4 
different fragments in solution (a - d) is shown for reference. The linewidths of the reference spectrum 
have been intentionally broadened to match those recorded in the presence of the sepharose support. The 
1H NMR spectrum of a mix of the 4 fragments in the presence of DsbB (e-red spectrum) or OmpA (e-blue 
spectrum) that have been immobilized on the sepharose support. The highlighted region shows the 
reduction in peak amplitude expected upon specific binding of a fragment to the immobilized target. 
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observe with TINS (3 - 9.5 %). The higher hit rates of TINS with respect to other ligand based, 
NMR detected methods is readily explained by the sensitivity of TINS to binding as weak as 15 
mM Kd, which is about 5 times lower than comparable screening assays. Application of the same 
criteria to OmpA binding identified 7 compounds as hits for a hit rate of 0.6 %, validating the 
earlier data suggesting that OmpA has minimal small molecule binding capacity and is therefore 
a good reference for membrane proteins. 
 
Hit validation and characterization using enzymatic assays 
 
Since the TINS assay simply identifies compounds that bind to DsbB, not necessarily hits 
which inhibit enzymatic activity, it is important to validate the hits in terms of biological activity. 
Enzyme inhibition studies using a single concentration (250 M) were used to generate an initial 
ranking of the biological activity of the fragment hits (Figure 4). Each of the fragments identified 
as TINS hits was assayed for inhibition of DsbB-dependent reoxidation of DsbA. Compounds 
which interfered with the assay when run in either fluorescence or absorbance mode and were left 
out of the analysis. The remaining 74 hits exhibited a distribution of potencies against DsbB 
(Figure 4), including 60 % with better than 30 % enzymatic inhibition and 16 % with either less 
than 20 % inhibition or mild stimulation.  
 
Figure 4. Distribution of 
biological activity of the hits 
found in the TINS fragment 
screen of DsbB. Each fragment 
was assayed singly at 250 M. 
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Figure 5.  Potency determination for 
selected hits from the TINS screen. An 
example of an inhibition curve used to 
determine the IC50 (a). The curve represents 
the mean ± S.E.M. of three independent 
experiments performed in triplicate; (b) 
Inhibitory constants and Hill coefficients for 
the 8 most potent compounds.   
 
The 13 fragments showing more than 70 % 
inhibition in the single concentration point assay 
were further analysed for potency (IC50) by dose-
response experiments (Figure 5). Dose response 
experiments were carried out with increasing 
fragment concentrations, from 0.0001 to 10 mM, 
while both DsbA and UQ1 were kept in excess. 
Three of the 13 fragments showed artefacts 
including signs of protein precipitation at higher 
compound concentration and/or steeper than 
expected Hill coefficients. The remaining 10 
fragments titrated over 2 log orders and exhibited a 
Hill coefficient close to unity and are therefore 
well-behaved. The 8 most potent compounds had 
IC50 values between 7 and 200 M and consisted 
of a variety of scaffolds (see Figure 6).  
As an initial step towards delineating the 
molecular mechanism of DsbB inhibition, we 
carried out a more detailed kinetics analysis of the 
mode of action of the 8 most potent fragments. 
Substrate-velocity experiments were performed 
with either DsbA or UQ1 titrated in the presence 
of saturating amounts of the other. The titrations 
were then repeated in the presence of increasing 
amounts of the inhibitory fragment. There are 
several possible outcomes of such an experiment: 
a decrease in the apparent affinity for DsbA or for 
UQ1, in which case the fragment competes with 
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Figure 6. Mode of action determination for the most potent DsbB inhibitors. Fragment 2 was assayed in 
competition with synthetic UQ1 (a), the electron acceptor, or DsbA (b) the electron source. Fragment 8 was 
assayed in the same manner (panels c and d respectively). The Kcat and Km apparent determined from the data 
are shown in the table below (e) in the absence and presence of the indicated amount of each inhibitor. The 
structures of all 8 fragments are shown in f. The data indicates that fragments 1 – 3 are quinone competitive 
and fragments 4 – 8 are mixed mode inhibitors.
one of these for binding to DsbB, or mixed-model inhibition in which the apparent affinity for 
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In this analysis, fragments 1 - 3 behaved similarly (Supplementary Figure 1).  This group is 
exemplified by fragment 2 where increasing concentrations result in moderate perturbation of the 
maximum enzymatic turn over rate (Kcat) and apparent affinity of DsbA but a dramatic reduction 
(> 6 fold) in the apparent affinity of UQ1.  This data suggests that fragments 1 - 3 compete for 
the same binding site as UQ1. On the other hand, addition of fragments 4 - 8 simultaneously 
decreased both the apparent affinity and the Kcat for Q1 and DsbA as best exemplified by 
fragment 8 (Figure 6 and Supplementary Figure 2).  This data suggests a mixed model of 
inhibition of DsbB by these fragments. Mixed model inhibition could be explained if the 
fragments bound DsbB in such a way that limited access of both UQ1 and DsbA to their binding 
sites on DsbB.   To investigate this possibility we sought 3D structural information on the 
binding site of the fragments. 
 
Mapping of Fragment Binding on DsbB by NMR chemical shift perturbation 
 
If the sequential assignment of a protein is available, analysis of chemical shift perturbation 
data affords rapid access to low resolution structural data to characterize ligand binding sites28,236.  
While the sequential assignment of wildtype DsbB is not available due to the poor quality of the 
NMR spectra, spectra of the DsbB[CSSC] double cysteine mutant are of high quality, resulting in 
a complete backbone resonance assignment for this form of the protein62.  Accordingly, we 
titrated fragments 1 - 8 into 15N labelled DsbB[CSSC] and acquired HSQC spectra at 1, 5 and 10 
mM fragment concentrations. We titrated DMSO into 15N DsbB[CSSC] to control for solvent 
induced chemical shift perturbations and subsequently a fragment was selected from the library 
that was scored as a non-binder in the TINS screen. As expected these titrations resulted in 
minimal shifts of peak positions, which were subsequently subtracted from the titrations of 
binding fragments.  When purified from E. coli, DsbB[CSSC] contains the endogenous 
ubiquinone-899, thus compound specific for this site must compete with UQ-8 for binding. 
Synthetic UQ1 was titrated into a sample of 15N DsbB[CSSC] to locate the resonances which 
were affected by bona fide binding to the ubiquinone site (Figure 8).  We observed  
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Figure 7: NMR analysis of fragment binding to DsbB. The 8 most potent fragments were titrated into 15N 
DsbB[CSSC]. Data for the synthetic quinone UQ1 (a), competitive fragment 2 (b) and the mixed model 
fragment 8 (c) are shown.  
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Figure 7 (cont.): For each of these three compounds, the pattern of peak perturbations mapped onto the 
backbone structure, characteristic peak perturbations and the structure of the compound is shown. 
Residues with largest perturbations upon titration of the are indicated in red on the DsbB[CSSC] backbone 
structure (modified pdb ID 2k7462) viewed from the same orientation as in Figure 1 (left) and from the 
periplasmic face (right). The side chains of C41, S44, C104, and S130 are indicated in yellow.  The 
coenzyme UQ2 (orange) is shown to indicate its binding site and the 23 unassigned residues from this 
study and 10 prolines are colored white.   
significant chemical shift perturbations for a number of residues including the backbone amides 
of A22, Q33 and D136 as well as the sidechain indole of W135, all of which are in the 
areacorresponding to the endogenous quinone binding site, as reported previously in both the 
crystal and solution structures of DsbB62,92. In all cases, titration of UQ1 resulted in the 
appearance of peaks at a new chemical shift and the simultaneous disappearance of peaks from 
the spectrum of DsbB[CSSC] bound to endogenous quinone. This pattern of peak changes is 
indicative of slow exchange on the NMR time scale (e.g. koff < 30 Hz in Figure 7), a fact that 
is not surprising given the similarity of UQ1 to other known synthetic substrates of DsbB (e.g. 
UQ2). The appearance of the UQ1 HSQC spectrum and the lack of visible protein precipitation 
indicate that the displacement of endogenous quinone by UQ1 is a reversible phenomenon that 
maintains the overall fold of the protein.  
Addition of all 8 fragments to 15N labelled DsbB[CSSC] resulted in readily detectable changes 
in chemical shifts, suggesting that the fragments selected by TINS screening and biochemical 
assays on wild type protein also bind the cysteine mutated form. The presence of chemical shift 
perturbations in solvent exposed loops as well as portions of the protein buried within the micelle 
suggests that the fragments were specifically binding to the protein and not non-specifically 
partitioning into the micelle.  Fragments 1 – 3, which competitively inhibited ubiquinone binding, 
induced chemical shift perturbations located on the first periplasmic loop, in close proximity to 
the active site cysteine Cys41 and the mutated residue Ser44.  Unfortunately the key residue 
Arg48, previously identified as being involved in ubiquinone binding92 could not be clearly 
assigned in our experiments, along with a few other residues in close proximity to the ubiquinone 
binding site (Figure 7). The pattern of chemical shift perturbations induced by this group, as best 
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exemplified by fragment 2, closely resembles those induced by UQ1. First, titration of 2 into 15N 
DsbB[CSSC] resulted in chemical shift changes in the same residues as for UQ1 and further, 
these changes suggested slow exchange.  Similarly, R109HN, which is minimally affected by 
UQ1, undergoes only minor chemical shift perturbations in the presence of 2.  Further, mapping 
all of the chemical shift perturbations induced by 2 onto the backbone structure of DsbB[CSSC] 
reveals a pattern that strongly resembles that induced by UQ1 (compare Figure 7a to 7b).  
In contrast, the chemical shift changes induced by fragments 4 – 8 differ in both the overall 
pattern and the details (Figure 7c). Addition of 8, for example, to 15N DsbB[CSSC] resulted in 
chemical shift perturbations in TM1 and TM2 close to the quinone binding site as with 2, but 
additional extensive perturbations in the second periplasmic loop, especially the segment 
containing Cys104, involved in transferring electrons from DsbA to DsbB and the segment 
containing Pro100-Phe106, involved in DsbA binding92.  Interestingly, the section containing the 
hydrophobic residues Leu116 and Val120, which are suggested to be involved in associating with 
the membrane during charge transfer from DsbA to DsbB92, were affected by titration of 
fragments 4 - 8, but not by Q1 or fragments 1 - 3. Moreover, the details of the chemical shift 
perturbations differed significantly between fragments 4 - 8 and UQ1 or 1 - 3. There was no 
evidence for slow exchange for any of the fragments 4 - 8, although 4 & 7 show signs of line 
broadening of the backbone resonance of Q33 that may indicate intermediate exchange (not 
shown).  Addition of 8 resulted in gradual, concentration dependent changes to W135 NH that 
are indicative of rapid exchange while the position of the bound peak is very different from that 
in the UQ1 and 2 titrations. In contrast, the backbone amide of R109, which is only mildly 
perturbed by UQ1 or 2, is very dramatically perturbed by the presence of 8. This data suggests 
that fragments 4 - 8, which exhibit mixed mode DsbB inhibition, bind in either a different mode 
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Supplementary Figure 1. Competition binding analysis of fragments showing UQ1-competitive 
inhibition of DsbB.  The substrates UQ1 and DsbA were independently tested for competition by 
fragments 1 and 3. In both cases, fragments showed competitive inhibition of UQ1 binding (a, c) and non-
competitive inhibition of DsbA binding (b, d).  The data is represented as the mean ± S.E.M. of three 
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0 M 3.8 ± 0.1 2.2 ± 0.2 
75 M 
UQ1 
3.7 ± 0.5 8.8 ± 0.4 




1.9 ± 0.5 2.3 ± 0,5 
0 M 3.7 ± 0.1 1.6 ± 0.1 
75 M 
UQ1 
3.1 ± 0.2   13.2 ± 1.7 




2.5 ± 0.1 2.8 ± 0.1 
0 uM 3.8 ± 0,1 2,3 ± 0,2 
75 M 
UQ1 
2.9 ± 0.2 4.6 ± 0.2 




2.0 ± 0.5 3.2 ± 0.6 
Supplementary Table 1. Summary of values for DsbB competition binding analysis graphically 
represented in Supplementary Figure 1. Kcat and Km values for DsbB at 0 M and 75 M of 
fragments 1 to 3 are listed as the mean ± S.E.M. of three independent experiments performed in 
triplicates.   
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Supplementary Figure 2. Competition binding of fragments showing mixed model inhibition of DsbB.  
The substrates UQ1 and DsbA were independently tested for competition by fragments 4 to 7 and in all 
cases, fragments showed mixed model inhibition for UQ1 binding (a, c, e, g) and DsbA binding (b, d, f, 
h).  The data is represented as the mean ± S.E.M. of three independent experiments performed in 
triplicates.   
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0 M 3.9 ± 0.1 2.4 ± 0.2 
75 M 
 
UQ1 1.6 ± 0.5 4.3 ± 0.6 




DsbA 1.2 ± 0.1 3.0 ± 0.1 
0 uM 4.0 ± 0.1 2,4 ± 0,2 
75 M 
 
UQ1 1.9 ± 0.1 6.3 ± 0,2 





DsbA 2.3 ± 0.2 5.6 ± 0.1 
0 M 4.0 ± 0.2 2.4 ± 0.4 
75 M 
 
UQ1 3.6 ± 0.1 5.8 ± 0.3 





DsbA 2.7 ± 0.5 7.8 ± 0.5 
0 uM 4.2 ± 0.0 2.5 ± 0.5 
75 M 
 
UQ1 1.6 ± 0,1 5.9 ± 0.2 





DsbA 1.8 ± 0,3 5.9 ± 0.2 
0 uM 4.0 ± 0.1 2.2 ± 0.0 
75 M 
 
UQ1 2.3 ± 0.1 9.7 ± 1.5 





DsbA 2.4 ± 0.2 4.1 ± 0.5 
 
 
Supplementary Table 2. Summary of values for DsbB competition binding analysis graphically 
represented in Supplementary Figure 2. Kcat and Km values for DsbB at 0 M and 75 M of fragments 4 to 
8 are listed as the mean ± S.E.M. of three independent experiments performed in triplicates.   
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The use of Ro3 compliant, so-called “drug fragments” as a starting point for drug discovery, in 
combination with 3D structural information of target-fragment complexes, has delivered a 
number of innovative compounds which are currently in clinical trials21. However, this success 
has so far been strictly limited to soluble, moderately sized protein targets. Membrane proteins 
have not made good targets for FBDD due to their challenging physicochemical properties. In 
particular, the difficulty of generating sufficient quantities of purified, functional protein and of 
detecting specific binding to the target, as opposed to non-specific partitioning into hydrophobic 
phases, have limited the applicability of biophysical ligand screening approaches. Here we have 
addressed these two issues by a) immobilizing the target and reusing a single sample to screen an 
entire fragment collection and b) using a reference sample to cancel out non-specific interaction 
of the fragments with the hydrophobic phase. An additional, likely important, factor contributing 
to the low false positive rate is that the fragments that make up the collection are highly soluble, 
with each having been tested at 500 M in an aqueous buffer alone and in a mixture. Using our 
Target Immobilized NMR Screening approach we have screened a collection of nearly 1,100 
fragments with a single sample of less than 2 mg of protein and found 93 ligands. A number of 
observations suggest that these fragments are directly binding to DsbB and not indirectly via the 
micelle. First, there is a range of potencies in the enzyme inhibition studies that includes a small 
number of non-inhibitors and activators. Second, and perhaps more critically, inhibition is 
saturable and occurs over 2 log orders, strongly suggesting a stoichiometric interaction.  Third, 
titration of 8 different fragments into 15N labelled DsbB resulted in chemical shift perturbations at 
well defined sites in both solvent exposed and micelle buried portions of the protein. In 
particular, the similarity of the chemical shift perturbations induced by the synthetic quinone 
UQ1 and fragment 2 indicate the compounds are binding to the same site.   
The eight fragments with greatest potency in the single concentration enzyme inhibition assay 
were fully characterized for potency, mode of action, and binding site on DsbB. This analysis 
suggests that these fragments can be divided into two groups, one that competes only with 
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quinone for DsbB binding and a second that perturbs the apparent affinity of DsbB for both 
quinone and DsbA. The clearest examples of the different behaviour are fragment 2, which is 
quinone competitive and fragment 8 which exhibits mixed mode inhibition. The difference is best 
exhibited by the differing effect on the apparent Km for UQ1 or DsbA that these two compounds 
have. While addition of fragment 2 at 75 M reduced Km for UQ1 more than 8-fold, it had only a 
marginal effect on the Km for DsbA (only 5 % greater than experimental error). In contrast, 
addition of 8 at 75 M reduced Km for UQ1 more than 4.4-fold and Km for DsbA more than 2-
fold.  
Titration of fragments 2 and 8 into 15N labelled DsbB[CSSC] further supports a different 
mechanism of action of these two inhibitors. The differences can be most clearly seen by 
concentrating on the resonances from the backbone amide of R109 and the sidechain indole of 
W135. Titration of UQ1 into 15N labelled DsbB results in the simultaneous appearance of a new 
peak at a nearby position and the reduction of the peak from W135 from the endogenous 
quinone bound form. Since the other indoles are largely unaffected, we have tentatively assigned 
the new peak to W135in the UQ1 bound form. Addition of 2 resulted in concentration 
dependent shifts in the position of W135and the simultaneous disappearance and 
appearance of a new peak, as with UQ1. This new peak has an almost identical chemical shift (1H 
& 15N) as the UQ1 bound form. This behavior is consistent with two processes occurring. The 
first is a competition between 2 and the quinone moiety of the bound UQ8, consistent with the 
competitive kinetics observed for this inhibitor. However, we have shown that the isoprenyl tail 
of UQ8 extends down the groove between TM1 and TM4, making extensive interactions with the 
protein. Therefore, displacement of the quinone moiety likely does not immediately result in 
dissociation of UQ8 from DsbB[CSSC]. Apparently, this occurs on a slower timescale, resulting 
in the observation of a new peak with a quite different chemical shift. Addition of 8 to 15N 
labelled DsbB[CSSC] also causes chemical shift perturbation of the W135but these are 
exclusively concentration dependent and the bound state has a different resonance frequency than 
the bound state of UQ1 or 2. Also, addition of 8 causes a large downfield shift in the resonance of 
R109N that is concentration dependent while UQ1 and 2 had no or only minor effects on this 
peak.  
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When the chemical shift perturbations are plotted on the structure of DsbB[CSSC], a distinct 
difference is observed between UQ1 and 2 on the one hand, and 8 on the other. UQ1 and 2 induce 
similar shift perturbations which are primarily located in TM 1, 2 and 4. Fragment 8 induces 
fewer and smaller shifts which are primarily in the periplasmic end of TM1 and 4, but 
significantly more and larger shifts in both PL2 and PL2’. We propose a simple structural model 
that is consistent with the results of the biochemical mode of action study and the chemical shift 
perturbation analysis. In this model, the quinone competitive fragments 1 - 3, bind directly in the 
quinone binding pocket and displace the endogenous quinone. In contrast, the mixed mode 
fragments 4 - 8 bind on the periplasmic side of the ubiquinone binding site in the immediate 
neighbourhood of PL2’ and do not displace endogenous ubiquinone. This binding site would both 
reduce electron transfer to the ubiquinone and perturb the conformation of the periplasmic loops 
that form the binding site for DsbA, thereby reducing the binding affinity of DsbA. 
We note that the concentration of the fragments required to induce chemical shift perturbations 
in DsbB[CSSC] is significantly higher than the IC50 values measured for the wild type protein. In 
addition, UQ1 dependent chemical shift perturbations occurred in the same concentration range 
as the fragments. A likely explanation is that the conformation of the mutant differs slightly from 
the wild type protein, against which the fragments were selected. In addition, either the affinity 
for the quinone is higher for the DsbB[CSSC] mutant or more likely, the quinone binding site 
may be partially occluded. This latter possibility is clearly consistent with the reduced dynamic 
behaviour of DsbB[CSSC] with respect to the wild type protein, which results in the substantial 
improvement in the quality of the NMR spectra. This reduced dynamic behaviour of the disulfide 
mutant may be responsible for the slow exchange kinetics observed for UQ1 and 2 if release of 
the ligand from this binding site (endogenous ubiquinone, UQ1 or 2) can only occur from a 
sparsely populated conformation. 
Since TINS does not require any specific characteristics of DsbB, it should, in principle, be 
broadly applicable for fragment discovery with membrane proteins. Although the present study 
used deuterated detergent, this is not a priori a requirement. Many detergents that are compatible 
with membrane proteins have lower CMC values than DPC and therefore could be used at much 
lower concentration. Since the detergent would be at least 10 fold lower in concentration than the 
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compounds, its NMR signals would not interfere with the aliphatic signals of the compounds, 
while aromatic signals would occur in an entirely different portion of the spectrum. Furthermore, 
non-detergent media for solubilizing membrane proteins have been developed that are more 
compatible with protein function. These media, such as nanodiscs68,73,74 and amphipols72,180,181, 
are compatible with most membrane proteins and should prove highly complementary to the 
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The nanodisc: An alternative solubilization strategy for membrane proteins in TINS 
- 159 - 
Present drug discovery methods for membrane bound targets typically rely on cell based assays 
to detect small molecules that bind to and modulate the behaviour of the target. However, these 
assays are not sufficiently sensitive to detect the binding of so-called drug fragments, molecules 
less than 300 Da in mass. It is necessary to use highly sensitive biophysical assays such as SPR, 
NMR or X-ray crystallography to detect binding of fragments to proteins, but the surfactants 
required to solubilize membrane proteins interfere with these assays. These issues have been 
addressed by solubilizing the target and a reference protein in nanodiscs (ND), a self-assembling 
lipid bilayer surrounded by an amphiphilic, helical protein. We show that the target, the 
Disulphide bond forming protein B (DsbB), is functional in ND, both when in solution and when 
immobilized on sepharose beads. Here we compare the performance of ND solubilized vs 
detergent solubilized DsbB in fragment screens using Target Immobilized NMR Screening 
(TINS). In these studies the ND solubilized and immobilized DsbB is stable during repeated 
cycles of fragment injection and washing in the absence of added lipid. The stability of the ND 
allowed us to compare the performance of empty ND vs reference protein solubilized in ND as a 
means to account for non-specific binding of the fragments to either protein or lipid. Our results 
suggest that empty ND makes a nearly ideal reference system and using this system, previously 
validated hits from a screen of detergent solubilized DsbB were readily detected. Our findings 
suggest4a path to widespread application of fragment based drug discovery to membrane proteins. 
                                                          
4  4  This chapter is part of a manuscript: Früh, V.; Heetebrij, Grinkova,Y. N. , Sligar, S. G., Siegal, G. 
Self assembly of Protein – Nanodiscs Complexes: A solubilization strategy which enables fragment 
based drug discovery of membrane proteins in aqueous buffers. Manuscript in preparation 2009. 
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We describe the use of nanodiscs68 (ND) as an alternative, detergent-free, membrane protein 
solubilization approach that enables biophysical detection of small molecule binding and is 
broadly applicable to membrane bound pharmaceutical targets. 
Membrane proteins form the single largest class of targets for currently marketed small 
molecule drugs. High throughput screening has been a successful approach to discover small 
molecule modulators of membrane proteins, but the compounds derived from these studies often 
have chemical properties that are undesirable for an oral drug. Tailored, mechanism based 
compounds, such as kinase inhibitors, are showing great promise in the clinic with good 
specificity and reduced toxicity247. However, development of this class of drugs heavily relies on 
biophysical approaches such as Nuclear Magnetic Resonance (NMR), Surface Plasmon 
Resonance (SPR) and X-ray crystallography. Application of these techniques to soluble proteins 
is now widespread. In contrast, biophysical techniques, which require purified functional protein, 
have proven challenging to employ in studies of membrane proteins. Two particular issues that 
have been difficult to overcome are the necessity of solubilizing membrane proteins in a 
surfactant, such as in detergent micelles while maintaining protein function, and interference with 
the assay by the surfactant. Thus a possible solution to this bottleneck would be to employ non-
detergent media to functionally solubilize membrane proteins. 
The nanodisc has been developed as an alternative, surfactant free approach to solubilize 
membrane proteins. NDs consist of a lipid bilayer that is surrounded by a 23 kDa amphiphilic -
helical membrane scaffold protein (MSP). A variety of proteins have been functionally 
solubilized in NDs248, which are much better mimics of the native membrane. However, the 
suitability of NDs for biophysical assays of ligand binding to membrane proteins has yet to be 
determined. 
Target Immobilized NMR Screening (TINS) has been used to screen collections of small 
molecules (< 300 Da) for binding to a target77. TINS detects ligand binding via differences in the 
NMR spectrum of the compounds in solution recorded in the presence of an immobilized target 
and an immobilized non-binding reference protein. We have previously used TINS to identify 
inhibitors of the detergent solubilized, integral membrane protein DsbB (DsbB/DPC) using 
detergent solubilized OmpA (OmpA/DPC) as a reference (Chapters 4 and 5).  Here we assess the 
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combination of TINS and NDs to a) provide a proper reference to account for non-specific 
binding of compounds and b) to detect known ligands in a screening assay. 
We prepared empty NDs (-/ND), as well as NDs with embedded DsbB (DsbB/ND) or OmpA 
(OmpA/ND). Gel filtration analysis of our preparations revealed Stokes diameters of 9.63, 9.68, 
and 9.52 nm respectively, in accordance with literature values68, suggesting that the complexes 
were well formed (Figure 1). To check for functionality, we used an enzymatic assay previously 
established for DsbB99. DsbB in n-dodecyl--D-maltoside (DDM) detergent had a substrate 
(Coenzyme UQ1) turnover rate of 298 ± 6 U* while DsbB/ND had a rate of 346 ± 13 U. The 
substrate UQ1 may have partitioned into detergent micelles effectively lowering its final 
concentration in solution, accounting for the apparent activity difference. 
After immobilization on a sepharose 
resin using Schiff’s base chemistry, 
DsbB/ND had a substrate turnover rate of 
329 ± 26 U strongly suggesting that it 
remained completely functional23. 
Interestingly, the efficiency of the 
immobilization reaction of DsbB/ND was 
25 % higher than that of DsbB/DPC, 
suggesting that at least in part, 
immobilization involved MSP as well as 
DsbB. Immobilization via MSP could be a 
significant advantage because it is both 
general and avoids potential functional 
disruption by direct immobilization of the membrane protein.  
In order to assess the suitability of the nanodisc system for ligand screening we selected 20 
compound mixtures with and 20 mixtures without known ligands (a total of 183 compounds) 
from the screen of detergent solubilized DsbB. The influence of detergent or ND on the quality of 
the NMR spectra is shown in Figure 2. In both cases the compound whose spectrum is shown in 
                                                          
* Defined as M Q1/M DsbB-min-1. 
 
Figure 1. Characterization of empty NDs (-/N), 
DsbB/N and OmpA/N by gel filtration.  The Stokes’ 
Diameters were calibrated by using known proteins as 
standards. 
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2c is readily identified as specifically binding to DsbB.  However, the signal-to-noise ratio of the 
aromatic compounds (spectra a & b) in 2e is nearly double to that in 2d which enables better 
analysis of the aromatic peaks of the compound in 2b, which is now seen to bind DsbB. The 
reduced signal in the presence of detergent solubilized protein is likely due to non-specific 
partioning of 30 – 40 % of the compounds into the micelle, a result that is consistent with the 
biochemical data.  
Micelles are inherently unstable, 
and we found it necessary to 
continuously reapply the detergent 
to maintain the functionality of 
immobilized, DPC solubilized 
DsbB23. In contrast, NDs appear 
quite stable. We monitored the 
integrity of DsbB/ND, as 
determined by binding of a known 
ligand, during multiple cycles of 
compound application and washing 
in lipid free buffers (Figure 3a). 
Here binding is represented by the 
ratio of the average peak height for 
each compound in the presence of 
Target (T) or Reference (R). Equal 
(non)binding of a compound to the 
target and reference results in a T/R of 1, while lower values indicate binding to the target and 
higher values indicate binding to the reference. Figure 3a shows that after an initial small 
degradation, the ligand binding capacity of DsbB remained constant, which implies that the NDs 
remained intact.  
 In TINS the reference plays an important role in balancing non-specific binding of 
compounds and helps to ensure a low false positive rate. The stability of the empty ND affords 
Figure 2. Effect of membrane protein solubilization system on 
NMR spectra of small molecule ligands. A reference NMR 
spectrum of each of three compounds (a - c). 1D 1H NMR 
spectrum of a mix of the three compounds a - c in the presence 
of detergent solubilized OmpA (blue) or DsbB (red) (d) and 
respectively (magenta and green) the same solubilized in ND 
(e). The vertical scale in d and e is the same. The asterisk 
indicates the DMSO peak. 
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the possibility to use NDs directly as a reference to account for non-specific ligand binding to the 
lipid bilayer and MSP instead of requiring a reference protein as such. To investigate this, we 
screened all 183 compounds for binding to DsbB/ND using either OmpA/ND or -/ND as a 
reference (Figure 3b). 
 
 Overall there was a reasonable correlation (R2 = 0.78, slope = 1) in ligand binding, as 
determined by the T/R ratio. Clearly however, the correlation is offset towards a higher T/R ratio 
in the presence of OmpA/ND, suggesting greater non-specific binding to this reference system.  
 In order to fairly evaluate the performance of NDs and the various reference systems, we 
assessed the biochemical activity of the hits in the screen. The compounds were tested at 250 M 
using the previously described enzymatic assay. In total, 19 compounds gave significant 
biochemical activity (18 inhibitory and 1 stimulatory). Of these 19, 18 were detected as binding 
to micelle solubilized DsbB using micelle solubilized OmpA as a reference for TINS (Table 1).  
 
 
Figure 3. Stability of DsbB in nanodiscs 
(a, see text for details).  Comparison of 
empty ND or OmpA in ND as a 
reference (b). The solid line indicates 
the position of a perfect correlation. 
Table 1. Correlation of 
biochemical and biophysical 
assays 
 TINS Reference System 
Biochemical 
Hits: 
OmpA/DPC OmpA/ND -/ND 
 Detected 18 5 17 
 Not Detected 1 14 2 
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The TINS screen of DsbB/ND using -/ND as a reference detected 17 compounds binding to the 
target. The screen using OmpA/ND as a reference detected only 5 of the biologically active 
compounds. An identical cutoff was used for all 3 screens. In general the T/R ratio was higher in 
the screen vs OmpA/ND than in the -/ND screen, as shown in Figure 3b. Although the overall 
pattern was similar in both, the T/R ratio for many compounds in the OmpA/ND screen lay over 
the threshold that was used to detect binders. This data suggests that OmpA/ND has a higher 
level of non-specific binding than -/ND. Thus empty NDs appear to perform better as a reference. 
Importantly, the combination of TINS with empty NDs is capable of detecting nearly 90 % of all 
biologically active compounds and is therefore quite useful as a tool to detect ligands that weakly 
interact with membrane proteins.  
The reason for the higher level of non-specific binding of DsbB ligands to OmpA in NDs as 
compared to DPC micelles is not clear. Given the stability of OmpA, it is not likely that 
solubilization in the ND disrupted its structure, especially since it has been successfully 
solubilized in other non-detergent media72. One possibility is that the thickness of the POPC 
bilayer (46Å)249 may not match the width of the -barrel of OmpA (20Å), which could possibly 
leave exposed hydrophobic surfaces in the ND. The transmembrane portion of DsbB is about 
30Å, which while less than the POPC bilayer, is considerably more than OmpA. This size 
mismatch may present a limitation with respect to the range of membrane proteins that can be 
successfully inserted into NDs. However, since NDs can be formed with different phospholipids, 
it should be possible to vary the thickness of the bilayer to adapt to smaller proteins.  
Using the ND approach in TINS provided a more stable, biologically relevant mimic of the 
native membrane than detergent solubilization. Further, the partitioning of organic molecules into 
the hydrophobic phase appears to be significantly reduced in NDs. The empty ND forms an ideal 
reference system for ligand binding studies, accounting for non-specific binding of fragments to 
the MSP and POPC bilayer and greatly reducing false positives. These features make NDs a good 
choice for ligand studies using a variety of formats such as NMR. In view of the fact that a broad 
array of membrane proteins is compatible with NDs, it appears the path to widespread use of 
biophysical studies of ligand binding to membrane proteins may be open. The present protocol 
still requires purification and solubilization of the membrane protein. It may prove possible to 
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avoid both of these challenging steps by combining cell-free expression250 with direct ND 







Protocols for gene expression and protein purification were carried out as previously reported 
for both OmpA167 in n-octylpolyoxyethylene (C8POE) detergent micelles and DsbB62 in n-
dodecyl--maltoside (DDM) micelles.  Both of these proteins have a 6x-HIS tag at the N-
terminus. 
 
 Note that the OmpA used in this study is slightly different than the protein used in the ligand 
screening study of detergent micelle solubilized DsbB. The protein used in the current study is 
described in a study from the group of Popot72. This protein contains a 6 histidine affinity tag and 
three point mutation compared to wild-type, namely: K107Y, F23L and Q34K. The first mutation 
was deliberately introduced to enhance crystallization whereas the other two were inadvertently 
introduced88. The protein used in the previous study had 4 point mutation that were introduced to 
improve the quality of the NMR spectra53. In all cases, the mutations are on the outer face of the 
protein, in contact with the detergent or lipid molecules and therefore are not expected to have an 
influence on ligand binding. 
 
Nanodisc self-assembly 
The nanodisc self assembly procedure was repeated the same way for both OmpA and DsbB 
with slight adaptations from the previously reported procedures68,251. The reconstitution mixture 
contained Membrane Scaffold Protein MSP1D1(-) which lacked the HIS-tag, with mixed 
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micelles of POPC and cholate at a ratio of 1:65:130.  This reconstitution mixture was added to 
the OmpA or DsbB in detergent micelles (each with 10 x the detergent CMC) in a volumetric 
ratio of 1:1 and left to incubate on ice for 4 hours.  We always ensured a stoicheometry of 
MSP1D1(-) to OmpA or DsbB of 2:1.  Upon addition of 0.7 mg/ml of the hydrophobic adsorbent 
Bio-Beads SM-2 (Biorad, Hercules, CA) and gently mixing for 4 hours at 4 ºC, the nanodiscs 
would undergo self-assembly.  This step was limiting, whereby detergent removal below 4 hours 
was incomplete, but caused nanodisc complex malformation if carried out for longer (i.e 16h, 
data not shown). The HIS-tags of the embedded OmpA and DsbB were used to separate the 
empty non-tagged MSP1D1(-) complexes from the mixture by IMAC chromatography using Ni-
NTA resin with buffers containing 100 mM Tris, 300 mM NaCl, and imidazole at 0 mM, 10 mM, 
and 100 mM for loading, washing, and elution, respectively.   The assembly into a nanodisc 
appeared to have reduced the affinity of the proteins’ HIS-tags for the nickel column.  The eluted 
fractions were run through gel filtration (Superdex 200 10/300 from GE Healthcare) in order to 
remove the remaining aggregated non-embedded OmpA and DsbB, and to exchange the 
nanodisc-embedded proteins into Phosphate Buffered Saline (pH 7.6) for compatibility with the 
immobilization step required for TINS.  A set of standard proteins were run through the gel 
filtration column in the same conditions to calibrate the Stokes’ diameters of the eluted fractions  
Immobilization and TINS 
Fractions representing particles of 9.2 to 9.7 nm were pooled and quantified by SDS-PAGE 
band volume analysis (Quantity One by BioRad, USA) prior to immobilization and TINS 
screening, which were carried out as previously reported23,252.  Approximately 150 nmoles of 
DsbB/ND or OmpA/ND were applied to 1 ml of resin (bed volume) and left to rotate gently 
overnight at 4 ºC in Phosphate buffered saline, pH 7.6.  After this immobilization step, the 
supernatant was collected for quantification by centrifugation at 3000 rpm for 4 minutes at 4 ºC. 
The resin was further incubated for 2 hours at room temperature in 100 mM Tris, 100mM NaCl, 
pH 7.6 with 100 mM of reducing agent sodium cyanoborohydride in order to block the remaining 
unreacted aldehyde groups on the resin. Quantification of immobilized protein was carried out by 
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quantifying the supernatants before and after immobilization by measuring the absorbance at 
280nm and by SDS-PAGE band volume analysis. 
Once immobilized, the DsbB/ND and OmpA/ND were packed into two separate cells of a 
dual-cell sample holder205 which enables capillary tubing to connect the cell to the autosampler 
Gilson 210.  The dual-cell sample holder was then inserted into an 8 mm, 1H selective, flow-
injection probe in a 500 MHz magnet.  20 binder fragments and 20 non binder fragments, 
identified in a previous screen of DPC solubilized DsbB and OmpA, were present in 61 mixes, 
with 3 – 5 fragments per mix.  The fragments were initially solubilized in stock solutions of d6-
DMSO at 100 mM, and subsequently diluted 200 fold in PBS buffer with a final DMSO 
concentration below 5 %.  After each mix injection into the dual-cell sample holder, the pump 
flow was stopped and a 1D 1H proton spectra of fragments in each sample could be 
independently acquired by spatially selective Hadamard spectroscopy206.  Residual broad 
resonances from the sepharose resin were removed by a CPMG T2 filter of 80 ms.  After each 
acquisition, PBS buffer completely void of detergents was injected for several minutes in order to 
wash off the mix and prepare the resin for the next mix injection.  With a cycle time of 35 
minutes which includes a 30 minute acquisition time and 5 minutes for sample handling, the ND 
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General Conclusions  
 
As described in the review of membrane immobilization strategies in Chapter 2, there exists a 
variety of intricate protocols to express, solubilize, and immobilize membrane proteins for a 
range of applications ranging from ‘macroscopic’ functional cell-based assays to biophysical 
studies at the molecular level.  Most of these methods, however, have not enabled fragment based 
drug discovery in a high throughput manner on membrane proteins due to the challenging 
inherent properties of this class of proteins and the lack of general methods for their 
solubilization and immobilization. With the simple and mild Schiff’s base chemistry used to 
immobilize membrane proteins, combined with Target Immobilized NMR Screening, the 
research presented in this thesis has shown that fragment based drug discovery now has the 
potential to be applied to membrane proteins in general. As described below, the Schiff’s base 
chemistry made it possible to immobilize a wide class of membrane proteins including the 
histamine H1 and adenosine A1 GPCRs, the potassium ion channel KcsA, the membrane enzyme 
DsbB, and the reference membrane protein OmpA.  Although the GPCRs were immobilized in a 
functional manner, the intrinsic expression levels were too low to allow us to apply these proteins 
to the TINS methodology. On the other hand, the high levels of bacterial expression of KcsA, 
DsbB, and OmpA enabled us to apply these proteins to TINS. With available protocols for DsbB 
biochemical and biophysical characterization, the fragment hits identified for this enzyme were 
validated as specific binders, proving that fragment based drug discovery is now applicable to 
membrane proteins with exciting new perspectives, as described further. 
 
Simple and functional  immobilization chemistry generally applicable to membrane proteins 
 
The GPCRs used in Chapter 3 were an example of immobilizing membrane proteins within 
their native environment.  The immobilization efficiency was low, with only 20 % of the initial 
receptors functionally immobilized on the resin, with a maximum population of 2 pmoles of 
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receptor per ml of resin.  This is approximately 3 log units less than what is required for the 
current parameters of a TINS screen but nonetheless, the pharmacology profile of these 
immobilized receptors was very similar to the receptors which had not undergone the 
immobilization process. Immobilized receptors not only presented native pharmacology with 
regards to antagonist binding, but they also presented agonist two site binding profiles which 
confirmed the presence of G proteins as indicated by western blots of resin samples. 
Immobilizing GPCRs also had a positive effect on the relative stability of immobilized GPCRs 
compared to those in native membrane vesicles.  This physiologically relevant pharmacology of 
the receptors on the resin suggests that there is potential to apply this class of proteins to 
molecular based screening methods such as TINS. The limiting step in obtaining high amounts of 
immobilized GPCRs for TINS however, mostly has to do with the current low expression levels 
rather than the immobilization procedure itself.  For example, the increase in functionality which 
we report to occur upon immobilization with longer linkers between the protein and the surface  
has been reported for other GPCRs and is explained by the larger space available for the protein’s 
extracellular domain movement112. Other suggestions for obtaining higher functionally 
immobilized GPCRs are described in the perspectives section. 
The Schiff’s base chemistry also enabled the functional immobilization of detergent 
solubilized membrane proteins from bacterial sources, KcsA and DsbB (Chapters 4 & 5) and 
DsbB in the alternative solubilization agent, the nanodisc (Chapter 6).  These bacterial proteins 
have been extensively studied by molecular methods in the past, such as crystallography92,253 and 
NMR62,91, and a variety of protocols exists for their purification and functional solubilization in 
detergent micelles.  These conditions enabled us to produce sufficient amounts in E.coli to 
optimize the immobilization conditions.  The functional immobilization could be monitored 
either by injecting a known binder at different time points of the screen, or by an existing 
functionality assay.  The only protein for which we had a functionality assay available, however, 
was DsbB93.  We had no means to detect whether OmpA was properly folded upon 
immobilization, but our sole requirement for this protein was minimal small ligand binding 
properties, a quality which Chapters 4 – 5 demonstrated to be true.   These three detergent 
solubilized proteins were immobilized with an efficiency of 50 %, with a yield of 100 M 
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(volume equivalent) of immobilized protein, as required for TINS.  Upon the solubilization of 
DsbB and OmpA in the nanodisc complexes (DsbB/ND, OmpA/ND), the immobilization yield 
increased to 75 %.  This suggests that in detergent micelles, the N-terminus of both DsbB and 
OmpA may have been slightly buried into the DPC micelles and therefore less accessible to the 
immobilization reaction with the aldehyde groups on the resin.  In contrast, the N-terminus of the 
nanodisc membrane scaffold proteins may have participated in the immobilization reaction, 
thereby increasing the final yield of functionally immobilized DsbB/ND and OmpA/ND.  In 
contrast to the GPCRs in this study, the higher immobilization yield of DsbB (in detergents or 
nanodiscs) may be because the enzymes were immobilized in a more stable conformation due to 
the presence of the endogenous ligand, UQ8. Both DPC-solubilized DsbB (DsbB/DPC) and 
DsbB/ND were 90 % active on the resin compared to in solution and remained stable for a 
month. DsbB/ND however showed approximately 16 % increase in turnover rate compared to 
that in detergent micelles. This may be explained by the increased stability and functionality of 
membrane proteins in a better mimic of the native membrane, such as in the lipid bilayer of the 
nanodisc formation, as opposed to the less stable detergent micelle formation248.  The lower level 
of activity of detergent-solubilized DsbB may also be explained by the partial solubilization and 
consequent lowering of the effective concentration of the cofactor into the micelles during the 
enzymatic activity assay.  
 
Target Immobilized NMR Screening in DPC detergent 
 
The functional immobilization of membrane proteins in detergent micelles enabled us to carry 
out a TINS screen in the presence of detergent to identify fragments binding to KcsA (Chapter 
4) and DsbB (Chapter 4 and 5) with OmpA as a reference. The immobilization of DsbB and 
OmpA enabled an entire screen on the same protein samples for one week at room temperature, 
which resulted in a 7 % hit rate with a final set of 93 fragments which were listed for validation 
as DsbB inhibitors.  By comparing the intensities of the fragments injected from the same mix in 
the presence of the immobilized target or reference, one could immediately identify a target 
binder within a cocktail of fragments without any deconvolution.  This was facilitated by the 
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reference protein which accounted for non-specific levels of binding to proteins and to 
detergents, thereby providing information on specific binders to the target.  This proved the 
principle that TINS can be applied to membrane proteins, provided the appropriate distribution 
and concentration of detergent is used in the system. We tested the amount of detergent required 
in the wash buffer to enable continuous and stable protein functionality during a screen, and 
established that a concentration 5 x above CMC was sufficient. With KcsA, which is a tetramer 
protein, we could see an immediate drop in capacity to bind a control known binder upon an 
initial wash with an aqueous buffer void of detergents.  Interestingly, this drop in intensity was 
reversible with a fresh injection of buffer containing DPC, suggesting that the immobilization 
does indeed somewhat stabilize the protein. We established that keeping the detergent in the wash 
buffer rather than in the mixtures containing the fragments would limit the unwanted interactions 
between them while still enabling a full screen without loss of protein functionality.  DPC was 
used as a deuterated detergent, thereby rendering its signal invisible in the NMR spectra of the 
fragments.  
At this point, there was no method for us to establish whether the detergents were partially 
solubilizing the fragments, and, in doing so, were causing loss of fragment 1H 1D signal 
intensity.  Fortunately, the signal intensities remaining were high enough that fragments binding 
to the targets could be detected thanks to the reference system composed of immobilized OmpA 
in the same detergent micelles.  
 
DsbB hit validation by biochemical and biophysical analyses                
 
Of the 93 DsbB/DPC hits identified from TINS, a number of observations suggested that the 
fragments were indeed specifically binding to DsbB.  First, a well-distributed population of 
inhibitors was found by adding 250 M of fragments to the DsbB assay and calculating the 
subsequent percentage of enzyme inhibition induced by the fragments.  This resulted in 16 % 
showing less than 20 % inhibition or mild stimulation, 60 % of the fragments showing better than 
30 % inhibition of DsbB, and 17 % showing more than 70 % inhibition.  These were only single 
concentration point experiments which did not provide information on the mode of action, nor 
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whether this inhibition was due to protein precipitation or other assay artefacts.  Thus, secondly, 
the 13 fragments showing highest inhibition were chosen to be validated further by competition 
assays to quantify the potency (IC50) of the fragments as well as their mode of action 
(competition for the cofactor UQ1 or the DsbA binding site of DsbB).  These assays revealed 
artefactual inhibition by 3 fragments, but stoichiometric inhibition by the remaining 10 
fragments.  The IC50 values ranged between 10 and 200 M, and further competition analyses 
revealed two distinct binding modes. The most 8 potent fragments were thus grouped into two 
categories.  3 fragments caused the expected competition with the ubiquinone cofactor in the 
endogenous binding pocket of DsbB and the remaining 5 presented a mixed model inhibition, as 
defined by lowering the affinities of both DsbA and UQ1 for DsbB.   
Finally, because the biochemical assays were not providing structural insight into the 
mechanisms of DsbB inhibition by the fragments, an orthogonal biophysical method was used 
and confirmed the mechanism of the fragment modes of action in a structurally relevant manner.  
Unfortunately, as is the limiting factor for many membrane proteins, DsbB in DPC micelles was 
dynamically unstable and although part of the crystal structure was obtained in complex with 
DsbA92, there was no full structure nor sequential assignments available from NMR studies.  We 
therefore used 15N labelled DsbB[CSSC] for which the sequential assignments were available62.  
In this mutant, cysteines 44 and 104 have been mutated to serine, which had the consequence of 
creating a stable disulfide bridge between Cys41 and Cys13062, resulting in a stabilized and 
inactive form of DsbB.  Clearly, using the native protein would have been more ideal, but the 
mutant was a physiologically relevant intermediate of the disulfide oxidation pathway62 which, 
nonetheless, turned out to be useful in providing us with information regarding the structural 
interactions between the fragments and the enzyme.  HSQC experiments revealed detectable 
changes in the NMR spectra of DsbB[CSSC], which contained the endogenously bound UQ8 
cofactor, upon titration of UQ1 (positive control) and all 8 fragments.  This shows that the 
fragments identified by TINS and validated by biochemical assays also bound the double 
cysteine mutant, with a somewhat lower affinity as expected from this conformational variant of 
DsbB. The titrations revealed interesting information which confirmed the biochemical assay 
validation results.  Titrations of the positive control UQ1 yielded patterns which suggested slow 
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exchange of UQ1 into the DsbB ubiquinone binding pocket (already mapped by structural studies 
by crystallography on wildtype DsbB in complex with DsbA92) but also some elements of fast 
exchange. The 3 fragments showed similar slow and fast exchange patterns on the same residues 
as affected upon UQ1 titration:  these residues were located close to the first periplasmic loop of 
DsbB[CSSC] which contains the active cysteine pair in the wildtype DsbB, involved in reducing 
the ubiquinone in its native binding pocket.  Although the second group of fragments showed 
some similar patterns of chemical shift perturbations as the UQ1 and competitive fragment 
titrations close to the ubiquinone binding site, they also presented a distinctive pattern in the area 
of the second periplasmic loop.  The second periplasmic loop contains residues involved in DsbA 
binding (Phe100 - Phe106) and oxidation (Cys104) but also the hydrophobic residues (Leu116 
and Val120) involved in associating DsbB to the membrane upon charge transfer from DsbA to 
DsbB92.  The effects of mixed model fragment titrations also differed from the competitive 
fragment titrations in that they only presented patterns of fast exchange.  These differences can 
explain the mechanism of DsbB inhibition by these fragments.  Upon competitive inhibition, 
such as with competitive fragments or UQ1, the dissociation of the quinone within the binding 
pocket may have happened in two phases. The initial fast exchange displaced the quinone moiety 
which was bound towards the hydrophilic exposed part of the enzyme, but the dissociation of the 
isoprenyl tail, which extended deep into the hydrophobic groove, making extensive contacts with 
the hydrophobic residues between TM1 and TM4, happened at a slower rate.  Upon mixed model 
inhibition however, the fragments did not displace the ubiquinone but rather caused a 
conformational change which affected electron transfer to the ubiquinone and binding of DsbA to 
DsbB, as predicted by biochemical assays.  In conclusion, the fragments identified by TINS were 
validated as specific binders of DsbB and turned out to be either specific inhibitors of native 
ligand binding, or inhibitors of protein-protein interactions. 
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Target Immobilized NMR Screening in alternative solubilization medium: the 
nanodisc 
An attractive alternative to detergents is the use of amphiphilic polymers or complexes which 
on the one hand satisfy hydrophobic needs of membrane proteins while on the other maintain 
surface polarity contacts with the surrounding aqueous buffer.  In Chapter 6 we have shown that 
the nanodisc system has been a useful alternative to detergent in a TINS screen.  Although there 
were quite some conditions to test before obtaining a good population of well formed complexes, 
the procedure was simple and easy to characterize by gel filtration and SDS-PAGE gel band 
volume analysis. Not only was the immobilization yield more efficient in nanodiscs than in 
detergent due to the participation of the scaffold protein in the immobilization reaction, but the 
activity of DsbB was higher as well.  As previously mentioned, this suggests that either the 
protein was more active in lipid bilayers, as can be expected, or suggests that the detergent may 
indeed have partially solubilized the cofactor UQ1 in the assays, thereby resulting in lower final 
effective turnover rates. This last possibility has been further supported by the better quality of 
NMR spectra in the presence of nanodiscs as opposed to DPC. The signal to noise ratio was 
double to that in detergents, which, by NMR standards, suggests that there may have been a loss 
of 30 – 40 % of the effective amount of fragments into detergent micelles.  We had obtained 
particles of appropriate size upon gel filtration of nanodisc-embedded OmpA (OmpA/ND), but 
using these complexes as references for nanodisc-embedded DsbB (DsbB/ND) enabled us to 
identify only 5 known binders as opposed to 17 with the empty nanodiscs as a reference, and 18 
with the DPC screen of DsbB with the reference protein OmpA.  We used the same cut-off for all 
three screens, suggesting that the OmpA reference was now showing higher non-specific binding 
properties when embedded in a nanodisc complex.  Due to the highly stable nature of OmpA 
previously solubilized in a variety of detergents, however, it is unlikely that it was unfolded upon 
nanodisc entrapment, but it may more likely be a matter of mismatch in heights of the protein 
transmembrane domain of 30 Å and the corresponding lipid bilayer of 50 Å in the nanodisc254.  
This mismatch may have exposed areas with high fragment binding properties, either from 
OmpA hydrophobic residues or from the lipids in the nanodisc.  When using empty nanodiscs as 
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a reference, DsbB/ND proved to be stable throughout the screen without any addition of 
detergent.  Naturally, in the event that a target protein can not be solubilized in nanodiscs, 
however, screening the protein in detergent micelles still remains an option due to the sufficient 
level of fragment 1H 1D peak intensities remaining even after the fragments have been partially 
solubilized in the detergent micelles. 
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Perspectives 
 
The possibility of using molecular methods such as NMR for fragment based drug discovery 
on membrane proteins opens an exciting new venture for drug discovery.  Clearly, we are still 
limited from screening membrane proteins within their native membrane, and we could only 
obtain samples in the quantities and stabilities required for TINS by screening bacterial 
membrane proteins in detergent micelles. Work is underway to improve the conditions which 
would facilitate screening of membrane proteins in their native membrane. This includes 
enrichment of native membranes in situ, the use of more powerful NMR probes such as 
cryoprobes, improved NMR parameters, and downscaling of sample size by immobilizing 
proteins on the glass surfaces of microfluidic chambers compatible with the system.  In the 
meantime however, in combination with new solubilization and stabilization strategies70,71,255, 
there are a variety of perspectives for TINS on membrane proteins in vitro.    
 
Membrane protein immobilization 
 
In future studies, it would be interesting to see how we can maximize the population of 
functionally immobilized GPCRs and tailor the chemistry so as to immobilize these and other 
membrane proteins in a more oriented manner rather than the random Schiff’s base chemistry.  
There exists a variety of immobilization chemistries which can be used with the TINS compatible 
aldehyde resin used in this thesis.  In our case, although there were no structures available for the 
H1 and A1 receptors, mutagenesis studies on the adenosine receptor class has revealed the close 
homology between the recently solved A2A receptor structure
45 and the A1 receptor
256.  This type 
of information can be used to pinpoint structural elements of the receptors that can be involved in 
immobilization without affecting functionality, such as biotinylation of cysteines110.  For 
instance, the C-terminus has been found to regulate G protein coupling to GPCRs257, and should 
therefore be avoided in future immobilization reactions.  GPCRs can also be embedded in 
biotinylated forms of nanodiscs, which can then be immobilized to avidin-covered surfaces with 
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the benefit of leaving the target GPCR unaffected by the immobilization reaction. In addition, 
GPCRs which are in the ligand bound state tend to maintain a higher conformational stability, as 
can be seen by successful crystallization of the 2-adrenergic receptor in the presence of the 
partial inverse agonist carazolol34. This points to the potential of obtaining higher populations of 
functional GPCRs when they are immobilized in the presence of their ligands. The 
immobilization of membrane proteins will not only enable the elaboration of new drugs, but will 
also be interesting to use in studies looking at the physiologically relevant mechanisms.  With 
regards to GPCRs for example, this includes allosteric modulation, dimerization, and coupling to 
G proteins and other GPCR-interacting proteins (GIPs) such as the receptor-activity-modifying-
proteins (RAMPs)257,258. It may for example be useful to immobilize a GPCR in the presence of 
the ligand to establish whether it influences G protein coupling, as is the case for the C5a 
receptor, where C5a binding activates G protein coupling259. G protein coupling can therefore be 
potentially targeted in drug discovery by screening different mutants of a GPCR target with TINS 
to identify fragment scaffolds which interact with specific residues relevant for G protein 
coupling. The current immobilization procedure also has the potential to be used with other forms 
of solubilized membrane proteins, such as those in cubic lipid phases260, and is simple and 
generally adaptable to use with other chemical immobilization strategies, and with other proteins, 
surfaces, and assays.  
 
Target Immobilized NMR Screening 
 
Perspectives for TINS on membrane proteins are numerous because the technique can be 
adapted to various solubilization and immobilization strategies for primary screening of fragment 
binding. Screening a focused library based on known important scaffolds for the targeted 
membrane proteins can minimize the time of a screen down to a few days rather than an entire 
week, limiting the problems faced by low protein stability or quantities.  There may soon be 
improved NMR parameters with increased sensitivity which can enable one to downscale the 
amount of protein required per screen, thus enabling screens on proteins in their native membrane 
vesicles. In the meantime however, detergent or nanodisc solubilized membrane proteins may be 
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the only preparation available for current day fragment based drug discovery with TINS.  This is 
possible with the new stabilization mutations which have found to enable one to produce, for 
example, high quantities of GPCRs in E.coli, stabilized in either the agonist or the antagonist 
state, as has been previously reported for the A2A receptor
261 and the -adrenergic receptor70.  
The advantage of this technique is that E.coli can be grown in fermentors to provide large 
quantities as opposed to the adherent mammalian cell cultures, and carrying out a TINS screen on 
a specific state of the receptor minimises the need to carry out future assays to determine whether 
ligands are agonists or antagonists.  Furthermore, synergetic effects or allosteric modulation can 
be studied by designing appropriate libraries. 
The application of TINS to membrane proteins in nanodisc formations also enabled us to carry 
out a screen in complete absence of detergents. The lower signal to noise ratio obtained in screens 
containing detergents was still high enough to identify potent fragment hits. This leads to the 
advantageous possibility that screening nanodisc-embedded proteins in the absence of detergent 
can be carried out with 30 – 40 % lower protein and fragment concentrations and still obtain 
detectable fragment 1H 1D peak intensities.  GPCRs and GPCR-like proteins have been 
previously successfully embedded in nanodiscs, both as monomers (b2-adrenergic receptor)74 and 
as trimers (bacteriorhodopsin)262, suggesting that there are exciting possibilities of screening 
nanodisc embedded Class A and Class C GPCRs, the latter of which are obligate dimers263, with 
TINS. The use of empty nanodiscs as an appropriate and generalized reference, has now also 
been established for SPR technology264, and we believe future TINS applications should, when 
possible, be applied to nanodisc embedded targets.  Furthermore the use of the empty nanodisc as 
a reference would enable one to minimize the energy spent in finding an appropriate reference 
protein and developing a protocol for the appropriate self assembly into nanodiscs.   
Research is currently replacing old ideas about physiological processes, as can be seen by the 
increase in reports on GPCR multimerization50 and the multiprotein networks into what is now 
being coined ‘receptosomes’257.  Therefore, there are a variety of other topics aside from 
fragment based drug discovery to explore with TINS, in the event of obtaining better information 
for modulating a biological system in the body.  Without much information available on orphan 
receptors, TINS can be used as a tool to compare hits between different classes of protein, 
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leading to deorphanizing studies. As previous studies have shown, classification of GPCRs can 
be predicted by which class of G proteins they bind265,266, and therefore, deorphanizing studies in 
principle could also be carried out by immobilizing an orphan GPCR and injecting different G 
proteins instead of fragments.  Furthermore, the pharmaceutical industry is finding new and 
exciting ways of targeting drugs, such as pharmacogenomic profiling267,268 and the use of 
multitarget drugs269,270.   Thus, why not screen several targets within a specific pathway, or 
screen several physiologically relevant target mutants and identify a common hit between them, 
as has been suggested previously for drugs targeting multiple mutated version of kinases as an 
efficient treatment for cancer271.   
 
Fragment hit elaboration 
 
As we mentioned, structurally relevant information can be used to facilitate the elaboration of 
weak fragment hits into stronger, more potent and more specific ligands. For the hits which were 
found for KcsA and DsbB, clearly, obtaining structural key information of fragment binding to 
the wildtype protein would be an ideal next step. The intrinsic movement of the periplasmic loops 
upon DsbB enzymatic activity or upon KcsA dynamics may however hinder these kinds of 
experiments no matter how stabilizing the solubilization medium is. As with the stabilized GPCR 
mutants in literature70,261, and the DsbB[CSSC] mutant we used in Chapter 5, combining 
mutagenesis and molecular methods has the potential to provide worthwhile information on 
ligand-protein interactions.  However, some interactions are inherently weak, such as protein-
protein interactions involved in kinase domains272,273 and between G proteins and GPCRs258. 
Perhaps weak interactions in biological processes are currently undermined and targeting such 
interactions may enable to provide the medicinal chemistry realm with more specific inhibitors 
with lower amounts of side effects.  The advantage of using fragment based drug discovery in 
such a context is that fragment hits may suffice as weak inhibitors of protein-protein interactions, 
for example.   There are a variety of NMR based applications which can be applied to obtain 
valuable information on molecular interactions between ligands and proteins, as described in the 
outlook section of Chapter 4, such as modelling chemical shift perturbations235, sparse NOE 
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based methods236,237 and paramagnetic NMR238, but it is important to integrate other applications 
of medicinal chemistry, biology, and computational methodologies in order to be fully 
effective237.  The emerging era of new internet based software should be used to link data274 
across different databases, such as ones concerning diseases, targets, drugs, and clinical trials, in 
the global aim to make medicinal chemistry research more efficient by enabling the discovery of 
new connections between diverse data sets275.  Currently, work is underway to better understand 
how we can modulate the NMR parameters in such a way that TINS can be used for fragment 
binding quantification and hence, the ranking of fragment hits, and also as a competition binding 
assay which can provide information on fragment kinetics in relation to a given target.   TINS can 
be applied as a primary screening step, but once elaborated fragments have been made, it can also 
be worthwhile to use TINS as a secondary screening step.  
In conclusion, TINS can now pave the way to applying fragment based drug discovery to 
membrane proteins in general because it enables one to identify weak fragment binding to 
membrane proteins, whether solubilized in detergents or nanodiscs, in smaller quantities than 
those required for biophysical methods in general. The interesting perspectives which follow 
such applications are numerous because the immobilized target and references can be modulated 
to include, for example, different states or mutants of the same protein, and libraries can be 
modulated to include studies on allosteric modulation, and synergetic or competitive effects on 
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 This thesis describes how the Target Immobilized NMR Screening (TINS) method can be 
applied to identify small molecule hits on membrane proteins.   
 Screening small molecules, or fragments (< 300 Da), by fragment-based drug discovery 
(FBDD) has recently been shown to be an advantageous alternative to screening larger 
molecules, yet the concept is limited to soluble proteins.  Chapter 1 introduces the notion of 
FBDD and why it would be useful to find ways of applying this drug discovery approach to 
membrane proteins. In brief, FBDD has evolved with biophysical methods such as Nuclear 
Magnetic Resonance (NMR) because of the possibility of detecting weak binding of fragments 
on proteins. However, biophysical methods are demanding in terms of amount and purity of 
protein samples and, unfortunately, are currently limited to soluble proteins.  60 % of the drugs 
on the market however target membrane proteins which are involved in a variety of crucial 
cellular processes ranging from cell signaling to transport of ions and solutes in and out of the 
cell.  As the name indicates, membrane proteins are present within the cellular membrane and 
require a hydrophobic environment to maintain their structure and functionality.   Chapter 2 
reviews the extensive work carried out on immobilizing membrane proteins in a variety of 
membrane mimics, and shows that none of them are applicable to studying weak fragment 
binding on membrane proteins.  It is precisely this hydrophobic nature which limits the study of 
such proteins by FBDD due to the low protein yield and stability, and the problem of non-
specific binding of fragments to the membrane mimics used, such as detergents or lipids.  
 TINS is a reference system where the simultaneous screening of a reference protein (with 
minimal small molecule binding properties), solubilized in the same detergent as the target, can 
account for non-specific binding of fragments to the hydrophobic environment.  Identification of 
fragments which bind specifically to the target can be done immediately without any 
deconvolution, by simple comparison of the 1D 1H signal intensities of the fragments in the 
presence of the reference or target. This has the advantage over other NMR methods because no 
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structural information on the target is required, low amounts of protein are needed, and binders 
can be identified within cocktails of fragments, speeding up the process. 
 In Chapter 3, we showed that important pharmaceutical targets such as G protein coupled 
receptors (GPCRs) could in principle be studied by TINS due to their functional immobilization 
on a resin in a variety of biologically relevant agonist and antagonist conformations. This was 
possible because native membrane fragments of the cells overexpressing these proteins were 
immobilized, without further purification. This enabled the co-immobilization of other important 
players of the signaling cascade, such as G proteins. The low population of functionally 
immobilized proteins could be increased by increasing the linker length between the protein and 
the surface, yet the intrinsically low overexpression of these proteins was the limiting factor 
which prevented us from applying TINS to this class of proteins.   
 In Chapter 4, we proved the principle that membrane proteins in general could be applied to 
TINS.  We used the bacterial potassium ion channel (KcsA) and the bacterial membrane enzyme 
Disulphide bond forming protein B (DsbB) as targets, which were immobilized and screened 
with the bacterial reference protein Outer membrane protein A (OmpA), all solubilized in 
dodecylphosphocholine detergent. The immobilization efficiency of all three membrane proteins 
was calculated by detecting the amount of protein in the supernatant before and after 
immobilization, with a constant yield of 50 % for all three proteins.  The functionality of KcsA 
and DsbB was tested by using a known binder at various points of the screen.  DsbB was further 
tested for functionality by a robust enzymatic assay which detects oxidation of the electron donor 
DsbA, a soluble partner protein, or the reduction of the electron acceptor, the synthetic cofactor 
ubiquinone-5, also named coenyzme Q1 (UQ1). The fragment mixtures were void of detergent, 
in order to limit hydrophobic interactions between fragments and detergent micelles. However, 
detergent was required at a concentration equivalent to 5 x the critical micelle concentration, 
below which the detergent micelles would dissociate into monomers and eventually cause loss of 
protein conformation and hence, functionality. These optimal conditions allowed us to carry out a 
small test screen of 100 fragments on KcsA and a full screen of 1000 fragments on DsbB, both 
leading to a 7 % hit rate. 
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 TINS is an NMR method which enables to identify fragment hits on a target protein, but these 
hits should be further characterized for their potency and mode of action, as was carried out for 
DsbB in Chapter 5.  Enzymatic assays were used to determine the potency range of the 
fragments, along with their mode of action.  Bidimensional NMR experiments were used to 
identify which residues of the protein were affected upon titration of the fragments, such as those 
in proximity of DsbA or UQ1 binding sites on DsbB. Wildtype DsbB was too unstable to be 
studied by NMR, but a stabilized mutant from a physiologically relevant intermediate state of 
DsbB was used and resulted in the confirmation of the binding modes established by enzymatic 
assays. This suggested that the results found were not artefacts and that the fragments were 
binding specifically to DsbB. The final 8 fragments, with potencies ranging between 10 to 200 
µM (IC50 values), were thus classified into two groups. The first group, containing 3 fragments, 
consisted of competitive inhibitors for the endogenous ubiquinone binding site of the enzyme. 
These fragments therefore inhibited UQ1 binding and subsequent electron transfer from DsbA to 
the respiratory chain. The second group, containing 5 fragments, represented mixed model 
inhibitors which inhibited both UQ1 and DsbA binding by binding in an alternative site to the 
first class of fragments.  The existence of two binding modes provides exciting perspectives in 
chemically linking or elaborating these diverse fragment scaffolds from these two different 
groups into more potent and more selective DsbB inhibitors. 
  Chapter 6 demonstrates how an alternative solubilization technique enabled TINS in aqueous 
buffers, completely void of detergents.  The proteins were encapsulated into a bilayer stabilized 
by an amphiphilic membrane scaffold protein in a complex called the nanodisc which was 
entirely soluble in aqueous buffers. We demonstrated here that nanodisc embedded DsbB, as 
opposed to detergent solubilized DsbB, was more active in enzymatic assays, was immobilized at 
a higher efficiency, and was stable throughout the test screen of 180 fragments.  Furthermore, 18 
of the 19 fragments which showed high DsbB inhibition in Chapter 5 were also identified as hits 
in the nanodisc embedded DsbB screen, suggesting that TINS is a repeatable method. Empty 
nanodiscs were used as a reference system to account for the non-specific binding of fragments to 
the nanodisc environment.  The advantages of using nanodiscs in TINS are numerous, as they 
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alleviate the need to produce, solubilize, and immobilize a reference protein, they are more 
stable, and make it easier to handle membrane proteins in the absence of detergents.  
 Finally, Chapter 7 describes the conclusions and perspectives of this thesis. The results of this 
thesis show that TINS can be applied to a variety of membrane proteins, such as ion channels and 
membrane enzymes.  The fragment hits identified for DsbB were characterized as inhibitors in 
the micromolar range and could be identified with different solubilized states of the enzyme. The 
use of nanodisc embedded targets enables one to screen a target in aqueous buffers with empty 
nanodiscs as a good standardized reference.  These results, combined with the new methods for 
overexpression and thermostable mutagenesis should provide exciting new possibilities which 
may extend beyond the identification of fragments binding to membrane proteins. These include 
the identification of protein-protein or drug-drug interactions, depending on what one chooses to 
immobilize or inject in the place of proteins and fragments. 
 




 Dit proefschrift beschrijft hoe de Target Immobilized NMR Screening (TINS) technologie kan 
worden gebruikt om kleine moleculen als binder aan membraaneiwitten te identificeren. 
 Recentelijk is aangetoond dat het screenen van kleine moleculen, of fragmenten (< 300 Da) 
door middel van fragment-based drug discovery (FBDD) een goed alternatief is voor screening 
van grotere moleculen, hoewel de techniek is beperkt tot oplosbare eiwitten.  Hoofdstuk 1 
introduceert het begrip FBDD en waarom het nuttig zou zijn manieren te vinden om deze drug 
discovery benadering toe te passen op membraaneiwitten. In het kort, FBDD heeft zich met 
behulp van biofysische technieken  als Kern Spin Resonantie (NMR) ontwikkeld vanwege de 
mogelijkheid om zwakke binding van fragmenten aan eiwitten te detecteren. Biofysische 
technieken zijn echter veeleisend met betrekking tot de hoeveelheid en zuiverheid van het 
benodigde eiwit en, helaas, tot nu toe alleen toepasbaar op oplosbare eiwitten. Van de 
geneesmiddelen op de markt richt 60 % zich echter op membraaneiwitten die te maken hebben 
met een reeks van cruciale cellulaire processen, van het signaleren van cellen tot transport van 
ionen en andere opgeloste stoffen de cel in en uit. Zoals de naam al aangeeft bevinden 
membraaneiwitten zich binnen in de celmembraan en hebben een hydrofobische omgeving nodig 
om structuur en functie te behouden. Hoofdstuk 2 behandelt het uitgebreide werk dat is 
uitgevoerd op het gebied van immobilisatie van membraaneiwitten in verschillende systemen die 
membranen nabootsen en laat zien dat geen van alle toepasbaar zijn om zwakke bindingen van 
fragmenten aan membraaneiwitten te bestuderen. Het is juist de hydrofobe aard die het onderzoek 
aan deze eiwitten met FBDD limiteert door de lage eiwitopbrengst en stabiliteit en het niet-
specifieke karakter van fragment binding aan de pseudomembranen, zoals oppervlakteactieve 
stoffen of lipiden. 
TINS is een vergelijkende methode waarin de simultane screening van een referentie eiwit (met 
minimale binding eigenschappen aan kleine moleculen), opgelost in aanwezigheid van dezelfde 
oppervlakteactieve stof als het target eiwit, kan compenseren voor non-specifieke binding van 
fragmenten aan de hydrofobe omgeving.  Identificatie van fragmenten die specifiek aan de target 
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binden kan direct worden uitgevoerd zonder enige deconvolutie, door eenvoudige vergelijking 
van de 1D 1H NMR signaal intensiteiten van de fragmenten in aanwezigheid van het referentie en 
target eiwit. Dit heeft als voordelen boven andere NMR technieken dat geen structurele 
informatie van de target vereist is, kleine hoeveelheden eiwit nodig zijn en bindende moleculen 
kunnen worden opgespoord in mengsels van fragmenten, wat het proces versnelt. 
 In Hoofdstuk 3, lieten we zien dat belangrijke farmaceutische targets als G protein coupled 
receptors (GPCRs) in principe bestudeerd kunnen worden met behulp van TINS dankzij hun 
functionele immobilisatie op een resin in een serie van biologisch relevante agonist en antagonist 
conformaties. Dit was mogelijk omdat natieve membraan fragmenten van de cellen die deze 
eiwitten tot over-expressie brengen werden geimmobiliseerd, zonder verdere zuivering. Dit 
maakte de neven-immobilisatie mogelijk van andere targets die een belangrijke rol spelen in de 
signalerings cascade, zoals G proteinen. De lage populatie van functionele geimmobiliseerde 
eiwitten kon worden verhoogd door toename van de linker lengte tussen het eiwit en het 
oppervlak, maar de intrinsieke lage overexpressie van deze eiwitten was de beperkende factor die 
ons verhinderde om TINS toe te passen op deze klasse van eiwitten. 
 In Hoofdstuk 4, bewijzen we het principe dat TINS in het algemeen kan worden toegepast op 
membraaneiwitten. We gebruiken het bacteriele potassium ion channel (KcsA) en het bacteriele 
membraan enzym Disulphide bond forming protein B (DsbB) als targets, beiden geïmmobiliseerd 
en gescreened met het bacteriele referentie eiwit Outer membrane protein A (OmpA), en allen 
opgelost in dodecylphosphocholine detergent. De immobilisatie efficientie van alle drie de 
membraaneiwitten werd uitgerekend door het meten van de hoeveelheid eiwit in het supernatant 
voor en na de immobilizatie, met een stabiele opbrengst van 50 % voor alle drie de eiwitten. De 
functionaliteit van KcsA en DsbB werd getest door TINS metingen aan een bekende binder op 
verschillende tijdstippen tijdens de screen.  Bovendien werd DsbB getest op functionaliteit met 
behulp van een robuust enzymatisch assay dat oxidatie waarneemt van de electron donor DsbA, 
een oplosbaar partner eiwit, of reductie van de electron acceptor, de synthetische cofactor 
ubiquinone-5, ook genaamd coenzym Q1 (UQ1). De fragmenten mixen bevatten geen detergent, 
om de hydrofobe interacties tussen fragmenten en detergent micellen te beperken. Het 
membraaneiwit, aan de andere kant, had detergent nodig bij een concentratie gelijk aan 5 x de 
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kritische micel concentratie. Bij lagere concentratie zouden de detergent micellen dissocieren tot 
monomeren en uiteindelijk verlies van eiwit conformatie, en dus functionaliteit, veroorzaken. 
Deze optimale condities maakten het mogelijk om een kleine test screen van 100 fragmenten uit 
te voeren op KcsA en een volledige screen van 1000 fragmenten op DsbB, beide resulterend in 
een hit rate van 7 %. 
 De NMR techniek TINS maakt het mogelijk om fragmenten hits van een target eiwit te 
identificeren, maar deze hits moeten verder nog gekarakteriseerd worden op hun potentie en 
manier van werken, zoals uitgevoerd voor DsbB in Hoofdstuk 5.  Enzymatische essays werden 
gebruikt om het potentie gebied van de fragmenten, naast hun manier van werking, te bepalen. 
Tweedimensionale NMR experimenten werden gebruikt om aan te tonen welke eiwitresiduen, 
zoals die in de nabijheid van de DsbA of UQ1 binding sites bij DsbB, werden beïnvloed door 
titratie van de fragmenten. Wildtype DsbB was te instabiel om met NMR te bestuderen, maar een 
gestabiliseerde mutant van een fysiologisch relevante intermediaire toestand van DsbB werd 
gebruikt en resulteerde in de bevestiging van de binding karakteristieken die door enzymatische 
essays waren aangetoond. Dit leidde tot de veronderstelling dat de verkregen resultaten geen 
artefacten waren en dat de fragmenten specifiek aan DsbB binden. De uiteindelijke 8 fragmenten, 
met potenties variërend van 10 to 200 µM (IC50 waarden), werden nu geordend in twee groepen. 
De eerste groep, bestaande uit 3 fragmenten, waren competitieve inhibitors voor de endogeneuze 
ubiquinone binding site van het enzym. Deze fragmenten verhinderden op die manier UQ1 
binding en achtereenvolgende electronen overdracht van DsbA naar de ademhalingsketen. De 
tweede groep bevatte 5 fragmenten en vertegenwoordigde gemengde model inhibitors die zowel 
UQ1 als DsbA binding verhinderden door binding in een andere site dan de eerste reeks 
fragmenten.  Het bestaan van twee binding modes levert opwindende vooruitzichten op het 
gebied van chemisch linken of het nader onderzoeken van de fragmenten structuren van deze 
twee verschillende groepen tot meer potente en meer selectieve DsbB inhibitors. 
  Hoofdstuk 6 laat zien hoe het op een alternatieve manier in oplossing brengen van 
membraaneiwitten TINS mogelijk maakte in waterige buffers, totaal zonder toevoeging van 
detergent. De eiwitten werden ingekapseld in een bilaag gestabiliseerd door een amfifiele 
membraan structuur eiwit in een complex, nanodisc genoemd, dat volledig oplosbaar was in 
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waterige buffers. We toonden hier aan dat in nanodisc ingebedde DsbB, in tegenstelling tot in 
detergent opgelost DsbB, actiever was in enzymatische essays, met grotere efficiëntie werd 
geïmmobiliseerd, en stabiel was gedurende de test screen van 180 fragmenten. Bovendien, 18 van 
de 19 fragmenten die hoge DsbB inhibitie vertoonden in Hoofdstuk 5 werden ook 
geïdentificeerd als hits in de in nanodisc ingebedde DsbB screen, suggererend dat TINS een 
reproduceerbare techniek is. Lege nanodiscs werden gebruikt als referentie systeem om te 
compenseren voor de non-specifieke binding van fragmenten aan de nanodisc omgeving. Er zijn 
veel voordelen aan het gebruik van nanodiscs in TINS, zoals het overbodig maken om een 
referentie eiwit te produceren, op te lossen en te immobiliseren. Ze zijn ook stabieler, en ze 
vereenvoudigen het werken met membraaneiwitten door de afwezigheid van detergent. 
 Ten slotte beschrijft Hoofdstuk 7 de conclusies en vooruitzichten van dit proefschrift. De 
resultaten van dit proefschrift laten zien dat TINS kan worden toegepast op een verscheidenheid 
aan membraaneiwitten, zoals ion channels en membraan enzymen. De gevonden fragmenten hits 
voor DsbB werden gekarakteriseerd als inhibitors in het micromolaire gebied en konden worden 
geïdentificeerd met verschillende opgeloste toestanden van het enzym. Het gebruik van in 
nanodisc ingebedde targets maakt het mogelijk om een target te screenen in waterige buffers met 
lege nanodiscs als een goed gestandaardiseerd referentie eiwit. Deze resultaten, gecombineerd 
met de nieuwe methoden van overexpressie en thermostabiele mutagenesis zouden prikkelende 
nieuwe mogelijkheden moeten opleveren die verder strekken dan de identificatie van aan 
membraaneiwitten bindende fragmenten. Daarbij horen het opsporen van eiwit-eiwit of 
geneesmiddel-geneesmiddel interacties, afhankelijk van wat men kiest om te immobiliseren of 
NMR aan te meten in de plaats van achtereenvolgens eiwitten en fragmenten. 
 




 Cette thèse décrit la méthode de « Target Immobilized NMR Screening (TINS) », qui peux etre 
appiquée aux protéines membranaires afin d'identifier de nouveaux ligands de petite taille. 
 La méthode de criblage de petites molécules, ou fragments (<300 Da), par « fragment-based 
drug discovery (FBDD) » a été récemment identifiée comme une bonne alternative au criblage de 
molécules plus larges, mais le concept est restreint aux protéines solubles. Le 1er Chapitre 
présente la notion de FBDD ainsi que les raisons pour lesquelles il est intéressant de pouvoir 
appliquer ce genre de découverte médicinale aux protéines membranaires.  En gros, le FBDD a 
évolué avec les méthodes biophysiques telles que la Résonance Magnétique Nucléaire (RMN) 
grâce à la possibilité de détecter les liaisons faibles entre fragments et protéines.  De telles 
méthodes biophysiques sont exigeantes en ce qui concerne la quantité et le niveau de pureté d'une 
protéine.  60 % des drogues sur le marché pharmaceutique, cependant, ciblent les protéines 
membranaires qui sont beaucoup plus difficiles à produire et à purifier que les protéines solubles.  
Ces protéines sont à la base de multiples processus cellulaires vitaux au bon fonctionnement du 
corps, tels que la signalisation et le transport d'ions et de solutés intra et extra cellulaires.  Comme 
le nom l'indique, ces protéines sont localisées dans la membrane cellulaire et requièrent un 
environnement hydrophobe pour maintenir leurs conformations et par conséquence, leur bon 
fonctionnement.   
 Le 2ème Chapitre est une revue de différentes méthodes ingénieuses qui existent pour 
immobiliser les protéines membranaires dans une variété d’imitations de membranes cellulaires 
dont les propriétés ne sont pas évidentes à préserver. Ce chapitre démontre qu'aucune de ces 
méthodes d'immobilisation n’est applicable à l'étude des interactions faibles entre fragments et 
protéines membranaires.  C'est précisément cette nature hydrophobe qui limite l'application de 
FBDD aux protéines membranaires, car les imitations synthétiques de membranes cellulaires, tels 
que les détergents ou les lipides, ont tendance à créer des liaisons non-spécifiques avec les 
fragments, ce qui engendre souvent de fausses lectures de résultats.   
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 TINS est un système de référence qui permet le criblage simultané d'une protéine de référence 
(avec peu d'affinités pour les fragments), solubilisée dans le même détergent que la cible, pour 
permettre l'identification des liaisons non-spécifiques au niveau des protéines ainsi qu'au niveau 
de l'environnement hydrophobe présent autour des deux protéines.  Il en découle la possibilité 
d'identifier les fragments qui se lient spécifiquement à la cible.  Ceci peut être fait 
instantanément, sans déconvolution, en comparant simplement l'intensité des signaux 1D 1H des 
fragments en présence de la cible et de la référence.  Ceci à certains avantages par rapport aux 
autres méthodes par RMN car il n’y a a priori aucun besoin d'avoir résolu les structures 
protéiniques, de petites concentrations de protéine sont requises, et les fragments peuvent etre 
identifiés parmi des cocktails de plusieurs fragments à la fois, afin de rendre le processus plus 
rapide. 
 Dans le 3ème Chapitre, nous avons démontré que les cibles pharmaceutiques importantes telles 
que les récepteurs couplés aux protéines G: les « G protein coupled receptors (GPCRs) », 
peuvent, en principe, être criblés par la méthode TINS. Leur immobilisation dans les 
conformations d'importance physiologiques, tels que sous formes agonistes ou antagonistes sur 
résine était possible.  Ces différentes conformations pouvaient être présentes sur la résine car 
nous avons immobilisé des vésicules de membranes cellulaires natives, co-immobilisant d'autres 
protéines importantes à la cascade de signalisation et la fonctionnalité des GPCRs, tels que les 
protéines G.  La quantité de GPCRs fonctionels sur résine pouvait être améliorée en augmentant 
la distance entre les vésicules et la résine, mais le faible niveau d'expression intrinsèque des 
cellules mères était le facteur qui nous a empêchés de pouvoir appliquer la méthode TINS à cette 
classe de protéines.  
 Dans le 4ème Chapitre, nous avons établi que les protéines membranaires en général pouvaient 
être criblées par la méthode TINS. Nous avons utilisé le canal ionique de potassium bactérien 
(KcsA) ainsi que l'enzyme membranaire bactérien Disulphide bond forming protein B (DsbB) 
comme cibles, immobilisées et criblées en présence de la protéine Outer Membrane protein A 
bactérienne. Toutes trois protéines étaient solubilisées dans le même détergent 
dodecylphosphocholine (DPC).  L'efficacité d'immobilisation des toutes les trois protéines était 
constamment de 50 %.  Le fonctionnement de KcsA et DsbB pouvait etre testé par l'identification 
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de l'interaction avec un ligand connu par la méthode TINS.  L'activité de DsbB pouvait etre 
d'avantage confirmée par un essai enzymatique qui permettait de suivre l'oxidation de la protéine 
partenaire DsbA, ainsi que la réduction du cofacteur de DsbB: le coenyzme Q1 synthétique 
(UQ1).  Pour le criblage, afin de minimaliser les interactions entre fragments et détergents, les 
solutions de fragments ne contenaient aucun détergent. Cependant, le détergent était requis à une 
concentration équivalente à 5 x celle de la concentration de micelle critique dans le tampon de 
lavage, en dessous duquel les micelles de détergents se dissocieraient en monomères, 
éventuellement causant la perte de conformation protéinique et ainsi, leur bon fonctionnement.  
Ces conditions optimales nous ont permis de compléter un petit criblage de 100 fragments sur 
KcsA ainsi qu'un criblage complet de 1000 fragments sur DsbB. 
 TINS est une méthode par RMN qui permet d'identifier les fragments qui se lient par faible 
affinité aux cibles protéiniques immobilisées, sans donner d'informations quantitatives ou 
qualitatives en ce qui concerne leur constante d'inhibition enzymatique ni leur mode d'action (site 
de liaison).  Nous avons donc poursuivi l'étude de ces caractéristiques pour les ligands identifiés 
par TINS sur DsbB dans le 5ème Chapitre.  Les fragments démontrant plus de 70 % d'inhibition 
dans les essais enzymatiques ont démontré une rangée de constante d'inhibition entre 10 et 200 
M (IC50s).  Les essais compétitifs enzymatiques ont aussi démontrés que parmi ces 8 fragments 
finaux, il existait trois fragments compétitifs pour le site de liaison du cofacteur UQ1, ainsi que 
cinq fragments présentant le mode mixte, à savoir, un effet inhibiteur sur le cofacteur UQ1 ainsi 
que sur la liason de DsbA avec DsbB (inhibition d'interaction entre protéines).  Ces résultats ont 
été confirmés par des expériences parallèles par RMN sur des échantillons de DsbB mutants.  Le 
mutant est la seule forme de DsbB suffisamment stable pour ces expérimentations, et représente 
une conformation physiologiquement importante qui représente une conformation intermédiaire 
de cette protéine dans le processus d'échange d'électrons.  Ces expériences nous ont permis ainsi 
d'identifier les zones d'acides aminés qui participaient dans les liaisons avec les fragments.  
L'existence des deux sites de liaison nous permettra dans l'avenir de lier chimiquement des 
fragments des deux groupes distincts afin d'obtenir des composés inhibiteurs de DsbB avec 
d'avantage de spécificité et d'efficacité.  
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 Le 6ème Chapitre nous démontre la possibilité d'utiliser une technique de solubilisation 
alternative qui permet de répéter le criblage TINS sur DsbB en l’absence de détergents.  Les 
protéines DsbB et OmpA étaient encapsulées dans une couche lipidique stabilisées par une 
ceinture de protéine amphiphile (membrane scaffold protein MSP) dans un complexe nommé le 
nanodisque. Ce nanodisque est complètement soluble dans l'eau grace aux propriétés de l'MSP.  
Nous avons démontré que DsbB, une fois encapsulée dans le nanodisque (DsbB/ND) est plus 
active, peut être immobilisée avec d'avantage d'efficacité, et peut être criblée en l’absence totale 
de détergents en gardant sa fonctionnalité intacte.  De plus, sur les 19 fragments à haute efficacité 
inhibitrice, 18 ont été identifiés dans le criblage en utilisant les nanodisques vides (sans DsbB 
mais avec une couche lipidique) démontrant que les résultats d'une telle méthode sont répétables 
et qu'il est possible d'éviter la nécessité de produire, purifier, et solubiliser une protéine de 
référence. 
  Le 7ème chapitre décrit les conclusions et les perspectives de cette thèse. Les résultats de cette 
thèse prouvent que TINS est une méthode que l'on peut appliquer de façon générale aux protéines 
membranaires, telles que les canaux ioniques et les enzymes. Les fragments identifiés comme 
ligands pour DsbB ont été caractérisés comme des inhibiteurs dans la gamme micromolaire et 
pouvaient être identifiés par TINS malgré les différents états solubilisés de l'enzyme. L'utilisation 
des cibles solubilisées dans les nanodiscs permet d'examiner une cible dans un environnement 
aqueux avec les nanodiscs vides comme bonne référence standardisée. Ces résultats, combinés 
avec les nouvelles méthodes pour la surexpression et la mutagénèse thermostabilisante devraient 
fournir de nouvelles possibilités passionnantes qui peuvent se prolonger au delà de l'identification 
des fragments ligands aux protéines membranaires. Ces expériences incluent l'identification des 
interactions entre protéines ou entre drogues, selon ce qu'on choisit d'immobiliser ou d'injecter au 
lieu des protéines et des fragments.  
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